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Inflammation for Acute Lung Injury
Abstract
The objective of the study is to demonstrate alleviation of pulmonary inflammation associated with acute
lung injury (ALI) using novel surface modified nanoparticles. ALI is characterized by three main
pathological events: I) pulmonary edema, II) excessive pro-inflammatory cytokines and chemokines
production from alveolar epithelial and endothelial cells and III) leukocyte migration from blood
circulation into alveoli. Currently, there is no FDA approved pharmacological treatment available except
the supportive mechanical ventilation therapy. Numerous clinical trials involving pharmacological
therapies aimed at different pathological targets turned unsuccessful. National Institute of Heart Lung
and Blood Institute (NHLBI) cited underappreciation of drug delivery systems as one of the attributed
drawbacks.
During ALI, the αvβ6/αvβ5 integrins of alveolar epithelium and endothelium, respectively play a critical
role in mediating pulmonary edema in interleukin-1b (IL-1b) stimulated ALI models. A transient blockade
of both integrins by antibodies (Ab) or small Arg-Gly-Asp (RGD) peptide sequences may provide new
causal therapies for pulmonary edema. A transcription factor, nuclear factor-kB (NF-kB) is associated with
the regulation of a battery of genes that encode for pro-inflammatory cytokines, chemokines and cell
adhesion molecules (CAMs). Glucocorticoids (GCs) exert their anti-inflammatory effects by NF-kB
transcriptional interference mechanisms. Besides the above inflammatory mechanisms, leukocyte
migration is another hallmark feature responsible for part of ALI pathogenesis. Leukocyte migration is
dictated by sequential activation of adhesion molecules and their ligands on both leukocytes and
endothelial cells (ECs). Intercellular adhesion molecule-1 (ICAM-1) located on alveolar endothelium plays
a significant role in the recruitment of leukocytes into alveoli. Blockade of ICAM-1 receptors using antiICAM-1 antibodies may impede leukocyte migration into alveoli.
In view of high mortality associated with ALI, there is an urgent need for a drug delivery system that
inhibits majority of pathological events. In drug targeting research, liposomes are considered as versatile
for their ability to carry drug payloads and flexible enough to modulate their surface for targeting
purposes. In the current investigation, I developed surface modified stable liposome formulation for
delivery of methylprednisolone succinate (a glucocorticoid; MPS) to the lung. Liposomes were targeted to
the disease sites through different routes of administration to avail the spatial expression of the receptors
in response to IL-1b stimulus. MPS-LcRGD targeted to avb6 integrins of alveolar epithelium attenuated
pulmonary edema. MPS-LAb were able to modulate neutrophil migration. Moreover, MPS released from
targeted liposomes inhibited the expression of pro-inflammatory cytokines and chemokines. The research
work demonstrated the concept of using drug encapsulated and surface modified nanoparticles for
therapeutic intervention of ALI.
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ABSTRACT
The objective of the study is to demonstrate alleviation of pulmonary inflammation
associated with acute lung injury (ALI) using novel surface modified nanoparticles. ALI
is characterized by three main pathological events: I) pulmonary edema, II) excessive
pro-inflammatory cytokines and chemokines production from alveolar epithelial and
endothelial cells and III) leukocyte migration from blood circulation into alveoli.
Currently, there is no FDA approved pharmacological treatment available except the
supportive mechanical ventilation therapy. Numerous clinical trials involving
pharmacological therapies aimed at different pathological targets turned unsuccessful.
National Institute of Heart Lung and Blood Institute (NHLBI) cited underappreciation of
drug delivery systems as one of the attributed drawbacks.
During ALI, the αvβ6/αvβ5 integrins of alveolar epithelium and endothelium,
respectively play a critical role in mediating pulmonary edema in interleukin-1 (IL-1 )
stimulated ALI models. A transient blockade of both integrins by antibodies (Ab) or small
Arg-Gly-Asp (RGD) peptide sequences may provide new causal therapies for pulmonary
edema. A transcription factor, nuclear factor- (NF- B) is associated with the regulation
of a battery of genes that encode for pro-inflammatory cytokines, chemokines and cell
adhesion molecules (CAMs). Glucocorticoids (GCs) exert their anti-inflammatory effects
by NF- transcriptional interference mechanisms. Besides the above inflammatory
mechanisms, leukocyte migration is another hallmark feature responsible for part of ALI
pathogenesis. Leukocyte migration is dictated by sequential activation of adhesion
molecules and their ligands on both leukocytes and endothelial cells (ECs). Intercellular
adhesion molecule-1 (ICAM-1) located on alveolar endothelium plays a significant role
in the recruitment of leukocytes into alveoli. Blockade of ICAM-1 receptors using antiICAM-1 antibodies may impede leukocyte migration into alveoli.
In view of high mortality associated with ALI, there is an urgent need for a drug delivery
system that inhibits majority of pathological events. In drug targeting research, liposomes
are considered as versatile for their ability to carry drug payloads and flexible enough to
modulate their surface for targeting purposes. In the current investigation, I developed
surface modified stable liposome formulation for delivery of methylprednisolone
succinate (a glucocorticoid; MPS) to the lung. Liposomes were targeted to the disease
sites through different routes of administration to avail the spatial expression of the
receptors in response to IL-1 stimulus. MPS-LcRGD targeted to v 6 integrins of
alveolar epithelium attenuated pulmonary edema. MPS-LAb were able to modulate
neutrophil migration. Moreover, MPS released from targeted liposomes inhibited the
expression of pro-inflammatory cytokines and chemokines. The research work
demonstrated the concept of using drug encapsulated and surface modified nanoparticles
for therapeutic intervention of ALI.
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CHAPTER 1. INTRODUCTION TO TARGETED LIPOSOMES
1.1

Statement of Problem

In 1967, at the Colorado General Hospital, Ashbaugh and colleagues were the first to
describe patients with a variety of underlying illnesses characterized by tachypnea,
hypoxemia resistant to oxygenation by regular ventilator support, decreased lung
compliance, diffuse bilateral infiltrates on chest radiographs and surfactant abnormalities.
Together, the above characteristics are defined as acute respiratory distress syndrome
(ARDS).1 Another term, acute lung injury was used in synonymous with ARDS in most
cases, but could only be applied to a broad range of pathological abnormalities in the lung
where as ARDS should be reserved for the most severe cases of lung injury.2
ALI is a major cause of acute respiratory failure with high morbidity and mortality in
critically ill patients.3 Recent epidemiologic data indicate that the incidence of ALI
defined by consensus physiologic criteria may account for 36,000 deaths per year in
U.S.A.4 Although, there is evidence that mortality in patients with ALI may have declined
over the last 10 to 15 years, it remains high (30-40%) and is an important cause of
pulmonary and non-pulmonary morbidity in ICU patients.5 ALI develops in patients of all
ages from a variety of clinical disorders. These conditions can be divided into two
categories based on whether the insult was direct (pulmonary) or indirect (extrapulmonary). Direct injury can be described as a condition in which the lung epithelium is
directly injured. Causes of such lung injury include pneumonia, aspiration of gastric
contents, inhalation of toxic substances and pulmonary contusion.6 Direct causes of lung
injury lead to a syndrome with more predictability and to a short latent period than do
indirect causes.7 Indirect lung injuries are conditions that activate a systemic
inflammatory response. Multiple trauma, burns, sepsis, fat emboli and hemorrhagic shock
are all associated with a high risk of developing ALI. So far, mechanical ventilation is the
lone supportive therapy for the alleviation of symptoms associated with ALI.
1.2

Overview of Acute Lung Injury

The most important pathological finding in the lung during the early stages of ALI is
severe pulmonary edema, due to increased permeability of the alveolar endothelial and
epithelial barriers. As illustrated in Figure 1.1, the morphological picture has often been
labeled as diffuse alveolar damage and includes cellular necrosis, inflammation and
fibrosis. Although, pathogenesis of ALI remains unclear, indirect evidence suggests that
pulmonary edema occurs after a direct activation due to acute lung inflammation, or as
the pulmonary manifestation of a systemic inflammatory response.8 The inflammatory
response in both cases involves alveolar migration of leukocytes, (e.g. macrophages,
monocytes and neutrophils) which are activated by pro-inflammatory cytokines and
chemokines.9

1

Figure 1.1
Schematic representation of the normal alveolus and the injured alveolus
in the acute phase of ALI/ARDS.
In the acute phase of the syndrome (injured alveolus), sloughing of alveolar epithelial
cells, with the formation of protein rich hyaline membranes on the denuded basement
membrane is seen Neutrophils adhere to the injured capillary endothelium and
extravasate into alveoli, which is filled with protein rich edema fluid. In the alveoli,
alveolar macrophages secrete cytokines, which further stimulate chemotaxis and activate
neutrophils. Neutrophils release oxidants, proteases, leukotrienes, and other proinflammatory mediators, such as platelet activating factor. The influx of protein rich
edematous fluid into the alveolus leads to the inactivation of surfactant.
Reproduced with permission. Ware, L.B. & Matthay, M.A. The acute respiratory distress
syndrome. N Engl J Med 342, 1334-1349 (2000).4
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1.2.1 Pulmonary Cytokines and Inflammation in ALI
A complex network of cytokines and other pro-inflammatory compounds initiate and
amplify the inflammatory response in ALI. Different cell types, such as endothelial,
epithelial and leukocytes produce cytokines and chemokines. Excessive or unregulated
release of cytokines and chemokines might result in unwanted systemic and/or local
effects that may cause ALI. The inflammatory process is regulated by the early response
cytokines (e.g. tumor necrosis factor- (TNF-α), IL-1β and IL-6), which are suggested as
key mediators in the pathogenesis of ALI.10 These early response cytokines induce an
intricate cascade of events, which include the production and release of chemokines (e.g.
IL-8, monocyte chemoattractant protein-1 (MCP-1), macrophage inhibitory protein-1
(MIP-1) and cytokine induced neutrophil chemoattractant-1 (CINC-1)) from endothelial
cells, epithelial cells or leukocytes.4,11-13 In addition, cytokines and chemokines cause
sequestration of leukocytes by inducing adhesion molecules (e.g. integrins, selectins and
members of immunoglobulin superfamily) expression on epithelial and endothelial cells,
and further activate the leukocytes, which trigger an extensive inflammation process.14-17
1.2.2 Pulmonary Edema
In the normal lung, fluid moves continuously outward from vessels to the interstitial
space according to the permeability of the capillary membrane as well as the net
difference between hydrostatic and protein osmotic pressures. Non-cardiogenic
pulmonary edema occurs when the permeability of the alveolar epithelial/endothelial
membrane increases because of direct or indirect lung injury resulting in a marked
increase in the amount of fluid and protein leaving the vascular space. As illustrated in
Figure 1.2, nature of the inflammatory stimulus/injury determines the mechanistic
pathway for an increase in permeability across alveolar epithelium or endothelium, thus
contributing to pulmonary edema.
1.2.2.1 Alveolar Epithelial Integrin Receptors: Pulmonary Edema
Pittet et al. showed that lipopolysaccharide (LPS) and IL-1 cause an increase in lung
vascular permeability. Both the stimuli exert this effect through activation of
transforming growth factor-beta (TGF- ) via v 6 integrin dependent mechanism in
alveolar epithelium. Under normal conditions, TGF- is latent and is non-covalently
associated with latency associated peptide (LAP) and latent TGF-β-binding protein-1
(LTBP-1). Activation of TGF- by integrin receptors is critical in the propagation of lung
edema in ALI.18-20 The v 6 integrin binds to RGD domain of the LAP of TGFcomplex and activates latent TGF- .19 Although, the exact mechanism of v 6 integrin
mediated TGF- activation is still not clear, it is likely that the activation process
involves multiple coordinated mechanisms.
Pittet et al. demonstrated that αvβ6 integrin mediated TGF-β activation is dependent on
cytoskeletal integrity. Inhibition of actin assembly by cytochalasin D and β6 subunit
3

Figure 1.2
Schematic illustration of the effect of interleukin-1β on the alveolar
capillary barrier.
The model demonstrates IL-1β signaling pathway that leads to an increase in lung
epithelial and endothelial permeability. IL-1β causes an increase in RhoA activity leading
to TGF-β activation via αvβ6 integrins. TGF-β activation induces an increase in
permeability and an inhibition of the Na+ driven fluid transport in alveolar epithelial cells.
In endothelial cells, IL-1β activates RhoA and increases lung endothelial permeability via
the phosphorylation and endocytosis of β-catenin and αvβ5 integrin dependent stress
fiber formation in lung endothelial cells.
Reproduced with permission. Ganter, M.T. et al. Interleukin-1 {beta} causes acute lung
injury via {alpha}v{beta}5 and {alpha}v{beta}6 integrin-dependent mechanisms. Circ
Res 102, 804-812 (2008).21
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cytoplasmic truncation mutants prevent integrin interaction with actin cytoskeleton,
each abolishes TGF-β activation by αvβ6.19 Jenkins et al. demonstrated that upon external
stimulus, PAR1 receptor signals to the αvβ6 integrins via RhoA and Rho kinase.20
Because of the well-known effects of RhoA in re-organizing actin, these findings are
consistent with the observation that αvβ6 mediated TGF-β activity is completely inhibited
by an inhibitor of actin polymerization, cytochalasin D. In fact, blockade of any
component in the sequence of events in actin polymerization leads to inhibition of TGF-β
activity. A complete blockade of TGF-β activity was observed using αvβ6 antibodies.
Recently, Ganter et al. demonstrated a complete inhibition of pulmonary edema using
anti-αvβ6 integrin and anti-TGF- antibodies in IL-1 instilled ALI model.21
1.2.2.2 Alveolar Endothelial Integrin Receptors: Pulmonary Edema
Physical passage of solutes through the endothelial barrier is thought to occur via
paracellular pathways or through receptor activated transcytosis.22 Direct modification of
actin cytoskeleton in endothelial cells is important for increasing paracellular
permeability. One frequently cited model describes paracellular gap formation as a
consequence of imbalanced competition between cytoskeletal, adhesive cell–cell and
cell–matrix forces.23,24 Actomyosin mediated generation of tension leads to alteration of
cell shape and formation of paracellular gaps. Stress fibers have been shown to form in
endothelial cells, stimulated by several vasoactive mediators.21,25,26 In TGF- stimulated
model, TGF- activates RhoA signaling cascade in endothelial cells. The TGF- induced
activation of the RhoA/Rho-kinase signaling cascade in endothelial cells increases Factin content, which contributes to an increase in stress fiber formation, interendothelial
gap formation and subsequent decrease in endothelial monolayer resistance.27 Ganter et
al. demonstrated that IL-1 activates RhoA, and increases lung endothelial permeability
via v 5 integrin dependent stress fiber formation in lung endothelial cells. Furthermore,
stress fiber formation induced by the agonists was attenuated by blockade of αvβ5
integrin, suggesting a mechanism for αvβ5 integrins to regulate paracellular endothelial
permeability in the lung. A complete inhibition of transendothelial permeability was
observed using anti-αvβ5 integrin antibodies.21
In summary, αvβ5/αvβ6 integrins play a critical role in mediating the development of
pulmonary edema in LPS or IL-1 or TGF- stimulated ALI models. Taken together,
transient blockade of both integrins by antibodies or small RGD peptides may provide
new causal therapies for pulmonary edema.
1.2.3 Leukocyte Migration in Pulmonary Vasculature
Circulating leukocytes infiltrate from blood circulation into tissues under both normal
and pathologic circumstances. As illustrated in Figure 1.3, leukocyte migration from the
vasculature occurs by a multi-step process, dictated by the sequential activation of
adhesion molecules and their ligands on both leukocytes and ECs.28,29 Leukocytes
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Figure 1.3
Schematic diagram of neutrophil and endothelial cell interactions in the
pulmonary vasculature.
E-selectin upregulation induces rolling of neutrophils, which adhere to endothelial cells
activated by ICAM-1. Followed by transendothelial migration, neutrophils infiltrate into
alveoli. Schematic diagram also shows various receptors and ligands involved in the
neutrophil migration process.

6

infiltrate by these sequence dependent mechanisms but differ in their responses to
chemotactic (e.g. MCP-1) and cytokine signals (e.g. TNF- or IL-1 ), particularly in
their qualitative and quantitative expression of adhesion molecules (e.g. selectins,
integrins and members of immunoglobulin superfamily).30-32 Leukocyte trafficking in
pulmonary circulation differs from systemic vasculature with respect to: I) the marginated
pool of leukocytes, II) the site of transendothelial migration and III) requirements of
adhesion molecules for leukocyte migration. Leukocyte migration begins with the
“capture” by the vessel wall of leukocytes from flowing blood and is followed by their
“rolling” to a small extent along the vessel wall. About 97% of pulmonary vascular
leukocytes (7-8 µm) are found in the capillary network where vessels are too small to
allow rolling (5-6 µm).33 Despite the lack of rolling in pulmonary capillaries, selectins
may be involved in the leukocyte-endothelial cell interactions.34-36 Only after appropriate
stimuli from alveolar capillary ECs, leukocytes become firmly adhered to ECs and are
positioned for migration from blood vessels into lung parenchyma.
The initiating signal for the next step of migration is firm adhesion, which is postulated to
be either a receptor mediated event in response to pro-inflammatory
cytokines/chemokines or an event propagated from signals from activated selectins.36-38
Cytokines/chemokines on inflamed endothelium interact with their receptors on
leukocytes. These interactions result in the activation of leukocyte integrins. Activated
integrins interact with members of the immunoglobulin superfamily (e.g. ICAM-1)
displayed on the inflamed endothelium, and these interactions cause the rolling cells to
arrest on endothelium. Transmigration of arrested leukocytes across the endothelium is
not as well understood. However, it is generally accepted that leukocytes migrate across
the endothelium by penetrating junctions that lie within the intercellular cleft. Leukocytes
move across blood vessel walls by passing between ECs (diapedesis).39 After
transmigration, leukocytes move into the interstitium along a gradient of chemoattractant
toward the source of the chemoattractant. In lungs, leukocytes then migrate across the
epithelium to reach the apical side. Molecular requirements of transepithelial migration
are not well understood but most likely involve a multi-step process that requires
sequential interactions of leukocyte adhesion molecules with their ligands on the
epithelial cells.40,41
Leukocyte migration depends on: I) nature of inflammatory stimuli and II) route of
exposure of stimuli to the alveolar capillary bed. Doerschuk et al. demonstrated that
neutrophil migration occurs through at least two distinct pathways. One pathway requires
2-integrins, whereas the other does not, and the distinction depends on the stimulus.42
Gram negative bacteria (e.g. E.coli) or LPS elicit neutrophil migration via pathways
predominately mediated by β2 integrins.42 Alveolar endothelial ICAM-1, which serves as
a ligand for neutrophil β2 integrins is upregulated in response to LPS stimulus. In
contrast, gram-positive bacteria (e.g. S.pneumoniae) elicit pulmonary neutrophil
migration independent of β2 integrins.43 In a situation where neutrophil migration is β2
integrin independent, antibody inhibition of β1 integrin or specific -subunits ( 2, 4,
5 and 6) blocks neutrophil migration into alveoli.44 Moreover, gram-negative stimuli
appear to elicit greater TNF- production than do gram-positive stimuli. Taken together,
integrin antibody studies and disparate cytokine production elicited by various stimuli
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suggest that the adhesion molecule requirements for migration might depend on the type
and quantity of cytokines and chemokines produced in response to inflammatory
stimulus.
Shang and Issekutz identified a role for β2 integrins, as well as 4, 5 and 6 1
integrins.45 With a cocktail of blocking antibodies to these integrins, neutrophil migration
was inhibited by 60%.46 Recently, a few studies indicated exceptions to the β2 integrin
dependent neutrophil migration in LPS stimulated models. These studies reported the
significance of 4 and/ or 5 integrins along with β2 integrins.47,48 Intratracheal (i.t.)
instillation of LPS (E.coli) results in β2 integrin dependent migration, while intravenous
administration results in sequestration that is β2-integrin independent.42,49 Airway
instillation of stimuli via trachea would presumably induce inflammation along airway
walls containing vessels of the bronchial circulation as well as pulmonary capillary beds.
Conversely, models that use intralobular instillation may deliver inflammatory stimuli
anatomically closer to alveolar regions, and may therefore induce relatively more
neutrophil migration from the pulmonary vasculature.
Clinical and experimental studies have provided circumstantial evidence of the
occurrence of neutrophil mediated injury in ALI. Broncho-alveolar lavage fluid (BALF)
in normal subjects yields normally only a few neutrophils.50 However, a subpopulation of
circulating neutrophils is always present within the pulmonary microvasculature.
Evidence shows that percentage of BALF neutrophils is markedly increased in ALI
affected patients.51 The migrated neutrophils release myeloperoxidase (MPO) and
reactive oxygen species (ROS) in alveoli, which can be potentially harmful to alveolar
epithelium.52 When produced in excessive amounts or when anti-oxidant defense is
insufficient, free radicals can damage DNA, lipids, proteins and carbohydrates.53
Alongside neutrophils, monocytes play a critical role in the propagation of inflammatory
response.54,55 From blood circulation, they migrate into lungs and differentiate into
alveolar macrophages, which amplify the inflammatory response through the production
and secretion of chemokines and other pro-inflammatory mediators.
1.2.4 Relevance of ALI Models in Therapeutic Intervention
Different animal models of ALI are in use to investigate pathological mechanisms of lung
injury.56 However, none of the ALI models adequately reproduces the full characteristics
of human ALI, and therefore, the choice of a particular model is made after considering
the specific features of each model. Most ALI models target the primary tissues, alveolar
epithelium or endothelium or both. Modeling strategies are an attempt to target specific
tissue. From a practical standpoint, there are three general types of model systems: I)
models in which the lung is injured directly by a noxious stimulus. These include
intratracheal or intranasal administration of bacteria or bacterial products, such as LPS or
pro-inflammatory cytokines, IL-1 ; administration of an acid, such as HCl to reproduce
aspiration;57,58 administration of high inspired fractions of oxygen;59 depletion of
surfactant by serial lavage with 0.9% NaCl60 or exposure to mechanical stretch using
mechanical ventilation with high tidal volumes,61 II) models in which the lung is injured
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indirectly. This category includes models based on reproducing sepsis, such as cecal
ligation and puncture (CLP);62 systemic administration of LPS or bacterial infusion63 and
III) combination models. Most commonly used model includes saline lavage followed by
mechanical ventilation, or CLP followed by hemorrhage.
Exposure to moderate doses of LPS is widely used as a prototypic ALI model,64 while
administration of high doses of LPS is considered as a relevant model of ARDS.65 Early
phase (4-6 h) of LPS instillation (i.t.) is characterized by an increase in BALF leukocytes,
albumin and pro-inflammatory cytokines/chemokines, and late phase (24–48 h) is
characterized by normalization of BALF cytokines and increase in BALF leukocyte
counts.66 Systemic administration of LPS in animals induces a septic shock resulting in
injury to various organs, including the liver67 and the lung.68 Following the systemic
administration of LPS, the capillary endothelium is the initial site of injury, which results
in apoptosis of endothelial cells.69 Neutrophil migration occurs before epithelial
permeability changes or alveolar barrier disruption.70 Other hallmark features include
elevated concentrations of cytokines/chemokines in blood circulation and coagulation
abnormalities.71 Altogether, these animal models clearly demonstrate that direct
(pulmonary) or indirect (systemic) challenges by endotoxins may cause lung tissue
damage that are severe enough to qualify as ALI/ARDS. In addition, animal models
provide a critical method for testing potential new therapies in a proof-of-principle
fashion.
1.2.5 Pharmacological Interventions of ALI in Preclinical and Clinical Trials
The pathophysiology of ALI is increasingly well understood; however, very little success
was achieved with regard to new treatment modalities. The spate of trial failures may
relate to participant heterogeneity or to intervention strategy. Important considerations for
trial failures are the timing of intervention (pre-ALI, the early exudative phase, the
intermediate fibro-proliferative phase or later), mechanism of drug delivery (intravenous,
enteral, inhaled or intrapulmonary instillation). As new information regarding the
pathogenesis of ALI evolves, more specific therapies are being studied, including
separate considerations for direct or indirect forms of ALI. Table 1.1 is a summary of the
therapies under preclinical and various phases of clinical development.
1.2.5.1 Anti-inflammatory Strategies: Corticosteroids
Transcription factor, NF-kB is associated with the regulation of a battery of genes that
encode for cytokines, chemokines and adhesion molecules.72,73 NF-κB is a heterodimeric
protein composed of the DNA binding proteins, p65 and p50 constitutively present in the
cytoplasm in an inactive form stabilized by the binding to the inhibitory protein, IκBα.74
Cellular activation by adverse stimuli leads to phosphorylation and degradation of
IκBα.75 The liberated NF-κB then translocates into the nucleus and binds to promoter
regions of target genes to initiate the synthesis of the pro-inflammatory cytokines,
chemokines and adhesion molecules.
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Table 1.1
Pharmacological agents in preclinical and clinical phases of drug
development.
Stage of study Pharmacological intervention
Preclinical
Cyclooxygenase inhibitors: Eltenac
Keratinocyte growth factor (KGF)
Neutrophil elastase inhibitors: EPI-HNE-4
Phase I
Anti-oxidant: OxSODrol
Cytoprotective therapies: CPC-111
Soluble complement receptors: TP-20
Phase II
Anti-coagulants: NAPc2
Anti-inflammatory: PAF-AH/Pafase™
Inhaled nitric oxide
β2-agonists
Soluble complement receptors: TP-10
Liquid ventilation: LiquiVent™
Albumin and furosemide
Nutrition
Phase III
Surfactants: Venticute™, HL-10, lucinactant
Prostaglandins: Prostacyclin/PGI2, PGE1/TLC C-53
Growth Factors: GM-CSF/leukine
Anti-coagulants: rhAPC/drotrecogin alfa, TFPI
Corticosteroids
G-CSF: Granulocyte colony-stimulating factor; GM-CSF: Granulocyte macrophage
colony-stimulating factor; hLS: Human lung surfactant; HNE: Human neutrophil
elastase; KGF: Keratinocyte growth factor; NAC: N-acetylcysteine; NAP: Anticoagulation protein; rhAPC: Recombinant human activated protein C; PAF-AH: Platelet
activating factor acetylhydroxylase; TFPI: Tissue factor pathway inhibitor.
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Glucocorticoids mediate NF- transcription interference by one of the following
mechanisms:75 I) physically interacting with the p65 subunit and formation of an inactive
(GR-NF-κB) complex,76 II) inducing the transcription of the inhibitory protein, IκBα,76-78
III) impairing TNF-α induced degradation of IκBα79 and (IV) competing for limited
amounts of GRα co-activators, such as steroid receptor co-activator-1.80 Through one of
the above mechanisms, GCs suppress the production of cytokines by target cells (e.g.,
endothelial, epithelial and leukocytes) in response to inflammatory stimuli. Furthermore,
they downregulate the expression of chemokines and adhesion molecules on these
cells.72,81-83 Studies in vitro demonstrate a direct effect of GCs on cultured ECs and
isolated neutrophils to inhibit expression of adhesion molecules.84-86 Several case series
reports87,88 suggested that glucocorticoids could lower mortality in some patients with
severe ALI when administered several days after ALI onset. In a small, randomized,
placebo-controlled trial important clinical outcomes were better in patients randomized to
receive methylprednisolone in the late phase of ALI.89
1.2.5.2 Prostaglandin Agonists/Inhibitors
Prostaglandin E1 is a vasodilator that blocks platelet aggregation and decreases
neutrophil activation. This agent showed promise in experimental and preliminary
clinical studies of lung injury.90 However, a multi-center study91 reported no evidence of
reduced mortality in those treated with prostaglandin E1. Liposomal delivery of
prostaglandin E1 was also not beneficial in a phase II study.92 Ketoconazole, a potent
inhibitor of thromboxane and leukotriene synthesis was reported to prevent the
development of ALI in high risk surgical patients. However, an NIH-sponsored multicenter phase III trial93 showed no decrease in mortality for ketoconazole treatment (35%)
vs. the placebo group (34%).
1.2.5.3 Phosphodiesterase Inhibitors
Pentoxifylline is a phosphodiesterase inhibitor that inhibits neutrophil chemotaxis and
activation.94 In animal studies, lisofylline inhibited release of TNF- , IL-1 and IL-6, and
attenuated shock induced lung injury in mice.95 However, phase III trial96 by the NIHARDS Network in ALI patients showed no beneficial effects of lisofylline.
1.2.5.4 Anti-oxidants
Evidence suggests that ROS plays a major role in mediating injury to the endothelial
barrier of the lung in ALI.97 In normal individuals, oxidant productions are normally
balanced by a number of anti-oxidants, including water soluble molecules, such as
glutathione and lipid soluble molecules, such as Vitamin E (α-tocopherol).98,99 Nacetylcysteine (NAC), a synthetic anti-oxidant mediates its effect as a precursor for
gluthatione.98 NAC was shown to protect lung tissue against oxidative damage in
preclinical models.100 However, clinical studies failed to improve survival in ALI
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patients.101 Vitamin E, considered as the principal anti-oxidant improved immune
responsiveness, and reduced the incidence and severity of infectious diseases.102
1.2.5.5 Anti-IL-8 Therapy
One approach is to reduce the number of neutrophils that migrate into the extravascular
space of the lung by interfering with neutrophil adhesion to the lung endothelium or by
reducing the release of chemotactic factors in the extravascular space. Monoclonal
antibodies that neutralize IL-8 reduced acid-induced lung injury in rabbits.103 Clinical
trials of anti-IL-8 therapy for prevention in high risk patients or in early ALI may soon be
warranted.
1.2.5.6 Surfactants
Surfactant is a lipoprotein complex produced by alveolar type II cells. Alveolar surfactant
secretion reduces surface tension, and prevents alveoli from collapsing.104 Whether
reduced in amount or dysfunctional in condition, surfactant abnormalities may lead to
problems, such as ventilation-perfusion mismatch, hypoxemia and reduced lung
compliance.105 Surfactant replacement therapy in animal models of ALI improved
oxygenation, lung mechanics and survival.104,106
1.2.5.7 Miscellaneous Therapies
Many other therapeutic interventions are under preclinical and clinical investigations.
Partial liquid ventilation uses perfluorocarbons to maintain open lung units and improve
oxygenation.107 The use of activated protein C108 and GM-CSF109 are all moving forward
in large scale clinical trials. β2 agonists110 and fluid balance manipulation111 appear
promising despite varied conclusions from previous trials. Various ligand based
pharmaceuticals (e.g. inhibitors of the upregulated receptors on alveolar epithelium or
endothelium or leukocytes) are in different stages of drug development.
Citing the multiple pathways involved in ALI pathogenesis, an „all-out‟ therapy that
contributes to the resolution of edema, and inhibition of leukocyte migration and proinflammatory mediators‟ production is most desirable rather than just limiting one or the
other.
1.2.6 Significance of Drug Delivery in ALI Pathogenesis
Numerous clinical trials involving pharmacological therapies aimed at different
pathological targets turned unsuccessful. One of the attributed drawbacks is the underappreciation of drug delivery systems in the management of ALI. Very few investigations
were directed at drug delivery perspective in the treatment of ALI. However, the results
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are promising both in the alleviation of the syndrome and improving the survival of
patients. As described previously, the alveolar epithelium and endothelium play an
important role in the vicious circle of production of pro-inflammatory mediators and
leukocyte recruitment. An attractive therapeutic approach is to selectively target antiinflammatory drugs to activated epithelium/endothelium, thereby increasing the
effectiveness of the targeted drug and simultaneously diminishing systemic side effects.
To selectively deliver drugs into activated alveolar epithelial/endothelial cells, integrins
and ICAM-1 receptors are suitable targets because of spatial and temporal expression in
response to inflammatory stimulus. Furthermore, both integrin and ICAM-1 receptors are
internalizing molecules, which results in the intracellular degradation of the drugtargeting systems and drug release, thereby leading to local anti-inflammatory activity.
Thus, targeting to integrin/ICAM-1 receptors facilitates multi-purpose: I) specific
delivery of drugs for inhibition of pro-inflammatory mediators‟ production and II)
blockade of receptors for inhibition of pulmonary edema/leukocyte migration.
Optimal targeted drug delivery systems incorporate the ability to preferentially recognize
and localize to sites of injury, while simultaneously avoiding uptake into normal tissue
beds.112 Therefore, active targeted drug delivery systems are investigated to improve
therapeutic efficiency and reduce side effects associated with systemic administration.
Liposomes are studied extensively as potential vehicles for selective drug targeting,
achieved by modulation of specific and non-specific cellular and molecular interactions.
Liposomal drug delivery systems have received considerable attention due to their
specific advantages: I) encapsulation of small and large molecules with a wide range of
hydrophobicity levels and pKa values, II) prolong and target therapeutic agents by
modification of liposome surface and III) minimize clinical drug dose and reduce toxicity
effects. The surface chemistry of liposomes can be controlled by the selection of
particular phospholipid moieties to incorporate several different molecules in well
defined molar ratios. As a result, liposomes can be engineered to provide great diversity
of structures with exceptional design control. Liposomes also have a relatively high
encapsulation volume available for carrying therapeutic agents compared with other drug
carrying nano sized vehicles.113 Therefore, liposomes are considered as potential targeted
drug delivery systems.
In the current investigation, we will apply the liposome drug delivery perspective to the
pathological mechanisms, and improve therapeutic benefits in the treatment of ALI. It is
perhaps this requirement that is most tenuous, but the one with the great potential.
1.3

Overview of Liposome Literature

Most of the medical applications of liposomes are in cancer and inflammation areas.
Ligand targeted liposomes perform best against targets in the vasculature or readily
accessible from the vasculature, e.g. as an adjuvant therapy in the treatment of residual
and micro-metastatic disease following primary therapy of solid tumors by surgery or
radiation.114 Over the next decade, the number of liposome based pharmaceutical
products will continue to expand, justifying the investment in research and development
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over the previous years. Table 1.2 illustrates the liposome products in preclinical and
clinical phases of development.
1.3.1 Basic Liposome Composition
Liposomes are spherical self-closed vesicular structures. The size of a liposome ranges
from 20 nm to 1-5 m, and they may be composed of one or several concentric
membranes, each with a thickness of about 4 nm. Liposomes possess unique properties
owing to the amphipathic character of the lipids, which make them suitable for drug
delivery. Liposomes, prepared using a lipid or combination of lipids carry water soluble
drugs in their aqueous compartments and lipid soluble drugs in their lipid bilayers. The
amphipathic phospholipid molecules, with distinct hydrophobic and hydrophilic domains,
spontaneously form bilayers in aqueous media as a consequence of the interaction
between the polar head group of the phospholipid and water. The charge, phase transition,
hydrogen-bonding capacity, membrane rigidifying potential and functional groups of
phospholipids all affect the retention of the encapsulated drug.
The inclusion of cholesterol (CHOL) stabilizes liposomal phospholipid membranes
against disruption by plasma proteins115,116 and results in decreased binding of plasma
opsonins responsible for rapid clearance of liposomes from circulation.117 Cullis and
coworkers118 showed that CHOL-free liposomes bound 3-4 times more protein than
CHOL containing liposomes. This increase in CHOL caused a substantial increase in
clearance from the blood of mice. CHOL-free liposomes were shown to aggregate rapidly
in the absence of steric stabilization, and further leads to increased clearance.119 The
fluidity of the membrane also affects the rate of clearance, with non-pegylated liposomes
composed of unsaturated phospholipids and CHOL display rapid clearance rates than
those containing saturated phospholipids.120-122 In the absence of CHOL, neutral
phosphatidylcholine liposomes composed of saturated lipids were cleared more
rapidly.118 However, high CHOL concentrations (30 mole%) resulted in the formation of
a highly ordered crystalline state, which decreased protein binding and dramatically
increased circulation life times.118 The rate of liposome clearance varied positively with
the phase transition temperature of the phosphatidylcholine.118 This is likely due to
increased protein binding to exposed hydrophobic domains originating from packing
defects in gel phase membranes. Substitution of sphingomyelin for the high phase
transition distearoyl phosphatidylcholine (DSPC) increased circulation life times in
CHOL containing liposomes.123 This is likely due to the highly cohesive membranes124
formed as a result of intermolecular hydrogen bonds between sphingomyelin and
neighboring CHOL122,125,126 or even other sphingomyelin127 molecules. Liposomes
composed of hydrogenated sphingomyelin and CHOL were shown to improve circulation
life times of vincristine encapsulated liposomes.128
Charged lipids affect liposome clearance, although the relationship is often very
complex.122 In general, low concentration of charged lipids provide sufficient
electrostatic repulsion to prevent liposome aggregation upon addition of hydrophobic
drugs to the membrane.129 However, the inclusion of high concentration of either anionic
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Table 1.2

Liposome products in clinical and preclinical studies.

Product
Clinical studies
Drug delivery
Caelyx
Doxil
Doxil+VAD
Doxil+VAD
Doxil+Yondelis
Myocet
Liposomal cisplatin
Aroplatin™
Annamycin
Paclitaxel
Vincristine
Topoisomerase inhibitor
Mitoxanthrone
Nystatin
DNA delivery
Interleukin-2 plasmid DNA
Antigen delivery
MUC-1 peptide; BLP25
Preclinical studies
Drug delivery
Adriamycin
Doxorubicin
Vincristine
Prednisolon
Clodronate
Glucocorticoids
Glucocorticoids
Budesonide
Tacrolimus
Interleukin-2
DNA delivery
Bcl-2 antisense ODNs
Interferon-b DNA

Application

Company; trial phase

Bladder cancer
Ovarian cancer
Myeloma
Multiple myeloma
Ovarian cancer
Breast cancer
Recurrent ovarian cancer
B-cell lymphoma
Leukemia
Head and neck cancer
Lung cancer
Lung and ovarian cancer
Other cancers
Leukemia

Schering Plough; EU
Ortho Biotech
Millennium
Millennium; III; J&J; III
J&J; III
Sopherion Therapeutics; III
Sequus; II
Antigenics; I
Aronex Pharm; II
Neopharm; II and III
Inex Pharm; II
OSI Pharm; II
Neopharm; II
Pfizer; III

Kidney and prostate cancer Vical; II
Lung cancer

Merck; III

Sarcoma
Neuroblastoma
B-cell lymphoma
Autoimmunity
Autoimmunity
Arthritis
ALI
Asthma
Skin disorders
Immunotherapy
Cancer
Glioma

VAD denotes vincristine, adriamycin and doxorubicin (DXR) combination
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or cationic lipids into liposomal membrane increases clearance of liposomes from the
circulation. High concentration of anionic lipids increases accumulation in liver and
spleen.122,130 In addition to liver and spleen, cationic lipids enhance uptake by vascular
endothelial cells of lung,131 tumor vasculature132 and blood brain barrier.133 In anionic
liposomes, net negative charge of liposomes is dependent on the specific anionic lipid
utilized in the formulation, with low concentrations of anionic gangliosides,
phosphatidylglycerol (PG), phosphatidylinositol (PI) and PEGylated
phosphatidylethanolamine (PEG-PE) result in substantial reduction in
clearance.120,122,130,134 The presence of anionic lipids, such as phosphatidic acid (PA),
phosphatidylserine (PS) and cardiolipin (CL) caused an increase in the rate of clearance
from the blood.122,130,135 This discrepancy is in part due to the differences in
protein/opsonins binding to membranes containing different anionic lipids. Liposomes
comprised of the anionic lipids exhibited high plasma protein binding, while liposomes
composed of PG, PI and PEG-PE show less protein binding.130 The presence of PS on
liposomal surface resulted in receptor-mediated clearance.136 Therefore, caution should
be exercised in the selection of charged lipid components in liposomal therapeutics.
The phase transition temperature (Tm) of the phospholipid component influences drug
retention. The phospholipid undergoes a shift from a well ordered gel phase to a fluid and
disordered liquid crystalline state at its phase transition temperature. In general, liposome
membranes are more permeable above the Tm of the particular phospholipid. For
unsaturated phospholipids, physiological temperature is above the phase transition, and
therefore, the drug retention is compromised. On the other hand, saturated phospholipids,
such as DSPC or hydrogenated soy phosphatidylcholine (HSPC) have a phase transition
temperature (50-58 C) above the physiological temperature, and therefore, the liposome
formulations are stable. The clearance rates of doxorubicin loaded pegylated liposomes
were correlated with the Tm of the phosphatidylcholine (EggPC>DPPC>HSPC),
reflecting the increased membrane permeability, and thus leakage of doxorubicin for the
EggPC and dipalmitoyl phosphatidylcholine (DPPC) formulations.137
Sphingomyelin stabilizes membranes in the presence of CHOL. It imparts compact
packing of membrane lipids138 with a decrease in permeability to water and other
solutes.139 The high cohesiveness and reduced permeability of the membrane could be
due in part to the strong hydrogen bonds between the amide nitrogen of sphingomyelin
and the hydroxyl group of CHOL.126 In addition, due to the amide linkage in its
backbone, sphingomyelin is also less sensitive to pH-dependent hydrolysis.140
Substitution of dihydrosphingomyelin for sphingomyelin was shown to improve the
stability of vincristine encapsulation. Thus, the ability of sphingomyelin and
dihydrosphingomyelin to reduce the membrane permeability of certain drugs can play an
important role in regulating the rate of drug release for certain small molecule drugs.
1.3.2 Physico-chemical Properties of Drugs: Liposome Encapsulation
The physico-chemical properties of the drug to be incorporated into liposomes play an
important role in determining its rate of release. Encapsulated drugs are classified as: (I)
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water insoluble hydrophobic drugs, (II) amphipathic weak bases, (III) amphipathic weak
acids, (IV) highly water and membrane impermeable small molecular weight drugs and
(V) polyions, such as nucleic acids. The most commonly studied drugs are the
amphipathic weak bases (e.g. camptothecins, anthracyclines). Typically, weak bases are
loaded into liposomes using ammonium sulfate gradient method, which even
significantly improved the pharmacokinetics of the encapsulated drug. However, within a
given class of drugs, the drug release rates can vary dramatically. Doxorubicin has an
improved toxicity and anti-tumor efficacy profiles. However, another member of the
same class, mitoxantrone is released more slowly compared to doxorubicin, its activity is
compromised and requires a modified lipid composition to promote release of the drug
and improve efficacy.141 Weakly acidic drugs can be loaded using reverse pH gradients
(i.e., pH lower on liposome exterior), including acetate gradient method.142 Drugs that
contain both weakly basic and weakly acidic groups pose a challenge, but are often
overcome depending on the pKa and number of the various ionizable groups. A drug that
contains both a weakly basic amine and a phenolic hydroxyl group, with its relatively
high pKa, is still viable for gradient method. The presence of low pKa acids, make it
difficult to find a pH where both the acid and the amine would be neutralized, enabling
the drug to readily penetrate the liposomal membrane and accumulate in the liposome
interior. Hydrophobic drugs represent a third class of drugs that are formulated in
liposomes. Lipophilic drugs rapidly transfer between liposomal membranes and various
biological interfaces, including cellular membranes and plasma proteins.143 Therefore,
these liposomes often demonstrate some improvement in pharmacokinetic parameters.
Highly water soluble molecules include both small molecules and polyionic compounds,
such as nucleic acid based therapeutics. Encapsulation of highly water soluble agents
may not be amenable to gradient-based drug loading methods due to their minimal
membrane permeability. However, nucleic acids, although highly water soluble can be
efficiently complexed with cationic lipids to form highly condensed lipidic
nanoparticles.144 These examples illustrate the barriers and opportunities for delivery of
various classes of drugs.
1.3.3 PEGylation of Liposomes
Conventional liposomes formed by natural phospholipids and CHOL are generally
recognized by the body‟s immune system as foreign bodies and are often destroyed
before significant amounts of drug reach the intended disease site. Liposomes are
engulfed by phagocytic cells of the reticular endothelial system (RES), and therefore,
drugs accumulate in the liver, spleen or bone marrow. Attachment of ligands, such as
polyethylene glycol (PEG) to a liposome surface results in the formation of sterically
stabilized liposomes, which prolong drug residence time in blood circulation.145,146 This
is the patented delivery form, termed stealth® liposomes (ALZA). As shown in Figure
1.4, targeted liposomes usually involve coating with functionalized ligands that bind
specifically with receptors on cell surface. The stealth® liposomes maintain chemical
stability of the drug in the body and lengthen drug circulation half-life.147,148 Therefore,
incorporation of steric stabilizing surface functional moiety became an essential
component of liposome formulation development. Among the various ligands
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Figure 1.4

Schematic representation of various classes of liposomes.

Conventional liposomes are PEGylated to obtain long circulating liposomes.
Conventional liposomes or PEGylated liposomes are surface modified with proteins (e.g.
antibodies) to obtain targeted liposomes. Cationic liposomes are obtained by
incorporation of cationic lipids (e.g. lipofectamine).
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investigated for improving the blood circulation half-life of liposomes, PEG is the most
widely used stabilizer in pharmaceutical applications because of its advantages, including
non-biodegradability, high solubility in aqueous solution, ability to bind to a large
number of water molecules, high flexibility of its polymer chain, and non-immunogenic
and limited accumulation in RES system.121 In addition, PEG prevents the adsorption of
proteins (opsonins) responsible for phagocytic removal, and thus provides the ability to
adjust the liposome physico-chemical (such as drug loading and leakage) and biological
properties (e.g. blood circulation and tissue distribution).149,150
1.3.4 Liposome Targeting
1.3.4.1 Passive Targeting
Targeting of drugs to specific cells and substrates is a critical objective of drug delivery.
The size control of liposomes and nature of liposome surface (e.g. surface/steric effect)
may be used to optimize passive targeting.122 The enhanced accumulation of liposomes at
inflammation and tumor sites is due to the leaky vasculature system,151,152 which is
unable to prevent small species (<100 nm) crossing the capillary membrane. Even
though, only a small fraction of liposomes eventually accumulate at target sites,
prolonged circulation indirectly enhances accumulation of liposome associated drugs in
the targeted tissues.
1.3.4.2 Active Targeting
Active targeting of liposomes to specific cell receptor sites involves modifying the
liposome surface with the incorporation of specific ligands, e.g. peptides, antibodies,
immunoglobulins, lectins and other proteins.153 A number of key issues must be
addressed before active targeting of liposomes using ligand-receptor interactions in
vivo.154 Targeted liposomes must circulate in blood long enough to perfuse into the target
organ and eventually interact with cells. Otherwise, liposomes will be cleared without
making contact with the cell targets.155 Targeted cell receptor expression should be high
compared to non-targeted cells, and receptors must provide sufficient specificity and
affinity. Therefore, knowledge of the density of the receptors in target tissue compared
with non-targeted sites and the degree of blood perfusion are useful to design targeted
liposomes.122 In addition, targeting moieties coupled to the surface of liposomes must be
sufficiently stable in vivo. In some cases, PEG incorporated into liposomes affects the
targeting action and interferes with target (e.g. receptor) recognition. To overcome the
barrier of PEG, attachment of targeting ligand to the distal end of a PEG molecule
precludes steric hindrance and improves targeting properties of liposomes.156,157 For
example, attachment of a targeting ligand to the maleimide residue of DSPE-PEGmaleimide.119,158 The PEG-PE liposomes with targeting moieties retain long survival
times in blood circulation and demonstrate target recognition in vivo.159 In addition,
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reports suggested that PEG chain length and charge density are crucial for targeted
liposomes.119
1.3.5 Methods for Attaching Targeting Ligands to Liposomes
Over the years, different strategies evolved to impart active targeting to liposomes. All
these strategies are based on two chemical methods for attaching ligands to the liposomal
surface: covalent and non-covalent coupling. Figure 1.5 describes various covalent
reactions used for coupling targeting ligands to liposome surface. Generally, ligands are
bound to the surface of liposomes through hydrophobic anchors with functional groups.
Long-chain fatty acids, such as palmitic acid160 and phospholipids, such as PE161,162 are
generally used as anchors. These anchors are incorporated into liposomal bilayers during
the formation of liposomes. There are two approaches to covalently attach the ligand to
the anchor. The first consists of carrying out the reaction between the ligand and the
anchor, and mixing the resulting ligand with other constituents of the liposome.163 In the
second case, the anchor is already included in the liposome bilayer, and the coupling
reaction occurs on the surface of preformed liposomes.164
1.3.5.1 Coupling of Ligands to the Surface of Liposomes Using thio-ether Bonds
The reaction between thiol and maleimide groups is an efficient reaction that gives a
stable thio-ether bond. Native thiol groups are present in some proteins, but in many
others, thiol functions are either absent or present in insufficient amounts. Thiol groups
are added either via hetero-bi-functional cross-linking agents165,166 or by reducing
disulfide bonds. N-hydroxysuccinimide 3-(2-pyridyldithio)propionate (SPDP) and
succinimidyl-S-acetylthioacetate (SATA)165,167 are commonly used as crosslinkers. Both
offer one primary reactive amine residue for coupling with the ligand. In both cases, thiol
functions are not directly available, and a deprotection of these functions under mild
conditions is necessary before the reaction with liposomes. In the case of SPDP,
dithiothreitol (DTT) or an alternative reducing reagent is used to reduce the disulfide
bond to thiol function. SATA offers one protected thiol function, which is deacetylated
with hydroxylamine. N-(4-(p-Maleimidophenyl)butyryl)phosphatidylethanolamine
(MPB-PE) is another commonly used functionalized anchor.168 The extended spacer arm
between the phospholipid head group and the maleimide moiety reduces the possibility of
a steric hindrance at the bilayer interface, and thereby ensures favorable thiol reactivity.
Once the liposomes with maleimide groups are formed, the ligands with thiol functions
are coupled to the liposomes by simple addition reaction.166,168 Now, there is commercial
abundance of functionalized lipids with terminal maleimide groups for ease of
conjugation with thiol groups of antibodies.
Immunoliposome technology can be combined with sterically stabilized liposomes to
give long circulating vesicles capable of delivering antibodies/immunoglobulins to target
cells. There are two ways of obtaining immunoliposomes: (I) antibodies are bound to the
surface of liposome in parallel with PEG168 and (II) antibodies are linked to the distal end
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Figure 1.5
Schematic representations of different coupling methods used for surface
modification of liposomes.
Reaction between maleimide and thiol functions (A), formation of a disulfide bond (B),
reaction between carboxylic acid and primary amine group (C), reaction between
hydrazide and aldehyde functions (D), cross-linking between two primary amine
functions (E).
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of PEG chains.169 For both approaches, PEG is incorporated into the bilayer via an
anchor, such as distearoyl phosphatidylethanolamine (DSPE).168,170 When antibodies are
coupled to the termini of PEG, (maleimidomethyl)cyclohexanecarboxylate-PEG-DSPE
(MCC-PEG-DSPE) or maleimido-phenylpropionate-PEG-DSPE (MP-PEG-DSPE) are
used.171,172 Thiol groups of the Fab fragments171 or monoclonal antibodies (entire IgG)
are then attached to the distal end of PEG chains via the maleimide groups. It is also
possible to link maleimido antibodies to liposomes offering thiol functions.170, 173
Antibodies can also be attached either directly to the surface of the vesicles via PDPdioleoyl phosphoethanolamine (PDP-DOPE)170 or to the PEG terminus via PDP-PEGDSPE170 or PDP-PEG-PE.169 Maleimido antibodies are obtained using a hetero-bifunctional cross-linker, succinimidyl 4-[p-maleimidophenyl]butyrate (SMPB)169,170,173
that is reactive with amino and sulfhydryl groups of antibodies. High coupling efficiency
is possible when ligands are coupled to the distal ends of PEG chains.170
1.3.5.2 Attachment of Ligands to Liposomes via a Disulfide Linkage
One of the most rapid and easy coupling chemistries involves the conjugation of two thiol
functions to form a disulfide bond. However, disulfide bonds are relatively unstable
under the reductive conditions in serum.174 For this reason, the disulfide linkage is
progressively replaced by other more stable ones. As seen before, thiolated ligands are
generated either by reduction of disulfide bonds174 or using SATA or SPDPlinkers.175 The
thiolated ligands are then made to react with the pyridyldithio moiety of the anchor (PEPDP) to form a disulfide linkage. Several studies demonstrated that the coupling method
is efficient in attaching antibody to the liposomes without denaturation of the ligand.175
1.3.5.3 Cross-linking between Carboxylic Acid Functions and Primary Amines of the
Ligand
Ligands are attached to the surface of liposomes by an amide bond using an anchor
functionalized with carboxylic acid end groups. Distearoyl-N-(3-carboxypropionoyl
poly(ethylene glycol)succinyl)phosphatidylethanolamine (DSPE-PEG-COOH) offers
carboxylic acid groups at the distant end of PEG chains.156,176 The coupling reaction is
carried out in the presence of N-hydroxysulfosuccinimide (NHS) and 1-ethyl-3-(3dimethylamino-propyl)carbodiimide (EDC) to form an acyl amino ester, which will
subsequently react with the primary amine of the ligand, yielding an amide bond.176, 177
The advantage of this method is that no prior ligand modification is required, thus
reducing the risk of denaturation and loss of specific activity.
1.3.5.4 Binding of Ligands to Liposomes via Hydrazone Bond
Antibodies are covalently bound through their carbohydrate moieties to hydrazide groups
grafted onto the liposomal surface to form a hydrazide bond. A mild oxidation of the
carbohydrate groups on the constant region of the heavy chain of the immunoglobulin is
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required to produce aldehyde groups. These react with hydrazide groups of the anchor.178
The carbohydrate groups are oxidized either by galactose oxidase or by sodium
periodate.178 Once the oxidized antibodies are formed, they are either directly coupled to
the lipid bilayer containing a hydrazide-hydrophobic anchor, such as lauric acid
hydrazide178 or to the distal end of the PEG chains of sterically stabilized liposomes.170,179
In the latter case, a functionalized PEG-lipid hydrazide, Hz-PEG-DSPE180 is used. This
coupling method is not very efficient because only a small percentage of antibodies
(17%) were attached to the liposomal membranes.170
1.3.5.5 Cross-linking between Primary Amines on Liposomes and Primary Amines of the
Ligand
In this method, direct amine-amine cross-linking is performed. Two homo bi-functional
cross-linkers are used: glutaraldehyde and suberimidate.181 The advantage of this
coupling approach is that no prior modification is required to add functional groups to the
ligand. The coupling method consists of first activating the primary amine of PE on the
liposome surface via the cross-linker and subsequently coupling the ligand. High
coupling efficiency (60 mole%) of antibodies to liposomes was reported.182 Despite the
fact that the coupling reaction is efficient, the use of homo bi-functional cross-linkers is
rarely exploited owing to the uncontrollable homo-polymerization of ligand during the
cross-linking reaction.
1.3.5.6 Multi-step Attachment Using the Avidin-Biotin Interaction
The avidin-biotin strategy is a popular and versatile tool for active targeting.157,183,184
Anita et al demonstrated the use of a biotinylated PEG-DSPE linker to form a noncovalent bond between streptavidin-conjugated monoclonal antibody (mAb) (e.g. OX26
mAb raised against the rat transferrin receptor) and liposomes.184 Furthermore,
biotinylated antibodies are easily obtained.185,186 Huwyler et al demonstrated specific
targeting of daunomycin to the rat brain using OX26 antibody conjugated liposomes.157
1.3.5.7 Non-covalent Methods
An alternative means to conjugate ligands to liposomes is the use of non-covalent
methods. The advantage of these methods is easy to be carried out without the need of
aggressive reagents. A simple method is to merely add the ligand to the mixture of
phospholipids during the preparation of the liposomes. However, the percentage of ligand
attached to the carrier is relatively low (4-40%) and aggregation of the liposomes is
frequently observed. Furthermore, the amount of ligand linked to the liposome is not
easily controllable and the correct orientation of the antibodies is not ensured. Finally,
detachment of the antibody in vivo might occur.
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1.3.6 Preparation of Liposomes
1.3.6.1 Passive Loading
Over the last 60 years, numerous methods are reported for the preparation of liposomes.
On a small scale, Bangham method is the commonly employed method. In this method
the lipid film is hydrated with drug solution/suspension to encapsulate or incorporate
drug moieties.154 Usually, hydrophilic drugs should have a large encapsulated volume. On
the other hand, the encapsulation efficiency of hydrophobic drugs depends on the
quantity and quality of lipids.187,188 In an appropriate preparation method, concentration
of lipids and drugs, drug/lipid ratio, presence of functionalized lipids, pH, buffer and
process parameters play a critical role in the encapsulation efficiency of drugs.122
1.3.6.2 Active Loading: Gradient Loading Strategies
The drug encapsulation method is important in determining the in vivo stability of
liposomes. Hydrophobic drugs are usually encapsulated passively by hydration of the
lipid film with drug solution.189,190 Some therapeutic agents, including small molecules
and proteins can be complexed with charged lipid components.144,191 However, one of the
most widely used encapsulation methods employs transmembrane gradients to efficiently
load and subsequently stabilize weakly basic amphipathic drugs inside the core of
liposomes. These include: (I) simple pH gradients using citric acid solutions,192,193 (II)
ammonium ion gradients employing citrate194 or sulfate,195 (III) alkyl,196 (di-alkyl) or trialkyl ammonium salts,197 (IV) transition metal concentration gradients (Cu2+, Mn2+,
Zn2+and Mg2+)198-200 and (V) transmembrane gradients of drug solubility.201 The cation
entrapped in the liposome interior plays a role either in establishing a pH gradient across
the membrane that drives the accumulation of weakly basic drugs into the liposome
interior, or directly exchanging with the drug molecule. The counter ion plays an
important role in stabilizing the formulation to premature leakage of encapsulated drugs.
Figure 1.6 depicts an example of active loading and subsequent stabilization process of
doxorubicin using ammonium sulfate gradient method.202
Liposomal formulation of the camptothecin prodrug, irinotecan, displayed a different
pharmacokinetic behavior in lieu of the encapsulation method.203 Using manganese
sulfate gradient method, Bally et al.203 prepared irinotecan liposome formulation, whose
drug release half-life improved from 8.3 h to 56.8 h.197 The intraliposomal drug
concentration also affects the stability of liposomal drugs prepared using gradient loading
methods. At low drug/lipid ratio, doxorubicin was retained in the liposomes due to the
strength of the residual gradient in the carrier.203 A high drug/lipid ratio resulted in the
exhaustion of pH-gradient across the membrane leading to an increased leakage of the
drug. Similarly, studies with high ionic concentration gradient using ammonium sulfate
improved doxorubicin formulation stability.202 Insoluble drug precipitates formed due to
the complexation of drug and intraliposomal ions may acquire desirable zero-order
release rates. This could be due to the fact that the dissolved drug maintains constant
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Figure 1.6
Schematic representation of the liposomal loading of weak bases (A) and
weak acids (B).
In the former case, liposomal aqueous core is acidic, which causes the formation of a gellike precipitate of DXR. In the latter case, unionized MPS diffuses across the lipid
bilayers and forms an insoluble calcium-MPS complex inside the liposome core.
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equilibrium with the precipitated drug fraction of the liposomes.204 In addition, the
potency of the drug determines the selection of drug/lipid ratios for the preparation of
liposomes. Many liposome formulations display dose-dependent pharmacokinetics;
therefore, a high drug/lipid ratio will result in low lipid doses, and thus may contribute to
rapid clearance of liposomes. Even pegylated liposomes are vulnerable for fast clearance
from the body. Therefore, high drug/lipid ratios may be viable for low to moderate
potency drugs, such as the prodrugs,197 but not for potent drugs.
Low concentration of anionic lipids was shown to enhance the stability of encapsulated
drugs using transmembrane electrochemical gradient.205,206 Fluoxuridine retention
increased upon inclusion of only 20 mole% of distearoyl phosphatidylglycerol (DSPG) in
DSPC liposomes, and in a separate study, the inclusion of 15-55 mole% of DSPG in
liposomes improved the retention of vincristine using a methyl ammonium gradient.206 It
was hypothesized that the inclusion of negatively charged lipids increased the membrane
partition coefficient of weakly basic drugs and improved their retention in liposomes
maintaining a transmembrane pH-gradient. However, the presence of a negative charge at
the membrane interface in other formulations caused leakage of encapsulated drug.207
Therefore, physico-chemical properties of drugs and phospholipids play a critical role in
the selection of active loading strategy for encapsulation of drugs.
1.3.7 Liposome In Vivo Kinetics: Systemic Administration and Aerosolization
The rate of in vivo drug release is an extremely important parameter since it influences
the rate of clearance of the drug from the general circulation, bioavailability, and activity
of the drug at its site of action and targeting ability of the drug.122 In vivo encapsulated
drug concentration can be determined either directly by measuring purified liposomal
drug in plasma197,208 or indirectly by assuming that the clearance rate of the
unencapsulated drug is sufficiently faster than the clearance rate of the liposomes (by
simply following changes in the plasma drug-to-lipid ratios). 197 However, challenges
pose for hydrophobic drugs that demonstrate significant protein binding. For some drugs,
the rate of in vivo drug release can be controlled by manipulation of physico-chemical
properties of the liposomes.
Different applications may require distinct release kinetics and different particles sizes.209
Following an intravenous injection, the first capillaries to be encountered by a delivery
vehicle are in the lung tissue, which tends to mechanically entrap large particles, such as
multilamellar vesicles (MLVs). The lung thus represents a unique site for drug delivery if
large liposomes are employed, but care has to be taken to avoid pulmonary emboli.
Administration of liposomal formulations to the epithelial cells in the lower airways of
the lung by nebulization requires smaller particles ( 300 nm) that are in the respirable
range.210 To deliver imaging agents, a rapid burst will achieve maximum contrast
between the circulation system and the target tissues.
The „„first pass‟‟ organ to be encountered after systemic administration is the liver, which
can thus be targeted with fast-release liposomes. Large vesicles are generally more
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rapidly eliminated from the bloodstream, whereas small ones circulate for longer,
especially those with neutral or positively charged, rigid bilayers. Liver, lung and spleen
may be circumvented using stealth liposomes. Usually, liposomes do not pass through the
endothelial barrier of the vascular system; however, under pathological conditions, small
particles (<100 nm) are able to extravasate through the poorly formed neovasculature of
some solid tumors.211 Regardless of the circulation time of an intravenously injected
liposomal dose, the majority will eventually be taken up by the mononuclear phagocyte
system. Using alternate parenteral routes, such as intraperitoneal, subcutaneous or
intramuscular, large liposomes generally tend to be retained longer at the site of injection,
while small ones are mainly taken up by the draining lymph system.
Aerosolized liposomal preparations became a feasible route for delivering drugs to the
lung. A combined aerosol of liposomal paclitaxel and cyclosporin A achieved better
results in the treatment of pulmonary metastases of renal-cell carcinoma.212 Spray-dried
liposome powder formulations were used as carriers for superoxide dismutase (SOD).213
Improved delivery of rifampicin by aerosolized liposomes to alveolar macrophages might
become significant in the treatment of tuberculosis.214 Aerosolized liposomal budesonide
is effective against experimental asthma in mice.215 Aerosol formulations of liposomal 9nitrocamptothecin are non-toxic, and efficiently treated melanoma and lung metastases in
mice.216 Liposomal paclitaxel in aerosol effectively treated pulmonary metastases in a
murine renal carcinoma model.217 Nebulization was recently proposed as a means to
deliver liposomal aerosols.218
1.3.8 Liposomes: Clinical and Diagnostic Applications
Recent advances in liposome technology have led to the development of “stealth
liposomes” whose prolonged circulation lifetime improved the therapeutic benefits. For
cancer and inflammation diseases, therapeutic potential could be improved by receptor
specific targeting and cell specific delivery of therapeutic moieties. Despite some
progress, one of the current challenges is the targeting specificity and affinity of the
binding motif to the disease sites. In an ideal targeted delivery system, high binding
specificity avoids adverse effects to the surrounding tissues within the vessel and/or
downstream of the injury site, while high binding affinity enables competition with
natural ligands. As targeted liposomal drug delivery systems are now becoming feasible,
it offers significant potential for local delivery of anti-cancer, anti-inflammatory, anticoagulants.
In addition to clinical applications, liposome formulations are used for as contrast agents
for experimental diagnostic imaging of liver, spleen, brain, cardio-vascular system,
tumours, inflammation and infections. Gamma-scintigraphy, near infrared fluorescence
imaging (NIRF) and magnetic resonance imaging (MRI) require a sufficient quantity of
radionuclide or fluorescent dye or paramagnetic metal to be associated with the liposome.
There are two possible routes to improve the efficacy of liposomes as contrast mediums
for gamma-scintigraphy or MRI or NIRF: I) increasing the quantity of carrier-associated
marker and II) enhancing the signal intensity. To increase the load of liposomes with

27

reporter metals, amphiphilic chelating polymers, such as N,α-(DTPA-polylysyl)glutaryl
phosphatidyl ethanolamine were introduced. These polymers easily incorporate into the
liposomal membrane and markedly increase the number of chelated Gd or In atoms
attached to a single lipid anchor. In the case of NIRF, fluorescent dyes are incorporated
into the lipid bilayers of liposomes. Imaging approach using contrast liposomes allows
the visualization of pathological areas. Liposomes loaded with imaging agents are also
used for the in vivo monitoring of tissue pharmacokinetics of liposomal drugs.
1.3.9 Stability of Liposomes
The shelf-life of liposomes is determined by physical and chemical aspects of
liposomes.122 Physical processes, such as aggregation and fusion result in loss of
liposome encapsulated drug and changes in size. In principle, this process is reversible;
however, fusion of liposomes further triggers coalescence of liposomes. As coalescence is
an irreversible process, liposomes cannot be retrieved.
1.3.9.1 Physical Stability
Stable liposome suspensions require a repulsive interaction that is at least comparable to
the magnitude and range of vander Waals forces.219,220 Repulsive interactions at the
surface of liposomes are a function of: I) electric potential (zeta potential, ) at the plane
of shear and II) surface charge density ( ). The zeta potential is calculated from
electrophoretic mobility by Equation 1.1154,221
ζ = η/εoεr

Equation 1.1

The surface charge density calculation is based on Gouy-Chapman double layer
theory.222-225 The theory is applicable to unabsorbed particle surfaces. However, ions
adsorb on the surface of liposomes giving rise to a Stern layer so that the double layers
must be described by the Gouy-Chapman-Stern theory (Figure 1.7).225 Later on, the
problems associated with the distortion of the electrical double layers due to the motion
of the charged liposomes (e.g. PE/PEG-PE liposomes) and the influence of surface
conductivity on electrophoretic mobility superceded the Gouy-Chapman-Stern theory
with Derjaguin-Landau-Verwey-Overbeek (DLVO) theory.
Jones223 stated that the classic DLVO model is applicable for determining the stability of
liposomes, considering that many of the physico-chemical properties of liposomes
resemble that of conventional colloidal particles. The total interaction potential is a
function of the repulsive and the attractive components. The short range attractive forces
between liposomes are of van der Waals forces, while the long range repulsive forces are
electrostatic repulsive forces. These forces are calculated using the Poisson-Boltzmann
equation. The repulsive force arising from the overlap of the electrical double layers
surrounding charged liposomes is the main reason for the stability of liposome
dispersion.226 The electrical forces increase exponentially as liposomes approach one
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Figure 1.7
theory.

Schematic diagram of the Gouy-Chapman-Stern diffuse double layer

The theory states that ions do have finite size so cannot approach the surface closer than a
few nm. The first ions of the Gouy-Chapman diffuse double layer are not at the surface,
but at some distance away from the surface. This distance will usually be taken as the
radius of the ion. According to Stern, it is possible that some of the ions are specifically
adsorbed by the surface in the plane of shear and this layer has become known as the
Stern Layer. The potential at the OHP is considered as the zeta potential. The double layer
is formed in order to neutralize the charged surface, and in turn causes an electrokinetic
potential between the surface and any point in the mass of the suspending liquid. This
voltage difference is on the order of millivolts, and is referred to as the surface potential.
The magnitude of the surface potential is related to the surface charge and the thickness
of the double layer. From the surface, the potential drops off linearly in the Stern layer
and then exponentially through the diffuse layer, approaching zero at the imaginary
boundary of the double layer. The potential curve indicates the strength of the electrical
force between the particles and the distance. The particle (liposome) mobility is related to
the dielectric constant and viscosity of the suspending liquid, and to the electrical
potential at the boundary between the moving particle and the liquid.
Adapted with permission. Jones, M.N. The surface properties of phospholipid liposome
systems and their characterisation. Adv Colloid Interface Sci 54, 93-128 (1995).223
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another, and the attractive forces increase as an inverse power of separation. Other forces
also contribute to the interaction between liposomes. Addition of other interactions
expands the DLVO model to an extended DLVO interparticle model. According to the
extended DLVO theory, the total force (FT) between the liposomes is given by Equation
1.2:
FT = Fvdw-Fhfo+Fest+Fund+Fhgd+Fsteric

Equation 1.2

As described previously, Fvdw and Fest represent van der Waals and double layer repulsive
forces between colloidal particles.225 For neutral liposomes e.g. EPC liposomes, the
bilayers can approach within the order of 5-20 nm, and under these conditions, the
repulsive hydration force (Fhgd) is the major repulsive interaction between lipid bilayers.
At small separations, a repulsive interaction may arise from out of plane motions or
undulations which give rise to an undulation force (Fund). Fund is only of importance for
fluid bilayers, e.g. egg lecithin bilayers account for approximately 25% of the van der
Waals forces.227 The hydrophobic force (Fhfo) is a long-range force and operates at a
greater distance than Fvdw.228
The electrophoretic mobility of PEGylated liposomes is very low when compared to nonpegylated liposomes, and the electrophoretic mobility show little variation with DSPEPEG levels of liposomes in the range 5-10 mole%. The inclusion of CHOL has little or no
effect on the mobility. The low electrophoretic mobility corresponds to low zeta
potentials. For PEGylated liposomes, a steric force will arise when the surface polymer
chains interact. Several theoretical approaches to the interaction between surfaces with
adsorbed polymers were proposed.229-231 There are two limiting cases of repulsive forces;
at low polymer density where the polymer separation exceeds the polymer coil size
('mushroom model'), and at high polymer density when the polymer chains take up
extended conformations ('brush model'). It is noted that bridging between two polymer
coated surfaces involves polymer interdiffusion and entanglements that lead to attractive
interaction.232-234 Needham et al.235 reported that steric stabilization is a result of the
combination of electrostatic and steric forces.
The electrostatic component results from a net charge on the liposome surface and/or the
charge associated with the adsorbed polymer (e.g. PEG chains). And the steric component
arises from the chain-chain exclusion of adsorbed polymeric material on one surface from
the other surface. The coalescence kinetics in colloidal systems was performed by von
Smoluchowski.236, 237 The total number of vesicles at time t, N may be approximated by
Equation 1.3:
N = 6φ/πd3

Equation 1.3

Where d is vesicle diameter and φ is the liposome volume fraction. For liposome
systems, the entrapped aqueous volume is estimated by NVOL method.238 The aggregation
process in colloidal systems is a second-order process. Mean diameter (Dt) of liposomes
at time, t is determined from Equation 1.4:
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Dt = [d3+(6kφ/π)t]1/3

Equation 1.4

Where d0 is the initial vesicle diameter at t = 0 and Dt is the liposome diameter at time t.
From DLS studies, mean liposome diameters can be estimated. By plotting d3 versus
time, we can calculate the rate constant for aggregation, k = 6kφ/π.
1.3.9.2 Chemical Stability
As phospholipids form the backbone of the bilayer, their chemical stability is important.
Two types of chemical degradation reactions affect the performance of phospholipid
bilayers: hydrolysis of the ester bonds linking the fatty acids to the glycerol backbone and
peroxidation of unsaturated acyl chains. The oxidation and hydrolysis of lipids may lead
to the appearance of short-chain lipids, and then soluble derivations will form in the
membrane resulting in the decrease of the quality of liposome products. The chemical
stability of liposomes is improved by inclusion of anti-oxidants, such as -tocopherol and
saturated phospholipids.
1.3.10 Lyophilization: Stabilization of Liposomes
Lyophilization of liposomes can prevent hydrolysis of the phospholipids and physical
degradation of liposomes during storage. In addition, it may stabilize the particle size and
leakage of drugs encapsulated inside the liposomes. Lyophilization of liposomes results
in an elegant dry cake, which can be reconstituted to obtain the original liposomal
suspension. On the other hand, the lyophilization process may induce physical changes in
liposomes, such as leakage of the encapsulated drug and changes in the vesicle size. The
interaction between the hydrophilic phospholipid head groups and water molecules plays
a key role in the formation of liposomal bilayers. Thus, removing water from the
liposomes by lyophilization presents a challenge. Evidence suggests that excipients, such
as disaccharides (e.g. sucrose and trehalose) protect the liposomes during the
lyophilization process (lyoprotectants).239 As illustrated in Figure 1.8, lyophilization
process is comprised of three phases: (I) freezing cycle, (II) primary drying and (III)
secondary drying. The parameters of each phase depend on the selected formulation. In
the freezing phase, buffer components and lyoprotectants form an amorphous matrix in
and around the liposomes that prevents fusion, and protects the liposomes against rupture
due to the growth of ice crystals. As the temperature of the frozen matrix is lowered, the
viscosity of the frozen matrix increases, until it forms a glass with low molecular
mobility. The temperature at which this occurs is called Tg‟, glass transition temperature
of the frozen matrix. The Tg‟ is a function of frozen matrix composition, but liposomes
do not contribute to the value of Tg‟.241,242 The freezing cycle carried at a slow rate
allows formation of pores and facilitates sublimation during primary drying phase. This
in turn minimizes the leakage of contents from liposomes after rehydration of the
lyophilized sample. Another option to increase water evaporation at the sublimation front
is annealing process.
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Figure 1.8

Schematic representation of different stages of a lyophilization cycle.

It describes the relation between the product‟s (green solid line)/shelf (blue solid line)
temperatures to the chamber pressure inside the lyophilizer. The product is frozen below
the glass transition temperature of the amorphous product matrix (Tg‟). Primary drying is
also carried below Tg‟ to avoid product cake collapse and crystallization of the product
matrix. Secondary drying is performed to remove residual moisture of the product.
Vacuum during the primary drying is usually 100-300 mTorr and 50 mTorr in secondary
stage.
Adapted with permission. Gea, G.H. Thermodynamic Lyophilization Control-TLC.
Process Analytical Technology 12, 1-9 (2008).240
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Crystallization of the ice can be optimized further by „„annealing‟‟ of the frozen samples:
the samples are heated to a temperature above Tg‟ and are cooled again before the start of
the lyophilization process. The energy that becomes available for the frozen matrix may
induce further crystallization of unfrozen water in the amorphous matrix
(„„devitrification‟‟). In addition, small crystals may re-crystallize into larger ones. The
result of annealing is often an increase in sublimation rate during primary drying.243 In
addition, liposomes may be better protected against lyophilization stress. The effect of
annealing may depend on the specific formulation (e.g., excipients, lipid composition,
and vesicle size).244
During primary drying, the ice crystals are sublimated, resulting in the porous cake
structure of the freeze-concentrated matrix. The temperature at the sublimation front is
maintained 5 C below Tg‟. The product temperature at the sublimation front is
determined by local pressure, according to the ice vapor pressure-temperature. The set
point of the chamber pressure is chosen at a value that corresponds to an ice temperature
of about 4 C below Tg‟. The shelf temperature should be higher than the ice temperature
in order to transfer the heat to the sublimation front for drying. The driving force of the
drying process is the difference in temperature, and therefore, difference in water vapor
pressure between the condenser of the lyophilizer and the sublimation front. Heat transfer
from the shelf to the sublimation front occurs via conduction by glass and ice as well as
by gas molecules.245 In conclusion, careful control of chamber pressure and shelf
temperature as well as knowledge of the sample Tg‟ are prerequisites for successful
lyophilization.
In the secondary drying phase, the residual water content of the amorphous matrix is
further decreased. Followed by the primary drying phase, when the product temperature
approaches the shelf temperature, the secondary drying phase can be initiated. In the
secondary drying phase, the pressure is reduced to a minimal value and the shelf
temperature can be gradually increased. Reduction of the water content of the cake occurs
during primary drying, but the cake is further dried to <1% w/w of the total moisture
content. Reduction of the water content increases the glass transition temperature (Tg) of
the cake, and this allows for a gradual increase in shelf temperature. The shelf
temperature is a key parameter for obtaining low residual water content. Vials can be
closed under vacuum or after (partially) releasing the vacuum with nitrogen gas or argon.
The optimal liposome size for high retention of a water soluble compound after freezedrying is 0.1–0.2 m.246 Rigid liposomes are more vulnerable to high cooling rates
(0.5 C/min) than liposomes with flexible bilayers, but give a high retention (70–90%
w/v) of the encapsulated hydrophilic compounds. Rigid liposomes are usually composed
of saturated phospholipids. Addition of CHOL (e.g. 30 mole% of the total lipid content)
may increase the resistance of liposomal bilayers to lyophilization stress. Lyoprotectants
form an amorphous, glassy matrix in and around the liposomes. Interaction between the
lyoprotectant and the phospholipid head groups is important for preventing leakage
during rehydration of liposomes.247 Recently, a different mechanism247-249 was proposed
by which sugars may reduce the stress on bilayers during drying. Bilayers dried without
lyoprotectant approach each other and the suction of water by the phospholipid causes a
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lateral compressive stress. The mere presence of a glass between adjacent bilayers during
drying provides spacing between the bilayers, and in combination with the attraction of
water by the sugars (osmotic properties), the compressive stress on the bilayers is
reduced. The preferred lyoprotectants are disaccharides, such as sucrose and trehalose.
Trehalose has a high Tg (100-115 C) in the dried state (<0.5% w/w residual water) than
sucrose (70 C), which may be an advantage for the storage stability of the dried product.
Lyoprotectants provide optimal protection of the liposomes if present at high
sugar/phospholipid ratios. In addition, the lyoprotectant should be present on both inside
and outside the liposomes.250 A total solute concentration of more than 30% w/v may
hinder the drying process. The use of crystallizing excipients, such as glycine and
mannitol is not recommended for the lyophilization of liposomes.251 A crystalline
excipient can facilitate the primary drying process and improve the appearance of the
freeze-dried cake. However, the successful use of crystalline excipients for the
lyophilization of liposomes is not reported so far, and the lack of an amorphous phase in
and around the liposomes may damage the bilayers. The use of low molecular weight
excipients, such as sodium chloride, glucose and amino acids should be minimized. Such
excipients lower the Tg‟ of the freeze-concentrate and further, the Tg of the lyophilized
cake. A low Tg‟ requires lyophilization at a low product temperature, which is an
inefficient process. A decrease in product temperature of 5 C may double the primary
drying duration.
An acceptable shelf-life is a pre-requisite for successful introduction of liposome
formulations into therapy. With advances in formulation and lyophilization process
research, the shelf-life of the specialized targeted liposomes could be improved.
1.4

Summary and Rationale

Pulmonary edema, pro-inflammatory mediators‟ production and leukocyte migration are
the hallmark features of acute lung injury. In the current investigation, human ALI
features were mimed in IL-1 stimulated rat model. Pulmonary edema and leukocyte
migration are mediated via v 6 integrin and ICAM-1 receptors upregulated on alveolar
epithelium or endothelium, respectively. This poses a serious challenge to find a common
ground for targeting to each of the receptors. Citing a spatial and disparate expression of
receptors, the current problem was addressed using different targeting motifs
administered by nebulization and systemic routes of administration. In response to IL-1
stimulation, v 6 integrins of alveolar epithelium interact with RGD domain of the LAPTGF- complex inducing an increase in permeability across alveolar epithelium.
Therefore, RGD sequence was identified as the targeting motif to intervene the
interaction of v 6 integrins with LAP-TGF- complex.
Our first strategy is to utilize the cRGD-peptide as the targeting motif on the liposome
surface. Due to the apical expression of v 6 integrins on the alveolar epithelium, MPSLcRGD were nebulized to exert direct impact on epithelium for inhibition of pulmonary
edema. Also, ICAM-1 receptors are upregulated on alveolar endothelium to aid in the
neutrophil migration into alveoli during ALI. An anti-ICAM-1 antibody might disrupt the
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interaction of ICAM-1 receptors with 2 integrins of neutrophils, and thus impedes
neutrophil migration. Our second strategy is to conjugate antibody on the MPS
encapsulated liposomes to target ICAM-1 receptors, which are accessible by systemic
administration. Both the strategies deliver MPS to the targeted tissues for inhibition of
pro-inflammatory cytokine and chemokine production. Each of these strategies has the
potential to modulate ALI pathogenesis. The success of the strategies depends on the
answers of the following central questions: (I) how efficient are the conjugation reactions
of MPS-LcRGD and MPS-LAb, (II) how efficient are the MPS-LcRGD and MPS-LAb to
interact with their counter receptors, (III) how efficient are the MPS-LcRGD and MPS-LAb
to internalize in the targeted cells and (IV) how stable are the MPS-LcRGD and MPS-LAb
in vitro and in vivo. Through addressal of each of these critical issues, the underlying ALI
pathogenesis can be resolved.
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CHAPTER 2. CENTRAL HYPOTHESIS AND SPECIFIC AIMS
2.1

Central Hypothesis

The overall goal of the proposed research is to reduce inflammation associated with ALI.
To achieve the goal, I propose to design new liposome drug delivery systems that
selectively target and deliver methylprednisolone succinate to the inflamed alveolar
epithelium and endothelium. It is well accepted that RGD domain and ICAM-1 receptors
play a critical role in mediating pulmonary edema and neutrophil migration respectively.
Based on this, the proposed research is focused on the design and development of
liposomes that utilize the cRGD-peptide and anti-ICAM-1 antibody tethered to the
liposome surface as the targeting motifs. The proposed research is based on the central
hypothesis that “methylprednisolone succinate encapsulated targeted liposomes bind to
integrin or ICAM-1 receptors and modulate ALI pathogenesis”.
Completion of these studies provided a promising drug delivery system for receptor
mediated inflammatory diseases.Therefore, in order to test the hypothesis, I propose the
following specific aims:
2.2

Specific Aims

2.2.1 To Develop MPS Encapsulated Targeted Liposomes
The purpose of this specific aim was to prepare MPS encapsulated liposomes, surface
modified by cRGD-peptide and anti-ICAM-1 antibody. In the former case, (DSPEPEG2000-maleimide)-cRGD-peptide conjugate was synthesized by Michael addition
reaction and the conjugate was incorporated into MPS encapsulated liposomes by postinsertion method. In the latter case, anti-ICAM-1 antibody was fragmented, and the
generated mFab‟ fragments were coupled to the distal ends of MPS encapsulated
liposomes. Since stable colloidal properties of liposomes are critical for the application,
size distribution and zeta potential of the prepared liposomes were characterized by
dynamic light scattering studies.
2.2.2 To Lyophilize and Develop Stable MPS Encapsulated Targeted Liposomes
The purpose of this specific aim was to improve the shelf-life of the targeted liposomes.
MPS-LcRGD and MPS-LAb formulations were prepared in the presence of intra and
extraliposomal lyoprotectants. The formulations were then subjected to lyophilization
process to preserve the liposomes as dry powder. As a result of lyophilization, the original
liposome properties were retained with minimal or no damage to the reconstituted
liposomes.
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2.2.3 To Modulate Pulmonary Edema via MPS-LcRGD Targeting to v 6 Integrins
An IL-1 instilled rat ALI model was used to investigate the effect of MPS-LcRGD on
pulmonary edema. MPS-LcRGD were nebulized to bind to v 6 integrins of alveolar
epithelium and inhibit pulmonary edema. Simultaneously, the effect of MPS on inhibition
of pro-inflammatory mediators production was investigated. BALF samples were
collected for analysis of protein, cytokines, chemokines and neutrophils.
2.2.4 To Impede Neutrophil Migration via MPS-LAb Targeting to ICAM-1 Receptors
MPS-LAb were targeted to ICAM-1 receptors of alveolar endothelium to attenuate
neutrophil migration into alveoli. In this study, MPS-LAb were administered by
intravenous route prior to IL-1 instillation in rats. MPS-LAb disrupt the interaction of 2
integrins of neutrophils with endothelial ICAM-1 receptors, and thereby attenuate
neutrophil migration. BALF samples were collected for analysis of neutrophils and
protein content.

37

CHAPTER 3. HPLC METHOD FOR DETERMINATION OF LIPIDS IN
LIPOSOMES
3.1

Introduction

Liposomes are lipid vesicles prepared by dispersing lipids in an aqueous phase.
Liposomes were used as a carrier of drugs.252 One of the most significant advantages of
using liposomes as a drug delivery carrier is the reduced toxicity and improved
therapeutic efficacy. While different lipids could be used for formulating drugs in
liposomes; invariably most formulations contain phospholipids and CHOL. Most
commonly used phospholipids are egg phosphatidylcholine, hydrogenated soy
phosphatidylcholine, 1, 2-distearoyl-sn-glycero-3-phosphocholine and 1, 2-dipalmitoylsn-glycero-3-phosphocholine. Several liposome formulations contain different anticancer agents, e.g., paclitaxel, doxorubicin and amphotericin.253, 254 These formulations
contain HSPC, CHOL and α-tocopherol in product-specific ratios. There are several
reported high performance liquid chromatography (HPLC) methods in the literature that
use silica columns with UV detection, wide and varied mobile phase compositions of
organic solvents (acetonitrile, hexane, methanol and isopropanol) and water for detection
and estimation of phospholipids.255,256 Separation of several classes of phospholipids was
achieved using silica column by gradient elution with hexane-isopropanol-water mobile
phase.257,258 While estimation of CHOL and other phospholipids in liposome formulation
has been reported,259,260 some methods require lipid extraction from samples prior to
injecting into HPLC system,261 whereas others use complicated gradient elution for
separation.259 Recently, evaporative light scattering detection (ELSD) has been used for
estimation of CHOL and other phospholipids in liposome based formulations.262 While
the methods that use ELSD are considered universal, they are cumbersome to reproduce,
calibration of standards require non-linear regression analysis due to varying sensitivity
of the detector and often give results with high variations compared to UV detection
methods. In this report, we describe a rapid HPLC method for separation and
simultaneous estimation of HSPC and CHOL components of liposome formulations. This
method uses a C8 column, isocratic mobile phase and UV detection at 205 nm. The
results generated show that this method can also be used to quantitate α-tocopherol, an
anti-oxidant used in liposome formulations.
3.2

Experimental Section

3.2.1 Materials
CHOL used for calibration standard was purchased from National Institute of Standards
and Technology (NIST, Gaithersburg, MD). HSPC and CHOL were purchased from
Avanti Polar Lipids (Alabaster, AL) and were of research grade. Anti-oxidant, αtocopherol was purchased from Sigma (St.Louis, MO). HPLC grade methanol, water,
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monobasic ammonium phosphate and 85% w/v phosphoric acid (H3PO4) were purchased
from Fisher Scientific (Suwannee, GA).
3.2.2 Methods
3.2.2.1 High Performance Liquid Chromatography
The HPLC system was equipped with Waters Alliance System (Waters®, Milford)
consisting of vacuum degasser, temperature controlled well-plate auto-sampler, column
thermostat, quaternary pump and photo diode array detector. Chromatographic analysis
was performed using a Hypersil BDS C8 (15 cm×4.6 mm i.d., 5 µm particle size, 80°A
pore size) column (Alltech, Deerfield, IL) at column temperature, 60 C. The analytical
column was protected with a disposable pre-column (Alltech, Deerfield, IL). Mobile
phase flow rate was set to 1.0 mL/min with a run time, 30 min. The diode array detector
was operated at 205 nm with 4 nm of bandwidth and slit setting, off reference mode and 2
s response time setting. Injection volume was set at 50 µL. An isocratic mobile phase
containing 50 mM solution of ammonium phosphate buffer (pH 3.0)-methanol (15:85 %
v/v) was used.
3.2.2.2 Preparation of Reagents
Ammonium phosphate buffer (50 mM, pH 3.0) was prepared by dissolving ammonium
phosphate in water and adjusting the pH to 3.0 with 85% w/v H3PO4. The clear solution
was filtered through a 0.45 µm nylon membrane filter and stored at room temperature.
Mobile phase was prepared by mixing the buffer solution and methanol in 15:85% v/v.
Standard stock solutions of CHOL (1.0 mg/mL) and HSPC (2.0 mg/mL) were prepared
using methanol. Intermediate stock solutions were prepared by mixing the stock solutions
of CHOL and HSPC in the product-specific ratio to bracket the target concentration for
analysis. Calibration standards were prepared by further diluting the intermediate
solution. Five levels of calibration standards were prepared by diluting the intermediate
solution. Mobile phase was used as diluent for intermediate and calibration standard
solutions. The calibration standards used for liposome based MPS analysis were prepared
in the range of 20-200 and 40-400 µg/mL for CHOL and HSPC, respectively. For other
drug formulations, similar preparations were made based on the lipid ratio in the
particular formulation.
3.2.2.3 Preparation of Liposome Formulations for HPLC Analysis
Liposome based formulations were prepared as described elsewhere. The samples for
HPLC injections were prepared by diluting the liposome formulations with mobile phase.
To bring the concentration of the samples into the calibration range, the required dilution
depends on the expected concentration of CHOL and HSPC in samples.
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3.3

Results and Discussion

The HPLC method described here was developed for estimation of CHOL and HSPC
(Figure 3.1) following the FDA and international conference on harmonization of
technical requirements for registration of pharmaceuticals for human use (ICH)
guidelines.263,264 Linearity, accuracy, precision, specificity, quantitation limit and
robustness of the method were tested to ensure that the method is suitable for
identification and quantitation of CHOL and HSPC components of liposome
formulations. Chromatographic performance data for a typical run are presented in Table
3.1. Resolution of 2.0 or greater is desired for critical band pair. Critical resolution of
2.543 was observed between CHOL and HSPC peaks. Tailing factors for both CHOL and
HSPC are <1.20. Retention factor in the range of 0.5<k‟<20.0 is desired to separate the
first peak from void time and to avoid higher retention time for the last band. Retention
time of 4.316 and 6.205 were found for CHOL and HSPC, respectively. Retention factors
of the CHOL and HSPC peaks were optimized by varying the mobile phase composition.
However, it was necessary to increase column temperature to 60 C to achieve acceptable
resolution between critical band pair of CHOL and HSPC.
3.3.1 Linearity and Range
Linearity of the calibration standards was tested in the concentration rage, 20.0-200.0 and
40.0-400 µg/mL for CHOL and HSPC, respectively. Five levels of calibration standards
were prepared at various concentration levels. Correlation coefficients (r) were found to
be >0.999 for both CHOL and HSPC (Table 3.2). Typical chromatogram of a standard
solution is shown in Figure 3.2.
3.3.2 Accuracy
The accuracy study was performed to determine the closeness between the true
concentration value and the experimental results. CHOL and HSPC were spiked into the
excipients that include other lipids, anti-oxidant and MPS, expected to be present in the
formulations. Spike recovery was performed at three levels (500, 100 and 150%) of the
target concentration. For each level, three preparations were performed. Table 3.3
summarizes the results from accuracy experiments. Average recovery of 99.80 and
100.14% were observed for CHOL and HSPC, respectively, which is within ±2.0% of
normally accepted value.
3.3.3 Precision
Instrument precision was performed as part of each sequence run at the beginning of the
sequence. Six injections of the target level of calibration standard were performed and the
data were evaluated. Table 3.4 shows the mean retention and area response for both
CHOL and HSPC. Relative standard deviations (RSDs) for both CHOL and HSPC are
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Figure 3.1

Chromatogram of calibration standards of CHOL and HSPC.

Table 3.1

Chromatographic performance data of the method.
Analyte Retention time (min) Tailing factora Retention factorb Plate countc
CHOL
HSPC

4.316
6.205

1.025
1.206

7.362
11.41

a

5440
6826

Resolution between
critical band pair
2.543
-

Tailing is defined as W0.05/2tw, where W0.05 is peak width at 5% of peak height (min), tw is distance between peak front and peak
retention measured at 5% of the peak height (min). bRetention factor is defined as (tR-t0)/t0, where tR is retention time of peak (min)
and t0 is void time (min). Void time = 0.5 min for the method. cPlate count is defined as 16(tR/WB)2, where WB is the tangent peak
width (min).
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Table 3.2

Summary of linear regression data for calibration standards.
Analyte
CHOL
HSPC

Figure 3.2

Intercept
6.641
3.689

Slope
11.239
5.604

Linear regression parameters
Correlation coefficient (r)
Coefficient of determination (r2)
0.99998
0.99995
0.99999
0.99999

Typical chromatogram of linearity of standards containing CHOL and HSPC.
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Table 3.3

Summary of method accuracy results.

Analyte
CHOL
HSPC
a

Recovery solution at
target level (%)
50
100
150
50
100
150

Theoretical
concentration ( g/mL)
81.95
163.900
245.850
112.682
225.363
338.044

Recovered average
concentration ( g/mL)
81.73 (0.449)
163.71 (0.507)
245.651 (0.598)
112.931 (0.416)
225.509 (0.683)
338.540 (0.543)

RSD (%)
0.268
0.115
0.080
0.220
0.100
0.146

Results are based on six data points. Standard deviation is given in parenthesis.

Table 3.4

Summary of method precision results.
Analyte Average concentrationa (mg/mL) RSD (%)
Day 1
CHOL
22.433 (0.276)
1.16
HSPC
31.692 (0.730)
0.216
Day 2
CHOL
21.887 (0.050)
0.096
HSPC
31.888 (0.307)
1.075
Between days 1 and 2 CHOL
22.705 (0.236)
0.919
HSPC
31.609 (0.367)
1.245

a

Based on 12 data points. Standard deviation is given in parenthesis.
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Analytical
recoverya (%)
99.73
99.88
99.91
100.22
100.06
100.14

<2.0%, which indicates sufficient instrument reproducibility of the method. For sample
precision measurements, six replicate samples were prepared and analyzed on the first
day. For each sample preparation, three injections were performed. On the second day,
the same analyst prepared a second set of six samples from the same sample vial and
independently analyzed on the same system. The RSD values are found to be <2.0% for
both CHOL and HSPC on each day and <2.0% between days 1 and 2. These results
clearly indicate sufficient sample repeatability with this method.
3.3.4 Quantitation Limit
There are at least four different ways to determine quantitation limits of analyte, and
signal-to-noise ratio (S/N) is one of the most commonly used procedures. We used this
procedure for determining quantitation limits of CHOL and HSPC. Stock solutions of
individual lipid components, CHOL and HSPC were progressively diluted and signal-tonoise ratios for CHOL and HSPC were determined until a minimum S/N ratio of 10 was
achieved. Quantitation limits of 0.5 and 10.0 µg/mL were observed for CHOL and HSPC,
respectively. Previously, a detection limit of 1.5 µg/mL was reported for CHOL in
liposome formulations.256
3.3.5 Robustness
Robustness is the capacity of a method to remain unaffected by small, deliberate
variations in method parameters and measures reliability of the method. To test the
robustness of the method, we deliberately varied four parameters, pH of the buffer,
column temperature, mobile phase composition and flow rate. The buffer solutions with
pH values of 2.8, 3.0 and 3.2 were used to study the effect of pH variation on the
performance of the method. With each variation of buffer pH, analysis of a sample
solution was performed and the chromatographic results were evaluated. Data were
collected at three column temperature settings, 58, 60 and 62 C to study the effect of
column temperature variation on the performance of the method. With each variation of
column temperature, analysis of a sample solution was performed and the
chromatographic results were evaluated. The mobile phase flow rates were set at 1.3, 1.5
and 1.7 mL/min to study the effect of mobile phase flow rate variation on the
performance of the method. Three different mobile phase compositions (13:87, 15:85 and
17:83 (v/v) of buffer-methanol) were used to study the effect of varying the mobile phase
composition on the performance of the method. Robustness data from the above
experiments are summarized in Table 3.5. The retention times for both CHOL and HSPC
decreased with increasing column temperature, mobile phase flow rate and pH of the
buffer, which is expected. The chromatographic performance of the method does not
change significantly. The retention times for CHOL and HSPC increased with increasing
polarity of the mobile phase composition. However, it is important to note that the overall
performance of the method remained unaffected.

44

Table 3.5

Summary of robustness of the method.
Critical
resolution

Parameters

Tailing factor
CHOL

Column
temperature ( C)
Flow rate
(mL/min)
Mobile phase
Buffer pH

HSPC

Plate count

Overall RSDa (%)

Correlation
coefficient (r)
CHOL
HSPC

CHOL

HSPC

CHOL

HSPC

6026

7136

1.24

1.36

0.99992

0.99978

58

3.68

1.02

60
62

3.60
3.40

1.02
1.04

1.24
1.23

5884
5436

6927
6638

0.98
1.69

0.41
0.38

0.99988
0.99975

0.99989
0.99971

1.3

3.66

1.02

1.23

5997

7206

1.85

1.47

0.99984

0.99963

1.5
1.7
13:87
15:85
17:83
2.8
3.0
3.2

3.60
3.38
3.45
3.60
4.25
3.38
3.60
3.36

1.02
1.03
1.03
1.02
1.02
1.04
1.02
1.04

1.21
1.21
1.21
1.21
1.22
1.22
1.22
1.22

5883
5513
5201
5884
4986
5115
5884
4970

6927
6505
6498
6927
6334
6728
6928
6725

0.87
0.65
1.74
0.89
1.60
1.29
0.71
0.80

0.94
1.02
1.15
1.62
0.71
0.68
0.95
1.09

0.99996
0.99977
0.99983
0.99993
0.99971
0.99987
0.99992
0.99986

0.99981
0.99978
0.99984
0.99993
0.99987
0.99975
0.99989
0.99977

a

For each sequence run, a calibration standard solution was injected at the beginning of the sequence, after the five levels of
calibration standards (two injections) and at the end of the sequence (two injections) to verify the system suitability of the overall run
sequence. The %RSD data are based on the response (area) of these 10 system suitability injections for each run.
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3.3.6 Conclusions
A rapid isocratic HPLC method for simultaneous quantitation of CHOL and HSPC in
liposome formulations was developed. The method is linear, precise, accurate, sensitive,
robust and specific for quantitation of CHOL and HSPC in liposome formulations. In
addition, this method is applicable to several of the liposome formulations for
quantitation of CHOL and HSPC, and does not require preprocessing of the samples. This
method also improved the quantitation limits of CHOL compared to other reported
methods.
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CHAPTER 4. MPS ENCAPSULATION AND SURFACE MODIFICATION OF
LIPOSOMES
4.1

Introduction

Methylprednisolone sodium succinate treatment is widely used in the treatment of
inflammatory diseases.85,265 MPS is more effective anti-inflammatory agent than are nonsteroidal anti-inflammatory drugs. However, the systemic administration of MPS is often
accompanied by substantial side effects, especially when long-term treatment is used.
Due to the fast clearance of MPS from the body, frequent high-dose intravenous (i.v.)
and/or oral administration is required to achieve efficacy, but this affects many tissues
and causes serious side effects. Therefore, improvement of the therapeutic efficacy would
be beneficial. A systemic “targeted” administration will bring the MPS selectively to the
inflamed areas and increases the therapeutic index of MPS. This can be achieved by MPS
delivery via liposomes. Although, MPS delivery via liposomes is one of the earliest
attempts to use liposomes as drug carriers, until now no liposomal MPS formulation has
reached clinical application. A systemic liposome formulation needs to fulfill several key
requirements in order to be efficacious enough to justify development as a drug: I)
liposome formulation should accumulate at the inflammation site as a result of prolonged
circulation due to reduction in uptake by the RES, II) low drug leakage rate during the
circulation, III) liposomal formulation should be chemically and physically stable during
storage, IV) liposomes should have a high [drug/lipid] ratio to avoid toxicity induced by
high liposome dose and V) high drug encapsulation is required. Herein, I describe the
development of MPS liposome formulations using passive and active loading strategies.
In both the strategies, the influence of formulation composition and process variables
were investigated comprehensively to improve the MPS encapsulation efficiency and
meet the above criteria. However, the formulation based on a novel acting loading
approach, calcium acetate transmembrane gradient efficiently loaded MPS into
liposomes. Approximately, 63% w/v MPS encapsulation efficiency was achieved using
the acetate gradient method. In addition, MPS-L were surface modified with cRGDpeptide by post-insertion method to exert control on the incorporation of targeting ligand.
In this method, an incorporation efficiency of 45.3% (molar) was achieved.
In this chapter, the influence of formulation composition, process parameters and loading
strategies were investigated to obtain an optimized MPS encapsulated formulation for use
in in vivo studies.
4.2

Materials

HSPC, 1, 2-dipalmitoyl-sn-glycerophosphoethanolamine-poly (ethylene glycol)2000amine (DSPE-PEG2000), 1, 2-dipalmitoyl-sn-glycerophosphoethanolamine-poly (ethylene
glycol)2000-maleimide (DSPE-PEG2000-maleimide) were obtained from Avanti Polar
Lipids (Birmingham, AL). MPS and CHOL were purchased from Sigma (St.Louis, MO).
cRGD-peptide was purchased from Peptide International Inc. (Louisville, KY). PBS and
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HEPES buffers were purchased from cellgro Inc. (Herndon, VA). All other chemicals
were obtained from Sigma or Fisher Scientific.
4.3

Methods

4.3.1 Preparation of MPS-L by Passive Loading (Bangham Method)
Liposomes were prepared with a composition of HSPC: CHOL: DSPE-PEG2000 in 50: 45:
3: 2 molar ratios. The lipids were solubilized in chloroform-methanol solution and
subjected to evaporation to form a thin lipid film. Hydration of the lipid film was carried
with HEPES buffer (50 mM, pH 6.5) containing MPS at 100 mg/mL. The resulting
MLVs were extruded through 100/200 nm sandwiched polycarbonate membrane filters
using liposome extruder (LIPEX™, Northern Lipids, Canada). MLVs were subjected to
the required number of extrusion passes to form small unilamellar vesicles (SUVs) in the
size range, 100-120 nm. This was followed by the incubation of SUVs with cRGDpeptide solution, pH 6.5, overnight at 25 C. The conjugation reaction was quenched with
100 µL of 1 µM of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC; Sigma, MO).
Unconjugated free RGD-peptide and free MPS were isolated by dialysis at 4 C for 6 h
using equilibrium chambers (Harvard Apparatus, MA), separated by a 10,000 Da MWCO
membrane. The dialysate was subjected to HPLC analyses to determine MPS
encapsulation and cRGD-conjugation efficiency. The surface modified liposomes were
stored at 4 C until further use.
4.3.2 Active Loading of Amphipathic MPS into Liposomes
Remote loading was performed using calcium acetate transmembrane gradient method.
Ca.acetate]liposome >> [Ca.acetate]medium transmembrane gradient was used as the driving
force for the remote loading of MPS, an amphipathic weak acid. Such a gradient is
characterized by an excess of the membrane-impermeable Ca+2 ions over the membranepermeable acetic acid; the leakage of acetic acid of the liposomes leads to creation of a
pH gradient in which the pHliposome >> pHmedium. In such liposomes, the amphipathic weak
acid, such as MPS in its unionized form is diffused into the slightly alkaline
intraliposomal aqueous phase. Inside the aqueous core, it is de-protonated and becomes
negatively charged. Now, the ionized MPS forms a poorly soluble calcium-MPS
complex, which precipitates in the intraliposomal aqueous phase. The loading process
continues till the exhaustion of intraliposomal acetate ion concentration. Lipids,
HSPC/CHOL/DSPE-PEG2000 were dissolved in ethanol and then were hydrated with 200
mM calcium acetate at 65°C. The large MLVs formed upon lipid hydration were extruded
at 65°C through sandwiched polycarbonate filters (100/200 nm). Approximately, 100-120
nm sized liposomes were obtained. To create the transmembrane calcium acetate
gradient, the calcium acetate of the external liposome medium was replaced by 0.9%
NaCl (w/v) at 4°C by dialysis. MPS was dissolved in 0.9% NaCl to a concentration of 19
mM (9 mg/mL) and mixed with preformed liposome dispersion (30 mM phospholipids)

48

in which a transmembrane calcium acetate gradient was created. The remote loading was
achieved by incubation of the liposome dispersion at 48°C (near the Tm of HSPC, i.e.
52 C) for 6 min, and then liposomes were cooled to 4°C and dialyzed against 0.9% NaCl
to remove any residual traces of acetate ion. After dialysis, MPS and phospholipid
concentrations were 12.03 mM and 27.2 mM, respectively.
4.3.3 Synthesis of DSPE-PEG2000-maleimide-cRGD Conjugate
DSPE-PEG2000-maleimide-cRGD conjugate was synthesized and incorporated into MPS
encapsulated liposomal bilayers for targeting to lungs via the integrin receptors. The
conjugate was synthesized as described in Figure 4.1. Briefly, 11.34 mg of DSPEPEG2000-maleimide and 1.16 mg of cRGD peptide were dissolved in 100 µL of HEPES
buffer (50 mM, pH 6.5) containing TCEP and 1 mM disodium EDTA. The reaction was
carried overnight at 25 C on a tube shaker (Barnstead/Thermolyne, IA). The product was
dialyzed in 1000 Da MWCO Slide-A-Lyzer® dialysis cassettes (Pierce, Rockford, IL)
against HEPES buffer (pH 6.5) at 4 C for 6 h. Followed by dialysis, the product was
subjected to further de-salting on micro bio-spin chromatography columns (Bio-Rad,
Hercules, CA). The product was then lyophilized and stored at -20 C until further use.
The product was characterized by vMALDI. For vMALDI analysis, the product ( 1 nM)
was purified with a ZipTip C18 spin column using the procedure recommended by the
manufacturer (Millipore, Billerica, MA). The purified product solution was eluted with 2
L of α-cyano-4-hydroxycinnamic acid (α-CHCA) matrix solution (2.5 mg/mL in
ACN/Water/TFA mixture) on a micro-column. The product/matrix mixture was spotted
on a vMALDI plate and air-dried at room temperature. The product was analyzed with
vMALDI–LTQ mass spectrometer (ThermoFinnigan, San Jose, CA) operated in positiveion mode. For the vMALDI source, the crystal-positioning system and auto spectrum
filter (ASF) were enabled and ASF threshold was set at 500 counts for an MS scan.
Automatic gain control (AGC) was enabled to adjust the number of laser shots and
maintain the quality of vMALDI spectra. For an MS scan, high-mass range (m/z 500–
4000) and normal scan rate were used. Product spectra were acquired and analyzed using
Xcalibur software (ThermoFinnigan, San Jose, CA). The amount of residual free cRGD
peptide was determined by Ellman reaction,266 which quantifies the sulfhydryl groups of
cRGD peptide.
4.3.4 Insertion of DSPE-PEG2000-maleimide-cRGD Conjugate into Liposomes
DSPE-PEG2000-maleimide-cRGD conjugate was micellized and inserted into liposomes
to exert control on the number of targeting ligands per liposome. A micellar solution of
the conjugate was prepared by a procedure described elsewhere.267,268 Briefly, 28.9 mg of
the lyophilized conjugate was solubilized in 1000 L of water to form micellar solution.
The resulting micellar solution was lysed in 5% w/v Triton-X surfactant solution and the
total cRGD peptide content was determined by Ellman reaction. Based on the liposome
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Figure 4.1
Schematic representation of Michael addition reaction between the lipid,
DSPE-PEG2000-maleimide and cRGD-peptide.
The reaction was carried between equimolar concentrations of the lipid and the peptide.
The synthesized conjugate was de-salted, and futher purified using dialysis cassettes
(MWCO, 1000 Da) at 4 C for 6 h. The peptide and phospholipid contents were estimated
by Ellman reaction and phosphorus assay to determine the conjugation efficiency. The
lipo-peptide conjugate was qualitatively characterized by MALDI-MS in positive ion
mode.
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number, a specific micellar concentration of the conjugate was added to liposome
suspension to obtain the required number (1,500) of targeting ligands per liposome. The
number of liposomes was determined by NVOL method.238 As illustrated in Figure 4.2,
both micellar conjugate and liposomes were incubated together at 48°C for 6 min and
stored overnight at 4°C. The liposome formulation was then centrifuged (1,500xg, 15
min) in mini bio-spin chromatography columns to remove any unincorporated conjugate.
Followed by centrifugation, liposome formulation was lysed with 5% w/v Triton-X
surfactant solution, and cRGD peptide content was determined to estimate the conjugate
incorporation efficiency.
In active loading strategy, MPS encapsulation was evaluated with respect to formulation
composition and process parameters, before surface modification with cRGD-peptide.
4.3.5 Chemical Characterization of Liposome Dispersion
The total and intraliposome concentrations of MPS were quantified using RP-HPLC
method. The concentrations of HSPC and CHOL were determined using HPLC method
as described in Chapter 3.
4.3.6 Physical Characterization of Liposome Dispersion
Mean diameter (Zavg) and zeta potential of liposomes were evaluated by dynamic light
scattering (DLS) studies using zetasizer® (Malvern Inc., Westborough, MA) equipped
with a 4.5 mW diode laser as a light source operating at 670 nm. Particle scattered
photons were detected at 173 . Medium refractive index, 1.335; medium viscosity, 1.0
mPa; and a dielectric constant of 80.0 were used as reference parameters for experimental
investigations. Samples were suitably diluted with 0.22 µm filtered HPLC water to avoid
multi-scattering phenomena for Zavg and zeta potential determination. A Smoluchowski
constant of 1.5 was used to measure zeta potential values from electrophoretic mobility.
The mean diameter and zeta potential of liposome formulations were expressed in
nanometers (nm) and millivolts (mV), respectively. Morphology was determined by
negative staining of the SUV specimens on carbon support films by the single droplet
procedure. 2% w/v aqueous solution of uranyl acetate (pH 6.5) was employed to stain the
specimens. Specimens were studied using transmission electron microscope, functioning
at 200 kV (JEOL-FX 2000). A magnification of 50,000x was employed to acquire the
electron micrograph.
4.3.7 MPS Encapsulation Efficiency
MPS encapsulation efficiency studies were carried to evaluate the MPS loading as a
function of composition and process parameters. In passive loading strategy, formulation
composition parameters include drug/lipid ratios, CHOL fraction and PEGylated lipid
fraction. Process parameters include primarily, the effect of extrusion passes and pressure
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Figure 4.2
Schematic representation of the insertion of the targeting conjugate by
post-insertion technique.
The micelles of the conjugate were incubated with MPS encapsulated liposomes to yield
targeted liposomes, MPS-LcRGD. All targeting ligands on the external leaflet of the
liposomes are presumed to be available for targeting. The conjugate insertion efficiency
into liposomes was determined to be 34% (molar) as determined by Ellman reaction and
phosphorus content analysis.
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on MPS encapsulation. Extrusion parameters do not have a significant influence on MPS
encapsulation in active loading strategy as preformed small unilamellar liposomes were
used for MPS incorporation. MPS encapsulation efficiency (% EE) was calculated using
the Equation 4.1
% EE = (At-Af/At)

Equation 4.1

Where At is the total amount of drug used for encapsulation and Af is the amount of free
drug left in solution.
4.3.8 In Vitro Leakage Kinetics of MPS from Liposomes
The kinetics of MPS leakage in buffers was quantified using dialysis cassettes (MWCO,
10000 Da) equilibrated with HEPES buffer (pH 7.4, 50 mM). At definite time points,
aliquots were taken and analyzed for MPS leakage.
4.3.9 Mathematical Models
Mathematical models were applied to describe the MPS release kinetics in liposome
formulations. Higuchi and Korsenmeyer-Peppas (K-P) models were applied to describe
the diffusion kinetics of MPS from liposomes, prepared by passive loading method. For
active loading method (See Figure 1.6B), a mathematical model based on Rippie‟s
assumptions was proposed to describe the drug release diffusion kinetics in liposomes
(Figure 4.3). The same model was used to estimate the encapsulated drug (At-Af) in
liposomes prepared by active loading method.
4.4

Results and Discussion

4.4.1 Passive Loading Strategies
4.4.1.1 MPS Encapsulation Efficiency (% EE): Influence of Drug/Lipid (D/L) Ratios
Initial work was devoted for selection of phospholipid and characterizing its effect on
MPS retention. Further work was extended to study the influence of D/L ratios on MPS
encapsulation. HSPC/CHOL (55/45 mole%; 27.2 mM total lipids) liposomes were
prepared with increasing amounts of MPS corresponding to D/L ratios from 0.1 to 0.8.
The liposomes were then dialyzed at 4 C for 6 h to remove unencapsulated drug, and the
D/L ratio was measured after quantitation of MPS inside the liposomes.As shown in
Figure 4.4, D/L ratio as high as 0.6 (molar) was achieved. However, a stable
encapsulation could not be achieved, and a substantial fraction ( 92% w/v) was desorbed
into the external medium in 6 h.
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Figure 4.3
Schematic representation of the mathematical model based on Rippie‟s
assumptions.
The model can be used to predict the drug diffusion in and out of particulate cores, where
pH transmembrane gradient is maintained across the membranes.
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Figure 4.4
Graph depicting the MPS encapsulation efficiency as a function of
drug/lipid ratios.
Each level is a mean SEM of n = 3 samples. Total lipid content of MPS-L was 27.2 mM.
* p<0.05 in comparison to [D/L] at 0.1 or 0.2. Statistical analysis was performed using
Newman-Keuls test for multiple comparison (one-way ANOVA).
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4.4.1.2 Influence of CHOL Incorporation on MPS encapsulation
Basic composition of liposomes includes HSPC and CHOL. Being a saturated lipid,
HSPC is stable to chemical degradation and avoids premature leakage of encapsulated
drug from the liposomes in comparison to unsaturated phospholipids. CHOL was
included in the formulation to enhance the rigidity of phospholipid bilayers. However,
with CHOL, MPS entrapment efficiency was reduced, which may be due to phase
separation of CHOL from the liposome formulation during hydration and extrusion
processes. Phase separation and CHOL crystallization may induce pore formation in
phospholipid bilayers and cause extensive drug leakage.As shown in Figure 4.5,
formulation composition of HSPC/CHOL at 55/45 mole% showed a % EE of 8.94.
Though, HSPC/CHOL at 65/35 mole% showed the highest entrapment, a substantial
amount of MPS leaked out in 6 h at 37 C.
4.4.1.3 Influence of PEG Incorporation on MPS Encapsulation
PEG-lipids were incorporated into the liposome membrane to enhance the in vivo
circulation half-life of liposomes. As shown in Figure 4.6, % EE values containing 1-10
mole% of PEGylated lipid in the liposome formulations are in the range of 2-8% w/v of
the MPS used for encapsulation. MPS encapsulation showed no significant effect till 5
mole% of the incorporated PEGylated lipids. Usually, the PEGylated lipid concentration
is limited to 5 mole% in long circulating liposome formulations. In this range, MPS
encapsulation efficiency is independent of PEGylated concentration.
4.4.1.4 MPS Encapsulation: Influence of Extrusion Pressure
Characteristics of the extrusion procedure (applied pressure, flow rate and pore size) as
well as physical properties of the lipids and the lipid suspension (surface tension, bending
modulus and concentration) may all play a role in the size and polydispersity of the
vesicles produced. Understanding the role of these factors will contribute to the
reproducibility achieved and should lead to production of more ideal vesicle solutions.
Size and polydispersity of vesicles produced by extrusion depend on the number of times
the solution is extruded, pore size of the extruded filters,269 lipid properties270 and
pressure.271 Optimization of extrusion pressure and cycles is critical for drug
encapsulation. As shown in Figure 4.7, MPS encapsulation reduced with extrusion
pressure.
4.4.1.5 Drug Release Models
The drug release data was analyzed with mathematical models, such as the Higuchi
model and the Korsmeyer-Peppas equation.272 One of the most often used mathematical
equations to describe the release rate of drugs from drug delivery systems is the Higuchi
model,273 which is described by Equation 4.2:
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no significant difference in MPS encapsulation as a function of PEGylated lipid
concentration.
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Figure 4.7
Graph depicting the MPS encapsulation efficiency as a function of number
of extrusion cycles.
For all the levels of lipid content, an extrusion pressure of 250 psi was maintained. Each
level is a mean SEM of n = 3 samples.
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Mt/A = [D(2C0-CS)CSt]0.5 for C0>CS

Equation 4.2

The Higuchi equation was originally applied to dissolution and growth from solid
particles.273 However, the Higuchi law was extended to colloid systems, such as
emulsions.274,275 The K-P equation organizes the cases of the drug release from a dosage
form, and the cumulative drug amount, Mt, released at time t is given by the Equation
4.3:
Mt/M0 = ktn up to Mt/M0≤0.07

Equation 4.3

where M0 is the initial amount of drug in the liposomes at time t = 0, k is the release
constant and n is the release exponent, indicative of the drug release mechanism. If n = 1,
the release is zero order. If n is between 0.5 and 1, the release follows an anomalous
transport (non-Fickian) mechanism, which is controlled by factors other than diffusion,
including the drug encapsulation matrix and liposome membrane structure. If n = 0.5, the
drug release is controlled by Fickian diffusion, and the drug release can be modeled using
Higuchi‟s law. All the factors influencing the relationships between Mt and t in Equation
4.2 are represented by the release rate constant k in Equation 4.3. The rate limiting steps
in MPS release include (I) MPS diffusion to the inside surface of the liposome and II)
MPS diffusion through the lipid bilayer.
4.4.1.6 Influence of PEG Incorporation on the Release Mechanism
The percentage cumulative MPS release (Mt/M∞) x 100%) from liposomes containing
PEGylated lipid was shown in Figure 4.8. As shown in Table 4.1, good correlation was
obtained between experimental data and the K-P equation with r2 values greater than
0.97. The release rate constant, k and the release exponent, n were obtained from the
intercept and slope, respectively, of the plot of Ln (Mt/M∞) versus Ln (t). It was found
that the value of n increased with PEG content in the liposomes. It is concluded that
Fickian diffusion (n = 0.5) is the main release mechanism for liposomes with less than or
equal to 2.5 mole% DSPE-PEG2000 in liposome formulations. While the release
mechanism followed non-Fickian diffusion mechanism at DSPE-PEG2000 greater than or
equal to 5 mole%. This data shows that MPS release is controlled by the interfacial
structure of the liposomes with tethered PEG chains at the surface.
In this case, liposomes can be considered as reservoir systems, where the drug was
surrounded by a barrier,276 e.g. MPS molecules in liposomes composed of lipid
membrane and PEG chains.Narasimhan et al.277 suggested that diffusion through the
polymer (such as PEG) is the rate-limiting step. If the Fickian diffusion law is obeyed for
MPS release from liposomes, the diffusion rate is proportional to: (I) membrane
permeability, therefore, DSPE-PEG2000 in liposomes can reduce the diffusion rate because
HSPC bilayers are less rigid than PEG layers, (II) thickness of the bilayer; hence MPS
diffusion from PEGylated liposomes. PEGylated liposomes exhibited high release rates.
The phospholipid membrane generally is ~2-4 nm,278 whereas the PEGylated coat of the
liposome is ~5 nm, (III) drug concentration gradient across the liposome bilayer leads to
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Figure 4.8
Graph depicting the MPS release from liposome formulations containing
different fractions of DSPE-PEG2000.
The release studies were performed at 25 C using dialysis cassettes (10,000 Da MWCO).
All the values are a mean SEM of n=3 samples.
Table 4.1

Parameters in the K-P equation for MPS release kinetics from MPS-L.

DSPE-PEG2000 mole%
0
2.5
5
10

n
Release mechanism k (min-n)
0.51
Fickian diffusion
0.12
0.53
Fickian diffusion
0.05
0.68 Non-Fickian diffusion
0.3
0.71 Non-Fickian diffusion
0.01
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r2
0.98
0.98
0.99
0.97

a high diffusion rate for high MPS encapsulation and (IV) surface area of liposomes, i.e.
size of the liposomes.
Silvander et al.279 indicated that the PEGylated lipids impose restrictions on the
molecular motion in the outer as well as the inner parts of the hydrocarbon region of the
lipids. PEGylated lipids may cause an increased packing order at the water/hydrocarbon
interface. At 5 mole%, both diffusion and PEGylated surfaces of liposomes controlled
MPS release. The release rate constant, k decreased dramatically as the PEG was
incorporated, and k values were not significantly different when the PEG-lipid in
liposomes was >5 mole%. The MPS release from liposomes with PEGylated lipid less
than 5 mole% followed a t0.5 dependence (Higuchi law) rather than a t0.7 law (for PEGlipid >5 mole% in liposomes).
4.4.1.7 Influence of Mean Size of Liposomes on the Release Kinetics
Liposome diameter has been reported to influence the pharmacokinetics and disposition
of a drug, such as doxorubicin into the RES.280 The MPS release kinetics from PEGylated
liposomes of different sizes is shown in Figure 4.9. The data was fit by the Higuchi law,
which showed a good correlation of this model to MPS release from PEGylated
liposomes (r2 is 0.97-0.99). Higuchi law shows that the surface area of liposomes exposed
to the release medium is part of the release rate constant, k calculated from the
relationship between the cumulative drug release amount and t0.5. Therefore, MPS release
is related to the size/surface area of liposomes. The MPS release rate increased with
decreasing liposome size because the total surface area (TSA) of liposomes was
increased. TSA is equal to the average surface area (S) of liposomes multiplied by the
number of liposomes in suspension, which is equal to the inverse of the volume of a
liposome (V). Therefore, TSA is proportional to (A/V), i.e. (4 π r2)/(4/3 π r3) = 3/r (r is
the average radius of PEGylated liposomes). The MPS release rate constant as a function
of 3/r is shown in Figure 4.10. An increase in the surface area of liposomes led to an
increase in k values due to the increase in total surface area exposed to the release
medium, and also led to an increase in MPS diffusion from liposomes. For a PEGylated
liposome, Higuchi law is followed during the MPS release, and the release rate constant
is proportional to the inverse of liposome radius. In Figure 4.10, the relationship is, k =
(3.9/r)+0.0135. When r → ∞, k is 0.0135 min-0.7, which is the situation of MPS release
from a flat surface.
4.4.1.8 Influence of Temperature on the Release Kinetics
Temperature of the release medium may alter the viscosity of the liposome suspension,
and thereby change the solubility and diffusion rate of drugs incorporated in
liposomes.281 Figure 4.11 shows that MPS release as a function of temperature of the
medium. Release data was fit to Equation 4.3 with n = 0.7 for PEGylated (5 mole%)
liposomes. As shown in Table 4.2, temperature (25 vs.37 C) has a significant effect on
MPS release. An increase of temperature increases the value of the diffusion coefficient,
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Graph depicting the MPS release from PEGylated liposome formulations
with mean diameters of 100, 200, 400 and 800 nm.
The total lipid content in all the formulations was 27.2 mM, and the studies were carried
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Figure 4.10 Graph depicting the MPS release rate constant of the liposome
formulations with varied mean diameter, calculated from K-P equation.
The release rate constant is related to radius of the liposomes. The rate constants were
obtained from the slopes of the MPS release from different sized liposome formulations.
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Figure 4.11 MPS release rate from PEGylated liposomes stored at different
temperatures 4 (■), 25 (□), 30 (Δ), 37 (▲) and 40 C (*).
The MPS release rates were fit to K-P equation.
Table 4.2

Values of k from the t0.7 law for MPS-L at different temperatures.
Temperature (oC) k (min-0.7)
4
0.02
25
0.04
30
0.04
37
0.08
40
0.12

The release study was conducted at pH 7.4 and, the buffer has no added salt.
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D, which relates the diffusion process to temperature (T) and viscosity (η),282 In
Equation 4.4, kB is Boltzmann‟s constant and r is the liposome radius. The temperature
effect on the D value is also described by Equation 4.5.
D = kBT/(6πηr)

Equation 4.4

D = D0e(-Ead/RT)

Equation 4.5

Where D0 is a constant, Ead is the activation energy for the diffusion process (J/ mol), R
is the universal gas constant (J/ mol K) and T is the absolute temperature. From Equation
4.4, D increases with increase in T, which is in agreement with the experimental value. As
shown in Figure 4.11, over the temperature range, 4 to 40oC, MPS release showed
Arrhenius behaviour. The activation energy, Ea for MPS release through the liposome
bilayer was calculated from the temperature dependence of the release rate constant using
the Arrhenius equation.283 For PEGylated liposomes, the diffusion process is not the only
mechanism and Ea is larger than Ead. However, PEG chains impeded the drug diffusion.
4.4.1.9 Summary for Passive Loading Strategy
MPS encapsulation efficiency was ~8% w/v using passive loading process. The K-P
equation (n = 0.7) and the Higuchi model (n = 0.5) provided good fits for the
experimental data of MPS release/leakage from PEGylated liposomes at PEGylated lipid
concentrations, <2 and >5 mole%, respectively. The high surface area of small liposomes
led to increased MPS release. Changes in pH and salt concentration significantly
influenced the MPS release rate, indicating that electrostatic forces between liposomes or
between liposome and MPS molecules affect the drug release. In contrast to the
assumption that PEG incorporation into the liposome formulation reduces MPS release
rate, PEGylation increased the MPS release rate. A high molar ratio of PEGylated lipid in
the liposome formulations resulted in increased release rate. In addition, the release
mechanism was transformed from diffusion control to interfacial control based on the KP equation. These findings may be utilized for the improvement of the formulation, and
gives an insight into the actions of PEGylated liposomes in the body.
4.4.2 Active Loading Strategies
4.4.2.1 Dynamic Light Scattering (DLS) Studies for Particle Size and Zeta Potential
The average diameter and zeta potential of extruded liposomes were 120 13 nm and 27 4.7 mV, respectively as determined by DLS studies, which indicate the formation of
small and stable liposomes. MPS-LcRGD were stable at 4 C.
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4.4.2.2 Encapsulation of MPS by the Use of Salt Gradients
MPS liposomes loaded with gradients of calcium acetate showed a higher EE than those
loaded by sodium salts (Figure. 4.12). The liposomes showed a constant particle size and
low polydispersity index during the loading process (data not shown). The EE declined in
the line: calcium>sodium>ammonium. Among the acetate salts, only calcium showed a
high MPS loading. All salt gradients resulted in active MPS loading, when compared to
the passive loading, which is calculated by the ratio of encapsulated MPS amount to the
total MPS concentration.
4.4.2.3 Influence of Intravesicular Acetate Concentration on MPS Encapsulation
Dried lipid was hydrated with various buffers containing 50, 100, 200, 300 or 400 mM
calcium acetate (pH was adjusted to 7.0 with 0.1 N NaOH). The size of the liposomes
after extrusion was around 100-120 nm. External acetate was removed using de-salting
columns. After incubation of MPS with preformed liposomes at 48 C, the encapsulation
efficiency (EE) increased up to 63% w/v with a [drug/lipid] ratio of 0.4 at an acetate
concentration of 200 mM inside the liposomes. The lowest MPS EE (3.1% w/v) was
achieved with 50 mM HEPES buffer, containing no acetate ions. (Figure 4.13)
In the study, a stable pH gradient over the loading period is maintained in situ by
generation of acetate gradient, i.e. by a high intraliposomal acetate concentration and an
acetate ion-free, extraliposomal buffer. Due to the acetate gradient, the pH value
decreases outside the liposome from pH 4.3 to a lower pH, even though the
extraliposomal buffer was set to a pH of 4.3. The in situ generation of the pH gradient
from the higher permeation coefficient of acetic acid caused basification of the liposome
interior. In the absence of an acetate gradient, there is no decrease in extraliposomal pH
value. Instead, the internal pH adjusts to that of the outer pH. Due to de-protonation and
precipitation of MPS, high encapsulation efficiency was achieved. Due to the interaction
of MPS with calcium ions, negatively charged MPS precipitates with calcium ions to
form a gel-like structure within the liposomes.187, 195, 284 The solubility studies showed
consistently poor solubility of MPS in a 200 mM acetate solution in the investigated pH
range of values close to the pKa of MPS (pKa=4.3), where solubility drops to almost
zero.
4.4.2.4 MPS Encapsulation via Calcium Acetate Gradient with Different Interior pH
Values
Liposomes were prepared with intraliposomal calcium acetate buffer (200 mM) of
various pH values (pH 3, 4.3, 5, 6 and 7.0). Loading liposomes with MPS via acetate
gradient is a new, potent and alternative remote loading method. Loading of MPS by
means of salt gradients includes two synergistic effects, both of which result in the fact
that MPS can no longer pass the lipid membrane. On one hand, loading is driven by deprotonation and charging of MPS within the liposome, and on the otherhand, by
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Figure 4.12 Histogram of MPS encapsulation driven by various acetate salt gradients
in PEGylated liposomes.
The lipid formulations were prepared with a [drug/lipid] ratio of 0.4. The lipid film (27.2
mM phospholipid concentration) was hydrated with 200 mM salt solution adjusted to pH
7.0 (n = 3). *** indicates significant levels at P<0.001 (ANOVA) in comparison with
minimum EE.

**

MPS Encapsulation
(% EE)

70
60
50
40
30
20
10
0

50

100

200
300
Salt (mM)

400

Figure 4.13 Histogram of MPS encapsulation as a function of different ionic strengths
of calcium acetate inside the lipoosmes.
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precipitation of MPS in the hydrophilic interior of the vesicle when the concentration of
MPS solubility is exceeded. By means of a stable pH-gradient, MPS is de-protonated in
the basic interior of the liposome. When the extraliposomal pH is low, only a small part
of the MPS is de-protonated. The free uncharged acid is then able to pass the membrane
so that there is intra and extraliposomal adjustment in the concentration of the free acid of
the drug. When the intraliposomal pH value is higher, the free intraliposomal MPS acid is
de-protonated and new extraliposomal, unionized MPS can diffuse into the liposome
according to the concentration gradient. Therefore, a “proton pool” outside the liposomes
is necessary as a driving force for MPS loading.
As shown in Figure. 4.14, high pH values resulted in a higher EE of MPS. At pH values
<4.3, the solubility of MPS decreases. After protonation of MPS in the liposome aqueous
core, the complex is nearly insoluble in the calcium acetate solution. By using calcium
acetate gradients with various pH values, it could be demonstrated that with the
synergism of de-protonation and precipitation of MPS, higher encapsulation efficiencies
can be achieved.
4.4.2.5 Leakage of MPS Liposomes Loaded via Acetate Gradient
MPS leakage from liposomes was examined under different pH conditions at 25 C. These
include contact with physiological fluids at pH 7.0, pH 6.0 of tumor tissues285 and pH 5.0
after uptake into endosomes. The drug leakage properties of liposomes, which were
loaded via transmembrane acetate gradient differ completely from vesicles, which are
loaded with other ion gradients. The MPS release of liposomes, which were loaded via an
acetate gradient showed a negligible leakage at low pH, but leakage increased with pH
(Figure 4.15). At pH 6.0 and 7.0, the drug release is influenced by the extraliposomal
ratio of negatively charged MPS to neutral MPS. Furthermore, release experiments have
been performed with these liposomes at 37°C (data not shown). pH dependent release
from the liposomes significantly increased, which might be due to increased MPS
solubility and/or membrane fluidity.
Besides efficient loading, the release of the drug is also a critical factor for a drug
delivery system. As shown, the release of MPS from liposomes is highly dependent on
the extraliposomal pH value. In this study, pH values, 7.0, 6.0 or 5.0 similar to the
situations in most tissues, tumors and endosomes were chosen to imitate the various pH
environments of the liposome from the point of application to the reaching of the target.
In the case of MPS liposomes, a high extraliposomal pH value results in facilitated MPS
release, whereas liposomes are not significantly influenced by the low extravesicular pH
value.
4.4.2.6 (DSPE-PEG2000-maleimide)-cRGD Conjugate Synthesis and Micelle Formation
(DSPE-PEG2000-maleimide)-cRGD conjugate was micellized for later insertion into the
preformed liposomes at well defined numbers of targeting ligands. Final product yield
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was 34% (molar), as determined by Ellman reaction and phosphorus content of the lipid.
The product was analyzed qualitatively by MALDI-MS. As shown in Figure 4.16, the
peak corresponding to the lipid-peptide targeting conjugate was observed at 3458.29 Da.
Mass spectra for the starting materials were 586 Da for cRGD-peptide and 2941 Da for
DSPE-PEG2000-maleimide (data not shown).
4.4.2.7 (DSPE-PEG2000-maleimide)-cRGD Conjugate Insertion into MPS-L
In order to construct MPS-L bearing defined number of targeting ligands, (DSPEPEG2000-maleimide)-cRGD conjugate was incorporated into the lipid bilayers of MPS-L
by the „post-insertion‟ technique. Following dialysis, the unincorporated (DSPE-PEG2000maleimide)-cRGD conjugate was estimated as described elsewhere. The number of
cRGD peptides per liposome was determined by subtraction method. From the peptide
and phospholipid analysis, the number of targeting ligands intended for insertion was
1500 cRGD peptides per liposome. From the analysis, approximately 680 ligands were
inserted into liposomes. This is equivalent to 45.3% (molar) of the targeting conjugate
insertion efficiency.
4.4.2.8 Summary for Active Loading Strategy
The development of MPS-L for treating inflammatory diseases has been a long-sought
goal, as evident from numerous studies starting in the 1970s and continuing to this day.
However, although much progress has been made, some major limitations and restrictions
still prevent the pharmaceutical development of MPS-L formulations for clinical use.
From a historical perspective, in the early stage of research related to MPS-L, the main
idea was to utilize their lipophilic nature and to encapsulate them in the liposome
membrane. This form of encapsulation has encountered a major limitation of stability,
since most GCs are not lipophilic enough, as is obvious from their logD and mass
aqueous solubility. For instance, CHOL, one of the liposome membrane components, has
a logD of 9.85 at pH 7.0 and mass solubility of 6x10-9 gm/L, while hydrocortisone has a
much lower logD of 1.43 at pH 7.0 and mass solubility of 0.16 gm/L.282 Therefore, such
GCs are not suitable for “encapsulation” in the liposome bilayer, since upon dilution they
will desorb to the aqueous medium. Mishina et al.195 demonstrated that 50% w/v of
encapsulated methylprednisolone was released to the bulk medium during 10 days of
storage. In the present study, obstacles associated with passive loading approach were
overcome with active remote loading of MPS.
It seems that the cosmotropic properties of the counter-ion contribute to the solubility of
MPS. The salts used for loading, i.e., ammonium, sodium and calcium are all components
of the Hofmeister or lyotropic series.286,287 This series reflects the ranking of ions
according to their binding strength of bulk water and to the concomitant decrease in the
hydration of other compounds. The precipitation caused by these compounds is then
termed as salt-out effect. This also explains the requirement of the high salt concentration
of 200 mM for liposome loading, since this concentration is necessary to withdraw the
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Figure 4.16
conjugate.

MALDI-MS spectra of the (DSPE-PEG2000-maleimide)-cRGD-peptide

The product was characterized by vMALDI. For an MS scan, high-mass range (m/z 500–
4000) and normal scan rate were used. Product spectra were acquired and analyzed using
Xcalibur software. MADLI-MS analysis was performed in positive ion mode, and
therefore, the mass obtained on the spectra is usually M+1.
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hydration shell of MPS. This salt-out effect plays a role not only for proteins but for
amphiphilic substances as well, which has been shown in other studies.288 The
withdrawal of the hydration shell also explains the self-aggregation of MPS driven by
hydrophobic interactions, which is highly dependent on the respective buffer
composition.
In conclusion, the active loading process of MPS in liposomes via acetate gradient
depends on various factors: intraliposomal salt concentration, water binding potential of
the salt, the pH value in the liposome and the presence of acetate pool. The loading of
MPS in liposomes via calcium acetate gradient represents a potent alternative procedure
to the methods used to date. It allows fast and effective loading of the MPS into
liposomes at 48 C. Although, there is evident release of MPS at 37°C, under long term (3
months) storage conditions at 4°C, there is a minimal (8% w/v) release of MPS. We were
able to demonstrate that the novel active loading method facilitates dual purposes: I)
MPS encapsulation (63% w/v encapsulation efficiency) and II) high targeting ligand
insertion (45.3% molar) into lipid bilayers.
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CHAPTER 5. PROTECTION OF COLLOIDAL PROPERTIES OF MPS-LCRGD
5.1

Introduction

Liposomes have been successfully employed for the encapsulation of a range of synthetic
drugs and biologicals.289,290 However, the potential application of liposomes as
therapeutic tools is still challenged by their inherent physical and chemical instabilities,
which can result in increased bilayer permeability, subsequent drug loss and vesicle
aggregation/fusion. These instabilities can be stimulated by chemical degradation (e.g.
lipid oxidation and hydrolysis) and physical factors, such as heating or freezing.291 For
instance, changes in the arrangement of phospholipids within the bilayer of small vesicles
have been attributed to the loosely packed head-groups and tightly packed alkyl chains in
the outer layer, with the opposite arrangement in the inner layer of the bilayer.292 This
leads to a thermodynamically unstable state, which favors aggregation and/or fusion of
the vesicles. Therefore, it is clear that the composition of the lipid bilayer, bilayer-drug
interactions and the storage conditions of the liposomes will all influence liposome
stability.293-295 To circumvent these problems and achieve long term stability of
liposomes, lyophilization has been used as an effective approach to render liposomes
stable without compromising their physical state or encapsulation capacity. However,
lyophilization of liposome systems without appropriate stabilizers will again lead to
fusion of liposomes; a factor exploited by the dehydration-rehydration method.296 To
promote liposomes stability during the lyophilization process, lyoprotectants, including
saccharides (e.g. sucrose, trehalose) and aminoacids (e.g. lysine) are employed.297,298 A
detailed review by Crowe and Crowe295 outlines the mechanism of stabilization offered
by the saccharides. Briefly, the increase in liposome size and leakage of the encapsulated
material in non-lyoprotected liposomes during lyophilization is attributed to two factors:
phase separation of lipids around their gel-fluid transition temperature and fusion of the
liposome membranes. Thus, aggregation of liposomes could be prevented by the
formation of stable boundaries between the liposomes. The ability of lyoprotectants to
form these stable boundaries has been attributed to their ability to replace the bound
water around the bilayer via interaction with the polar region of the lipid head group
(water replacement hypothesis).295,299 Alternatively, Koster et al.300 proposed the
formation of a vitreous layer (glass formation around the bilayer) of the lyoprotectant
around the bilayer, which depresses the transition temperature of the phospholipids thus
preventing any drug leakage during gel to fluid phase transformations.
The role of various saccharides (glucose, sucrose, trehalose, etc.) has been investigated
thoroughly as stabilizing lyoprotectants.250 Despite the detailed investigations, these
systems have not been fully optimized, and in order to achieve effective lyoprotection
and reproducible formulation parameters, high concentrations (30 mole%) are required.
Therefore, the aim of this work is to assess various lyoprotectants, including
disaccharides and aminoacids as stabilizing moieties during the lyophilization of
liposomes. Crowe et al. investigated the influence of disaccharides and aminoacids as
lyoprotectants.301 It has been shown that sugars are able to protect membranes during
dehydration. In addition, very little has been reported on the ability of sugars to stabilize
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targeted liposomes, whose surface is modified with peptides or proteins. The present
study investigates the ability of disaccharides to protect lyophilized peptide or antibody
conjugated liposomes. Parameters, such as particle size distribution, drug leakage and
gel-to liquid phase transitions after rehydration were analyzed to investigate if the
lyophilized formulations could be reconstituted without physico-chemical changes. Also,
amino acids were investigated for use as lyoprotectants in simple liposome formulations.
5.2

Experimental Section

5.2.1 Materials
HSPC1, DSPE-PEG2000, DSPE-PEG2000-maleimide were purchased from Avanti Polar
Lipids (Birmingham, AL). CHOL, arginine, histidine, lysine, trehalose, sucrose and MPS
were obtained from Sigma (St. Louis, MO). cRGD peptide was purchased from Peptide
International Inc. (Louisville, KY). IgG antibody was purchased from Chemicon
(Minneapolis, MN). Acetonitrile was purchased from Fisher Scientific (Suwannee, GA).
All chemicals used were of analytical grade.
5.2.2 Methods
5.2.2.1 Preparation of Liposomes
MPS encapsulation into liposomes was achieved by transmembrane calcium acetate
gradient method. Liposomes were prepared with a lipid composition of HSPC, CHOL,
DSPE-PEG2000 and DSPE-PEG2000-maleimide in 50: 45: 3: 2 molar ratios. Lipid (27.2
mM total phospholipids) solution in chloroform-methanol solution (3:1% v/v) was
subjected to vacuum drying at 40 C to form a thin dry film, which was hydrated with
calcium acetate buffer (200 mM) at 65 C to form MLVs. These vesicles were extruded
through 200/100 nm sandwiched polycarbonate membrane filters using LIPEXTM
extruder The MLVs were subjected to 6 extrusion passes to obtain liposomes with a mean
diameter of 100-120 nm. To create a transmembrane calcium acetate gradient across the
liposomes, the extraliposomal calcium acetate buffer was replaced with 0.9% saline
solution by dialysis (10,000 Da MWCO). Followed by generation of calcium acetate
gradient, liposomes were mixed and incubated with MPS solution [19 mM] at 48°C for 6
min and then cooled to 4°C. Unencapsulated MPS and any traces of calcium acetate were
removed by dialysis of MPS-L at 4°C for 6 h. cRGD peptide-lipid conjugates were
inserted into lipid bilayers for formation of targeted liposomes. Detailed procedure for
preparation of targeted liposomes was described elsewhere. Empty liposomes were
prepared by Bangham method without MPS encapsulation.
5.2.2.2 Lyophilization of Liposomes
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Liposomes were mixed with different lyoprotectants (trehalose, sucrose, lysine, histidine
and arginine) to obtain [lyoprotectant/lipid] ratios at 2, 4, 6 and 8:1. The liposome
suspensions were then subjected to lyophilization. Vials were loaded into a lyophilizer
(Virtis Genesis ES25) and run according to the protocols listed elsewhere.
5.2.2.3 Determination of MPS Encapsulation and Retention in Liposomes
The amount of MPS encapsulated in liposomes was determined after dialysis at 4 C.
Purified liposomes were dissolved and suitably diluted with ethanol before analysis. MPS
determination was performed by RP-HPLC using a Nova-pak® C-18 column (3.9x150
mm, 4 µ) (Waters, MA). An isocratic method was run with a mobile phase comprised of
sodium acetate: acetonitrile in 67: 33% v/v. The pH of the mobile phase was adjusted to
4.8 with glacial acetic acid. The retention time of MPS was between 5-6 min with
absorbance maximum at 250 nm.
5.2.2.4 DLS Studies for Particle Size and Zeta Potential
Mean diameter and zeta potential of liposomes were evaluated by DLS studies as
described elsewhere.
5.2.2.5 Transmission Electron Microscopy
Morphology of liposomes was determined by negative staining of the SUV specimens on
carbon support films by the single droplet procedure. 2% w/v aqueous solution of uranyl
acetate (pH 6.5) was employed to stain the specimens.
5.2.2.6 Differential Scanning Calorimetry (DSC)
The gel-to-liquid phase transition temperature of the undiluted vesicles in liposome
suspension was determined using DSC. Thermograms were obtained using a Q2000
series DSC (TA Instruments, New Castle, DE). Samples were run at 10°C/min from 45°C to 80°C. Q2000 series software was used for data analysis. The first of three scans
of each sample (n=3) was used for data analysis.
5.2.2.7 Stability Studies of Lyophilized Liposomes
To investigate the stability offered by the addition of lyoprotectants, lyophilized
liposomal formulations were tested for their particle size and MPS retention for a period
of 4 weeks. The lyophilized formulations were stored at 25 C. The samples were then
hydrated and drug leakage was studied.
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5.2.2.8 Moisture Content Analysis using Karl Fisher Titration
Residual moisture content of the lyophilized cakes was measured using the Karl Fisher
titration method.302 A minimum of 100 mg of pulverized cake was dispersed into an
anhydrous methanol bath and titrated with Karl Fisher reagent (Acros, NJ).
5.2.2.9 Statistical Analysis
Statistical analysis was carried out by analysis of variance followed by Bonferroni t-test
using GraphPad Prism™ software.
5.3

Results and Discussion

5.3.1 Disaccharides as Lyoprotectants: Evaluation of Appearance of MPS-LcRGD
In the present study, MPS-LcRGD were lyophilized in the presence of sucrose or trehalose
at various concentrations. The lyophilized formulations were examined by visual
inspection. A uniform cake matrix was obtained after lyophilization of MPS-LcRGD in the
presence of trehalose or sucrose at concentrations ranging from 200 to 400 mM or at
[lyoprotectant/lipid] ratios, 4:1 or 8:1. At lower concentrations (<100 mM), a collapse of
the cake was observed indicating that these concentrations of sugars were insufficient to
prevent aggregation of MPS-LcRGD. This collapse is illustrated in Figure 5.1 with pictures
of cakes containing 400 mM and 50 mM trehalose. The collapse was more pronounced
for the formulations containing sucrose (data not shown). Formulations containing 200
mM trehalose and 400 mM sucrose were readily rehydrated, and the process occurred
within 10 min with no visual sign of aggregates (Figure 5.2). Formulations with lower
concentrations of sugar were rehydrated more slowly, and the formulations with the
lowest concentrations showed signs of aggregates even hours after rehydration. These
results suggest that with sufficient amounts of trehalose or sucrose, it is possible to
lyophilize MPS-LcRGD and create a stable dry cake. Furthermore, insufficient amounts of
lyoprotectant cause slow rehydration. A successful lyophilization should enable the
product to rapidly reabsorb solvent, and restore the substance to its original state.
5.3.2 Effect of Lyoprotectants on Particle Size
The particle size of MPS-LcRGD was analyzed to determine which sugar concentration
was sufficient to preserve the average particle size upon lyophilization. The average
particle size of MPS-LcRGD prior to lyophilization was 120±13 nm. The average particle
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Figure 5.1
Representative samples of the MPS-LcRGD lyophilized with high (400 mM;
left) and low (50 mM; right) concentrations of trehalose.

Figure 5.2
Transmission electron micrographs ofMPS-LcRGD before and after
lyophilization (i.e. reconstituted) with trehalose.
Micrographs depict the morphology of the targeted liposomes lyophilized with 200 (1:4)
and 400 (1:8) mM of trehalose.
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size of the lyophilized formulations was measured 10 min after rehydration. The
formulations with above 200 mM trehalose regained their normal particle size after 10
min of rehydration (P>0.01). This was not the case for the formulations with lower
concentrations of trehalose indicating that these liposomes were not fully rehydrated or
that the membrane structures were not preserved during lyophilization. For sucrose, only
at a concentration of 400 mM sucrose, rehydration of the MPS-LcRGD took place in 10
min. The particle size increase of the lyophilized formulations containing less than 100
mM sugar was 8-12 times over the original size. At low levels of sugar concentrations,
not even 24 h of rehydration resulted in a normal particle size suggesting that aggregation
is irreversible. Since MPS-LcRGD is a monodisperse formulation, it was important to
analyze if any changes in the particle size distribution could be detected.
As illustrated in Figure 5.3, MPS-LcRGD with 200 mM trehalose or 400 mM sucrose, the
particle size distribution did not change suggesting that the size distribution was
preserved upon lyophilization. Formulations containing 400 mM trehalose or sucrose
were found to be more monodisperse than MPS-LcRGD lyophilized formulations with low
sugar concentrations. The results thus show that at trehalose concentrations 200 mM,
the formulation can be reconstituted within 10 min without change in average particle
diameter as well as particle size distribution, whereas sucrose only preserves the particle
size at the highest concentration (400 mM). The results also confirm the conclusion from
the visual inspections, that much more sucrose than trehalose is needed to obtain a quick
rehydration of lyophilized formulations.
5.3.3 Effect of Lyoprotectants on the Thermotropic Phase Behaviour of HSPC before
Lyophilization
The thermotropic phase behaviour of HSPC in the presence of trehalose or sucrose was
determined before lyophilization to investigate the effect of sugars on the liposome
dispersions. The thermograms obtained are shown in Figure 5.4. The phase transition
temperature for HSPC was observed at 52.62±0.02°C. Low concentration trehalose
slightly increased the Tm to 54.02±0.08°C in non-lyophilized MPS-LcRGD formulation.
There was no apparent difference between Tm of the formulations containing different
concentrations of trehalose. Addition of sucrose also did not affect the main gel-to-liquid
phase transition temperature of HSPC. However, at 100 mM trehalose, a shoulder was
observed on the high temperature side of the peak, which developed into a distinct peak
at 67.68°C with 400 mM trehalose. The same pattern was observed with sucrose, though
not so pronounced. The small increase in Tm for the formulations containing trehalose
and the shoulder on the high temperature side of the peak could be explained by direct
interaction.303 Direct interaction of trehalose with the polar head-group of the lipids could
cause the formation of a depletion layer around the liposomes in which the concentration
of water is lower than in the bulk phase.The polar head-groups of trehalose, with
hydroxyl groups are available for hydrogen bonding. HSPC of MPS-LcRGD would
therefore have this sugar available on the membrane surface for interaction with
cosmotropic molecules like trehalose and sucrose. The cosmotropic effect can cause a destructuring of the H-bond network of bulk water, which affects the dynamic properties of
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Figure 5.4
Thermograms of MPS-LcRGD containing increasing concentrations of
trehalose (A) and sucrose (B) prior to lyophilization.
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water and reduces the amount of water in the solvation layer surrounding the liposome
membranes.304,305 This could cause the Tm of the liposome membrane to change due to
lower flexibility and higher thermal stability, and thus explains the shoulder on the high
temperature side of the peak.304 Another explanation for the shoulder on the high
temperature side of the peak could therefore be that a phase separation in HSPC local
domains with high concentrations of highly ordered HSPC with elevated phase transition
temperatures. This phase separation would lead to a lowering of the gel-to-fluid phase
transition of these areas. No reduction of Tm was observed suggesting that phase
separation cannot explain the shoulder on the high temperature side of the peak. More
investigations are required to explain this behaviour further.
5.3.4 Effect of Lyoprotectants on the Thermotropic Phase Behaviour of HSPC after
Lyophilization
A number of studies have been conducted to examine the interactions of trehalose with
the phospholipid membrane at various hydration levels; there is a lack of data pertaining
to how the interactions present in the hydrated state translate into those in the dehydrated
state. In previous sections, we have examined the effects of trehalose on the transition
behavior of HSPC before lyophilization in the presence of sugars. In this section, we
examine how these interactions are manifest upon lyophilization. Upon dehydration, the
phase transition temperature of HSPC increases from 52°C to 83°C. Removal of water
leads to a decrease in the head group spacing of the lipids, thus allowing for increased
van der Waals interactions between the lipid hydrocarbon chains.306 If the membrane (in
the liquid crystalline phase) is dried in the presence of trehalose, the contraction of the
phospholipids is avoided and the Tm decreases considerably.307 Figure 5.5 shows the
thermograms for the lyophilized liposomes (~100 nm) containing various outer trehalose
or sucrose concentrations. The lipid concentration for all of the samples is 50 mM, thus
the lowest amount of trehalose or sucrose in any of these systems corresponds to 1:1
ratio. During the freezing step of lyophilization, the membrane (prepared in the liquid
crystalline phase) undergoes a phase transition to the gel phase. The tighter packing of the
gel phase lipids results in a smaller number of trehalose molecules to interact (via water
replacement) with the phospholipids during the drying process. Therefore, Tm is shifted
towards high temperature, 83°C. For the sample containing 50 mM trehalose, the Tm is
observed at approximately 73.5°C (Figure 5.5; lower panel),). The transition is decreased
to 67.02°C upon increasing the trehalose concentration inside the vesicle to 100 mM,
while it decreases to approximately 55.62°C for the samples containing 400 mM
trehalose outside the vesicle. In the fully hydrated state, the decrease in Tm is mainly
observed for the sample containing high trehalose concentration inside the vesicle.304
Note that the shift in the Tm, observed at the various trehalose distributions, is amplified
significantly upon dehydration.The largest Tm change, observed upon the addition of 400
mM trehalose to liposomes, increases from 1°C in the fully hydrated state to 28°C in the
dried state. Additionally, a second peak, or a shoulder, is observed for the dry sample
containing 400 mM trehalose, mirroring the two transitions observed in the hydrated state
(before lyophilization; Figure 5.3A). Collectively, our results demonstrate that the
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Figure 5.5
Thermograms of lyophilized, rehydrated MPS-LcRGD formulations
containing increasing concentrations of sugar.
The top panel represents that of thermograms with sucrose and the lower panel with
trehalose.
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trehalose distribution in the fully hydrated state is maintained upon lyophilization. More
importantly, the direct interaction (via hydrogen bonding) between trehalose (400 mM
trehalose) and phospholipid in the hydrated state is not only maintained, but amplified
upon dehydration. Similar pattern was observed with sucrose.
Explanation for the peak at right hand side of the main transition, 52°C could be that the
lyophilization causes phase separation in the bilayer, resulting in highly ordered HSPC
domains, which are difficult to rehydrate. Since the particle size distribution is conserved
upon lyophilization and rehydration, the incomplete rehydration cannot be caused by
formation of larger aggregates. Further investigations are necessary to verify the reason
for the peak observed at 52°C. The results from this study show that sucrose is needed in
higher concentrations than trehalose to protect MPS-LcRGD during lyophilization and
maintain a similar gel-to-liquid phase transition pattern after rehydration. This is in
accordance with other studies308 and could be explained by a stronger interaction between
the lipid membrane and trehalose than with sucrose.303,309 Another reason could be the
larger hydration volume of trehalose compared to sucrose making it a better
kosmotrope.310
During freezing and drying this in turn leads to minimized damage by water
crystallization.311 A final explanation could be the high Tg of trehalose in the dry state
compared to other sugars248,312 making it a better vitrifier as it is less prone to
crystallization than many other sugars.248 Crystallization of the sugars could cause a
lowered Tg due to residual water, but this would also make the lyophilized cake collapse.
Since no collapse was observed in formulations with more than 200 mM sugar, residual
water is not believed to cause crystallization. Furthermore, since crystallization of the
sugars is a slow process below Tg, there is no reason to believe that trehalose should be
better to protect MPS-LcRGD during lyophilization, because of its abilities as a vitrifier. It
is therefore unlikely that the superior effect of trehalose compared to sucrose is due to its
vitrifying effects. In this case, we consider direct interaction with HSPC to be the major
reason for the protective effect of sucrose and trehalose. The beneficial effect of trehalose
compared to sucrose could on the other hand be due to its quality as a kosmotrope and its
strong direct interaction with HSPC.
The data presented here prove that trehalose is able to protect surface modified
liposomes. The mechanism of action is not yet fully understood, but these data suggest
that the direct interaction with HSPC possibly plays a role, whereas the cosmotropic
effect and vitrification of the sugars might be the main causes. Based on these physicochemical data, we have demonstrated that trehalose in concentrations from 200 mM
protects MPS-LcRGD during lyophilization and enables rapid rehydration (within 10 min).
5.3.5 Amino Acids as Lyoprotectants: Influence of Lyoprotectant Concentration
To investigate the efficiency of amino acids as lyoprotectants, liposomes were prepared
and subjected to lyophilization in the presence of various concentrations of the
lyoprotectants ranging from 2-8 mol/mol of lipid. Liposomes formulated from
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HSPC/CHOL/DSPE-PEG2000 (50:45:5 mol) were subjected to a freezing cycle at -45 C
for 2 h followed by primary drying at -36 C for 36 h and, secondary drying at 10 C for
24 h. Prior to lyophilization, liposomes were in the range, 100-120 nm. When lyophilized
in the absence of lyoprotectants, liposomes of 2-3 m size were formed after rehydration,
an almost 25 times over the original liposomes demonstrating aggregation/fusion of
liposomes. Alternatively, formulations lyophilised in the presence of the aminoacids
(lysine, histidine or arginine) showed lyoprotection with rehydrated liposomes smaller
than the control size ( 2250 nm). Both aminoacid and its molar concentration influenced
the lyoprotection efficiency. The lyoprotection profiles of the three amino acids were
biphasic in nature, but maximal protection against liposome aggregation varied with the
amino acids. At low [lyoprotectant/lipid: 2:1] concentration, lysine, histidine or arginine
increased liposome size to 3-4 times over the pre-lyophilized liposomes (Table 5.1). With
an increase in lyoprotectant/lipid ratio to 4:1, liposome size retention was observed with
all the three amino acids. However, lysine offered better protection with liposome size
similar to that of liposomes prior to lyophilization ( 110 nm). Histidine and arginine
showed a small increase in size to around 200 nm compared to pre-lyophilized liposomes.
TEM analysis of the rehydrated lysine incorporated lyophilized formulation revealed
stable, spherical and uniform sized liposomes (Figure 5.6).
Interestingly, a further increase in amino acid concentration resulted in the decrease of
lyoprotection. Liposome lyophilized in the presence of lysine or histidine or arginine
(8:1) demonstrated a significant (P<0.05) increase in liposome size (Table 5.1). Suzuki et
al.313 reported the biphasic nature of lyoprotectants. During lyophilization, liposomes if
unprotected will undergo membrane damage due to the formation of ice crystals and will
ultimately flatten and fuse during dehydration and subsequent rehydration.296 As amino
acids are charged molecules they are capable of interacting with the phosphate head
group of the lipid molecule, which is an important feature exhibited by most of the
saccharides.247 This offers the potential for the amino acids to form a layer on the
liposome surface which could possibly be acting as a protective shield against ice crystal
damage. In addition, all the amino acids used has a side chain functional group that reacts
with a proton at pH 6-7 to form a charged ionic group which is capable of forming
hydrogen bonds with the phosphate of the lipid head group. Histidine is characterized by
the presence of a pentacyclic ring in its structure. Arginine and lysine have the longest
side chains with lysine having a terminal amino group and arginine with a terminal
guanidinium group. During lyophilization, it is possible that the amino acids interact with
the phosphate group and form a barrier around the liposomes with layers of amino acids,
possibly acting as cushions against any damage during lyophilization.314
Saccharides as lyoprotectants suggested that interactions between the saccharide and the
lipid molecules may depend on the hydrophobic/hydrophilic nature of the saccharide
molecule, with more hydrophobic moieties promoting membrane fusion at higher
concentrations. Therefore, the biphasic nature of the amino acid lyoprotection shown in
Table 5.1 may be an outcome of high amino acid concentrations, promoting liposome
fusion via either hydrophobic interactions or electrostatic interactions between the
positively charged amino acids and the slightly anionic surface of the phospholipid
membranes.
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Table 5.1
The effect of lyoprotectant concentration on the mean diameter of empty
liposomes (after lyophilization).
Lyoprotectant/lipid ratio
2:1
4:1
6:1
8:1

Mean liposome diameter (nm)
Control
Lysine Histidine Arginine
NA
NA
NA
2250 320
489 45 645 35 389 15
127 15 190 8
184 14
512 18 644 18 672 12
985 47 751 18 653 12

All measurements are a mean±SEM, n=2 samples. Prior to lyophilization, liposomes
were in the 100-120 nm size range.

B

A

Figure 5.6
Transmission electron micrographs of MPS-L before (A) and after (B)
lyophilization with lysine as external lyoprotectant.
Samples were diluted 40 times and subjected to 2% w/v uranyl acetate treatment before
acquisition of images (50,000x magnification).
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5.3.6 Influence of Freezing Temperature on the Performance of the Lyoprotectants
To assess the influence of primary drying temperature on the lyoprotection, liposomes
with [lyoprotectant/lipid] ratio at 4:1 were lyophilized. Results (Table 5.2) show that the
primary drying temperature influences the liposome product characteristics; formulations
subjected to program 1 and 2 were offered protection during lyophilization, with
rehydrated liposome size remaining below 200 nm when any of the aminoacids were
employed. In contrast, rehydrated MPS-L subjected to primary drying at -20 C followed
by secondary drying at 10 C in the presence of lyoprotectant resulted in significant
liposome aggregation/fusion, with resultant liposome sizes similar to liposomes
lyophilized in the absence of lyoprotection. Crowe et al.247 showed that the lyoprotection
offered by various solutes is influenced by various factors, including the phase transition
temperature of the lipids (Tm) and the glass transition temperature (Tg‟) of the
amorphous frozen matrix.
In order to preserve the porous nature of the lyophilized cake, primary drying should be
performed at approximately 4 C below the Tg‟ of the amorphous frozen matrix. For
example, trehalose frozen matrix has a Tg‟ of -32 C and when the primary drying
temperature was maintained below this temperature (program 1 and 2; Table 5.2), stable
products were produced. However, when the frozen samples were subjected to a primary
drying temperature around the Tg of the lyoprotectant (program 3; Table 5.2), liposome
fusion occurs, possibly due to lack of formation of the glassy state which is responsible
for inhibition of liposome aggregation.247 Investigation of the influence of duration of
primary drying showed that there was no significant difference in the sizes of
lyoprotected liposomes when primary drying was carried out at -36 C for 36 or 48 h.
5.3.7 Influence of Lyoprotectants on MPS Leakage from MPS-L
Investigations on the protection offered by the amino acids were also extended to
determine MPS leakage from MPS-L. In the presence of the three amino acids, MPS-L
particle size showed a similar biphasic pattern (Table 5.3) to that of the lyophilized
„empty‟ liposome shown in Table 5.1. Thus, the presence of MPS within the liposomes
did not influence the lyoprotection offered by amino acids suggesting that MPS does not
interact with the cushioning effect of amino acids. The moisture levels of all the
formulations were less than 3% w/w. The presence of low moisture content in the product
confers improved stability and drug retention.213 This is also in line with the regulations
laid down by the regulatory authorities that prefer a maximum water concentration of 3%
w/w.
To determine the particle size distribution pattern and MPS leakage from MPS-L,
lyophilized MPS-L were stored at 2-8 C and 25 C for 4 weeks. With all the three
aminoacids as lyoprotectants, a slight increase in liposome size (Figure 5.7) and MPS
leakage (Figure 5.8) were observed. Among the three aminoacids, lysine offered
protection with a minimal size increase and MPS leakage. It is evident that lyoprotection
of liposomes is related to the structure-functional activity of aminoacids. An increase in
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Table 5.2

The effect of lyophilization protocols on the mean diameter of liposomes.

Size*

Vesicle diameter after rehydration (nm)
Lyophilization protocol temperature ( C)
Program Freezing Primary Drying Secondary Drying Control
Lysine
Histidine Arginine
1
-45
-36
10
110 13
2564 124 199 21
142 17
157 8
2
-45
-20
10
3012 241 145 14
187 16
146 21
3
-45
-10
10
3845 108 3084 92 4012 402 3157 274
Size prior to lyophilization (nm). All measurements were a mean±SEM, n=2 samples. Prior to lyophilization, liposomes were in the
100-120 nm size range.
Table 5.3

The effect of lyoprotectant concentration of the mean diameter of MPS-L.

Lyoprotectant/lipid ratio
2:1
4:1
6:1
8:1

Vesicle diameter (nm)
Lysine
Histidine
437 13
538 25
189 5
176 13
486 91
644 18
1356 91
751 18

Control
2850 124

Arginine
389 15
184 14
672 12
653 12

MPS-L (63% w/v loading efficiency) were prepared and mixed with increasing concentrations of lyoprotectants and lyophilized
according to protocol 1 as outlined in Table 5.2. Control liposomes were subjected to the same lyophilization protocol in the absence
of lyoprotectants. Mean diameter of liposomes was determined using a zeta sizer. All measurements were a mean±SEM, n=2 samples.
Prior to lyophilization, liposomes were in the 100-120 nm size range.
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Figure 5.7
Graph depicting the mean diameter of MPS-L as a function of aminoacids
as external lyoprotectants used for lyophilization.
Liposomes lyophilized with 4 moles of lyoprotectants/mole of the lipid were stored at
25 C. At selected time intervals, 1, 3, 7, 14, 21, 28 days, samples were reconstituted and
mean diameter of the liposomes was measured. All measurements are a mean±SEM, n=2
samples.
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Figure 5.8
Graph depicting the MPS leakage from MPS-L, lyophilized with
aminoacids as external lyoprotectants.
Liposomes lyophilized with 4 moles of lyoprotectants/mole of the lipid were stored at
25 C. At selected time intervals, 1, 3, 7, 14, 21, 28 days, samples were reconstituted and
MPS leakage from MPS-L was measured. All measurements are a mean±SEM, n=2
samples.
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liposome size and MPS leakage over time was observed with arginine or histidine as
lyoprotectants. These observations may be attributed to liposome fusion promoted by
weak interactions of the amino acids with the phosphate head groups. Therefore, the
stability of liposomes was compromised, thus promoting high rates of MPS leakage.The
results indicate that lysine appears to offer lyoprotection to liposomes similar to that of
trehalose. The ability of amino acids to protect the formulation during lyophilization
demonstrates another class of lyoprotectants.
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CHAPTER 6. INHIBITION OF LUNG INFLAMMATION USING MPS-LCRGD
6.1

Introduction

Acute lung injury is a fatal syndrome in critically ill patients with a high mortality rate.315
ALI syndrome is characterized by increased permeability of the alveolar-capillary barrier
resulting in influx of protein rich edema fluid, and consequently impairment in arterial
oxygenation. Low tidal-volume mechanical ventilation, a non-pharmacological approach
is the only proven strategy to improve the survival of ALI patients. Despite an improved
understanding of the pathogenesis of ALI, effective pharmacological therapies are
currently not available. Numerous clinical trials involving pharmacological therapies (e.g.
anti-inflammatory agents, anti-coagulants and pulmonary surfactants) aimed at different
pathological targets turned unsuccessful. One of the attributed drawbacks is the
underappreciation of drug delivery systems in the management of ALI.316
During the early ALI phase, numerous pro-inflammatory mediators are released into the
alveolar spaces in response to various inflammatory stimuli.4 Among them, IL-1 causes
pulmonary epithelial and endothelial barrier dysfunction leading to an increase in lung
permeability and edema.317-319 Ganter et al. reported that IL-1 mediates alveolar
epithelial permeability via v 6 integrin dependent TGF- activation.21 The v 6
integrin receptors of the alveolar epithelium mediate interaction of the latent TGF- with
RGD domain of the LAP. As a result, the latent TGF- undergoes activation leading to an
increase in epithelial permeability.19 A transient blockade of v 6 integrin receptors
would therefore be a potential strategy to prevent both TGF- activation and an increase
in epithelial permeability.
IL-1 stimulates pro-inflammatory cytokine and chemokine release, and upregulates
CAMs in alveolar epithelial cells.320 Due to a high chemokine gradient across the alveolar
barrier, leukocytes (e.g. monocytes and neutrophils) infiltrate from blood circulation into
alveoli, and exacerbate edema and lung inflammation.321,322 Of the various transcriptional
factors, NF- B plays a central role in regulating the inflammatory genes encoding CAMs,
chemokines and cytokines.75,323 NF- B is a heterodimeric protein present in the
cytoplasm in an inactive form stabilized by binding to the inhibitory protein, I B .74 In
response to IL-1 stimulation, I B undergoes phosphorylation and proteolytic
degradation. As a result, phosphorylated I B (p-I B ) is ubiquitinated allowing nuclear
translocation of NF- B, which binds to promoter regions of the target genes to initiate the
transcription of CAMs, chemokines and pro-inflammatory cytokines.324,325 And inhibitors
targeting the activated NF- B would suppress CAM expression and chemokines release,
which eventually prevent migration of leukocytes.326,327 Glucocorticoids, cited as NF- B
inhibitors mediate the effects through inhibition of NF- B transcriptional activity leading
to suppression of pro-inflammatory genes.328 Taken together, IL-1β mediates: I) v 6
integrin dependent epithelial permeability and II) induction of NF- B dependent proinflammatory genes. In order to alleviate both pulmonary edema and inflammation
associated with IL-1 stimulation, I used MPS-LcRGD.
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In the present study, liposomes were chosen for their flexibility: I) to anchor cRGDpeptide onto the surface of liposomes for targeting to v 6 integrin receptors located on
alveolar epithelium and II) to encapsulate and deliver MPS, an anti-inflammatory
glucocorticoid to alveolar epithelial cells for inhibition of pro-inflammatory cytokines
(e.g. TNF-α and IL-6), chemokines (e.g. MCP-1) and CAMs (e.g. ICAM-1) expression.
To evaluate the potential of MPS-LcRGD treatment in modulating epithelial permeability,
we examined IL-1 stimulated A549 cells. A significant decrease in albumin flux across
A549 cells was observed. In addition, MPS-LcRGD targeting the v 6 integrin receptors
undergo cell internalization and suppress MCP-1 and ICAM-1 expression. To determine
whether such an effect might have relevance to disease, we used IL-1 induced lung
inflammation rat model. MPS-LcRGD suspension was nebulized at a rate of 1 mL/min for
5 min prior to instillation (i.t.) of IL-1 in male Sprague-Dawley rats. In vivo results
demonstrated that MPS-LcRGD treatment show a decrease in epithelial permeability,
neutrophils migration and pro-inflammatory mediators‟ expression compared to IL-1
instilled (i.t.) positive control. The results of this study present evidence that MPS-LcRGD
reduces pulmonary edema by blocking v 6 integrin receptors; while MPS release from
MPS-LcRGD inhibits NF- B transcriptional activity, at least in part by increasing I B
leading to suppression of MCP-1 and ICAM-1 production.
6.2

Experimental Section

6.2.1 Materials
HSPC1, DSPE-PEG2000, DSPE-PEG2000-maleimide and 1-Oleoyl-2-[6-[(7-nitro-2-1,3benzoxadiazol-4-yl)amino]hexanoyl]-sn-Glycero-3-Phosphoethanolamine (NBD-PE)
were obtained from Avanti Polar Lipids (Birmingham, AL). MPS and recombinant
human interleukin-1 were purchased from Sigma (St.Louis, MO). cRGD-peptide was
purchased from Peptide International Inc. (Louisville, KY). DMEM medium, PBS buffer,
HEPES buffer, antibiotics and growth factors were purchased from Cellgro Inc.
(Herndon, VA). RPMI 1640 medium was purchased from Gibco (Carlsbad, CA).
Antibodies obtained include: Anti- v (P2W7; sc-9969; Santa Cruz Biotechnology Inc.,
Santa Cruz, CA), anti- 6 (H-110; sc-15329; Santa Cruz Biotechnology Inc), anti- 1
(mAb13, Becton-Dickinson, Bedford, MA), anti- v 3 (LM609; Chemicon, Temecula,
CA), anti- v 5 (P1F6; Chemicon) and IgG (Chemicon). Gel electrophoresis chemicals
were obtained from Bio-Rad Inc. (Hercules, CA). All other chemicals of ACS grade or
higher were purchased either from Sigma (St.Louis, MO) or Fisher Scientific (Suwannee,
GA).
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6.2.2 Methods
6.2.2.1 Preparation of Liposomes
MPS encapsulation into liposomes was achieved by transmembrane calcium acetate
gradient method. Liposomes were prepared with a lipid composition of HSPC, CHOL,
DSPE-PEG2000 and DSPE-PEG2000-maleimide in 50: 45: 3: 2 molar ratios. Lipid (27.2
mM total phospholipids) solution in chloroform-methanol solution (3:1% v/v) was
subjected to vacuum drying at 40 C to form a thin dry film, which was hydrated with
calcium acetate buffer (200 mM) at 65 C to form MLVs. These vesicles were extruded
through 200/100 nm sandwiched polycarbonate membrane filters using LIPEXTM
extruder. The MLVs were subjected to 6 extrusion passes to obtain liposomes with a
mean diameter of 100-120 nm. For flow cytometry studies, lipid solution was spiked with
3 mole% NBD-PE ( ex=488 nm, em=520 nm) dye during hydration.
To create a transmembrane calcium acetate gradient across the liposomes, the
extraliposomal calcium acetate buffer was replaced with 0.9% saline solution by dialysis
(10,000 Da MWCO). Followed by generation of calcium acetate gradient, liposomes
were mixed and incubated with MPS solution [19 mM] at 48°C for 6 min and then cooled
to 4°C. Unencapsulated MPS and any traces of calcium acetate were removed by dialysis
of MPS-L at 4°C.
To prepare cRGD peptide conjugated liposomes, MPS-L were incubated with cRGD
peptide solution (667 µg/30 L; pH 6.5) at 25 C for 12 h. The conjugation reaction was
quenched with EDC solution. Unconjugated cRGD peptide and excess EDC were
isolated by dialysis using equilibrium chambers separated by a 1000 Da MWCO
membrane (Harvard Apparatus, Holliston, MA). The amount of cRGD peptide
conjugated to MPS-L was estimated by subtraction of free cRGD peptide of the dialysate
from the total cRGD peptide used for conjugation. The free cRGD peptide fraction was
determined by RP-HPLC method. After dialysis, liposomal MPS and total phospholipids
concentrations were 12.02 mM and 23.8 mM, respectively. Approximately, 34% (molar)
cRGD peptide was conjugated to the maleimide group of MPS-L.
Mean diameter and zeta potential of liposomes were evaluated by DLS studies as
described elsewhere.
6.2.2.2 Cell Cultures
A549 cells from the American Type Culture Collection (Manassas, VA) were grown in
Dulbecco‟s modified Eagle‟s medium (DMEM) supplemented with 10% v/v heatinactivated FBS, antibiotics (10 µg/mL gentamicin and 0.25 µg/mL amphotericin), 1
µg/mL hydrocortisone, 10 µg/mL human epidermal growth factor, 3 ng/mL fibroblast
growth factor and 10 µg/mL heparin. The cell cultures were incubated in 5% CO2 at
37°C. Cells were cultured in T-75 flasks (Beckton Dickinson, Franklin Lakes, NJ) before
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transferring to plates for specific assays. For RT-PCR assays, cells were cultured in
collagen-I coated 60 mm petri dishes (Beckton Dickinson) at a seeding density, 2x106
cells per mL. For cell based ELISA, cells were seeded at 2x104 per well in collagen-I
coated 96 well plates (Becton Dickinson). For monocytes or neutrophils adhesion assays,
cells were passed from T-75 flasks and cultured in collagen-I coated 24 well Transwell®
filters (8 µM pore membrane; Becton Dickinson) at a density, 5x104 per well. For
pemeability assays, cells were cultured in collagen-I coated Transwell® 6.5 mm filters
(Costar, Cambridge, MA). Cells were then allowed to quiesce in DMEM incomplete
medium overnight before subjecting to treatments. Cells between the passages, 2-4 were
used for all studies.
6.2.2.3 AlphaVBeta6 ( v 6) Integrin Expression in A549 Cells
A549 cells were treated with IL-1 (10 ng/mL; 3 mL total volume) and DMEM
incomplete medium (control; 3 mL) for 0, 3, 6 and 12 h at 37 C. Following treatments,
cell monolayers were washed with PBS, fixed at 4˚C for 30 min in 2% v/v
paraformaldehyde and washed again with PBS. Non-fat dry milk (5% w/v; 300 µL) was
added to reduce non-specific binding. Cells were then incubated with primary
monoclonal antibodies (100 µL; 100 µg/mL in 1% w/v BSA-PBS solution) for 1 h. The
monolayers were washed with PBS-Tween20 (0.01% w/v; PBST) buffer and incubated
with biotinylated anti-mouse secondary antibody (100 µL of 1 µg/mL) for 1 h.
Subsequently, cells were washed as above and incubated with streptavidin horseradish
peroxidase (100 µL; DAKO, Carpinteria, CA) for 30 min. After washing with PBST
buffer, TMB peroxidase substrate (Sigma, MO) was added and incubated for 30 min. The
reaction was halted by addition of 2N sulfuric acid (50 µL/well). All incubations were
carried out at room temperature. The expression level of αvβ6 integrin receptors was
determined by difference in absorbance at wavelengths 450 vs. 630 nm. An isotype
matched control Ab (IgG) was used in place of primary antibody in three wells and
background was subtracted from the signal.
RT-PCR was performed to estimate mRNA expression of αvβ6 integrin receptors. Cells
were grown and subjected to treatments as described elsewhere. Cells were lysed with
TRIzol® reagent and total cell RNA was extracted according to manufacturer‟s
instructions (Invitrogen, Carlsbad, CA). Equal aliquots (4 µg) of RNA were quantified at
260 nm absorbance. RNA was reverse transcribed into cDNA synthesis with an oligo
(dT) primer using the Superscript III First-Strand Synthesis System as described in the
manufacturer‟s instructions. Primers were designed using Primer3 software
(http://frodo.wi.mit.edu). The primers were purchased from Integrated DNA technologies
(Coralville, IA). Primer sequences are listed in Table.6.1. The concentration of primers
was 200 nM for forward and reverse primers. PCR amplification conditions were: 50 C
for 30 min, 1 cycle; 94 C for 5 min, 1 cycle; 35 cycles of 94 C for 45 s, 55-58 C for 45 s
and 72 C for 2 min; 68 C for 7 min, 1 cycle. Ten microliters of PCR amplification
product and a 123-bp DNA ladder were separated using agarose (1.5% w/v) gel
electrophoresis. Gels were stained with ethidium bromide and photographed under
ultraviolet transillumination.
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Table 6.1

Primer sequences for v, 6, MCP-1, ICAM-1 and -actin.

Primer sequence (5‟ 3‟)

Product size (bp)

Tm

Genbank access
No.

V-integrin forward primer

5‟-TATGCTACATCTTGACCCACTA-3‟

104

55.0

NM_002210

V-integrin reverse primer

5‟-CCAATTAGCACTATCAGCAGTA-3‟

6-integrin forward primer

5‟-TGAATACTCCATGTCAACTGTC-3‟

150

55.14

NM_000888

6-integrin reverse primer

5‟-GTAGCTCCAGGAATAAGTTTTG-3‟
172

55.26

NM_002982

223

55.07

NM_000201

213

55.0

NM_001101

Primer

MCP-1 forward primer

5‟-AACTTATTTTCCCCTAGCTTTC-3‟

MCP-1 reverse primer

5‟-CCCCAAGTCTCTGTATCTAAAA-3‟

ICAM-1 forward primer

5‟-TCAGTCAGATACAACAGCATTT-3‟

ICAM-1 reverse primer

5‟-ATAGGCAGCAAGTTTCAGTATT-3‟

-actin forward primer

5‟-CATTGCTTTCGTGTAAATTATG-3‟

-actin reverse primer

5‟-TTATTCAACTGGTCTCAAGTCA-3‟
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6.2.2.4 Confocal Laser Scanning Microscopy (CLSM)
MPS-LcRGD affinity to v 6 integrin receptors of A549 cells was determined by
fluorescence microscopy using NBD-PE labeled, specific MPS-LcRGD and non-specific
liposomes (MPS-L). A549 cells were treated with either IL-1 or DMEM complete
medium (control) for 6 h at 37 C. Followed by IL-1 treatment, A549 cells were treated
with anti- v 3, anti- v 5 and anti- 1 integrin antibodies (10 µg/mL) to facilitate a high
degree of binding of MPS-LcRGD to v 6 integrins. After washing with DMEM
incomplete medium, cells were incubated separately with the NBD-PE labeled liposome
formulations (50 µM phospholipids/106 cells) at 37 C for 1 h. The total volume of
liposome formulation was 100 µL containing the following (in mM): NaCl (115), KCl
(5), NaHCO3 (10), HEPES (25), MgCl2 (0.5), CaCl2 (1), glucose (5.6) and BSA (1
mg/mL). Unbound liposomes were removed by washing the plates with ice-cold PBS
buffer. Followed by treatments, the cells were fixed in paraformaldehyde and subjected to
microscopy under 100,000x maginification.
6.2.2.5 MCP-1 and ICAM-1 Expression in A549 Cells
A549 cells were treated with IL-1 (10 ng/mL; 3 mL total volume) and DMEM
incomplete medium (control; 3 mL) for 0, 3, 6 and 12 h at 37 C. In pretreatment
protocol, A549 cells were pretreated with MPS-L or MPS-LcRGD (equivalent to 0.03-30
M MPS) or LcRGD for 1 h followed by IL-1 (10 ng/mL) incubation for 6 h. Cells were
analyzed for MCP-1 and ICAM-1 levels by Western Blot and RT-PCR procedures which
were described elsewhere. Primer sequences and RT-PCR conditions are listed in Table
6.1.
6.2.2.6 Isolation of Monocytes and Neutrophils
Blood collected from four healthy volunteers was subjected to dextran (Sigma, St.Louis,
MO) sedimentation to obtain leukocyte rich plasma, which was layered onto 2.5 mL of
Nycoprep, 1.068 (Invitrogen, Carlsbad, CA) and centrifuged (500xg, 20 min, 20°C). The
plasma and cells were then collected into separate tubes and centrifuged (600xg, 10 min,
20°C). The monocyte pellet was then resuspended in RPMI 1640 incomplete medium and
centrifuged (90xg, 15 min, 20°C) again to remove platelets. This was repeated six times.
The resulting cells were resuspended in RPMI 1640 containing 1% w/v PSG, 0.5% w/v
BSA and 10% v/v FCS (Cellgro) at 1 x106 per mL. Following this, cells were 90% pure.
For isolation of neutrophils, the leukocyte rich plasma was centrifuged, (400xg, 10 min,
4°C) and the supernatant was discarded. The cell pellet was resuspended in PBS and
centrifuged for a second time as before. Following washing, the cell pellet was subjected
to discontinuous Percoll gradient (Sigma). Using a discontinuous gradient consisting of
three layers (81, 70 and 55% v/v); the cell pellet was resuspended in 3 mL of 55% v/v
(the top layer), which was then overlaid onto the prepared gradient. The cells were then
centrifuged (750xg, 20 min, 4°C) and neutrophils were harvested from the 70%/81%
interface. The neutrophils were washed further in PBS for use in migration assays.
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6.2.2.7 Monocytes and Neutrophils Adhesion Assays
Isolated monocytes or neutrophils were suspended in RPMI 1640 (containing 1% w/v
PSG, 0.5% w/v BSA and 10 mM HEPES, pH 7.2) medium and radiolabeled by
incubating the cells (1x106 per mL) with 0.05 µCi NaCrO4 (Perkin Elmer, Waltham, MA)
at 37°C for 1 h. Radiolabeled monocytes or neutrophils were washed twice (250g; 5 min,
20°C) with ice-cold incomplete medium to eliminate excess of unincorporated
radioactivity and resuspended in RPMI 1640 incomplete medium, respectively. Twenty
min later, monocytes or neutrophils were washed and adjusted to a final concentration of
2x106 per mL in RPMI 1640 incomplete medium, supplemented with CaCl2 (1.3 mM)
and MgCl2 (1 mM). Prior to addition of radioactive monocytes or neutrophils, A549 cells
were exposed to IL-1β (10 ng/mL) or incomplete medium (control) for 6 h. In a
pretreatment protocol, A549 cells were exposed to MPS-LcRGD or MPS-L (equivalent to
0.03-30 µM MPS) or LcRGD for 12 h followed by IL-1β (10 ng/mL) exposure for 6 h.
Radiolabeled monocytes or neutrophils (5x105/well) were then added to treated A549
cells (monocytes or neutrophils /A549 cells: 10/1). After co-incubation at 37 C for 30
min, the percentage of monocytes or neutrophils adhered to A549 cells were quantified.
Non-adherent monocytes or neutrophils were removed by washing with 0.5% w/v BSAPBS solution. Adherent cells were lysed and counted in a gamma counter (Perkin Elmer,
Waltham, MA).
6.2.2.8 Epithelial Permeability Assay
Cells were cultured as described elsewhere. A549 monolayers were grown to confluence
until TEER reaches 30 .cm2 (EVOM; World Precision Instruments, Sarasota, FL).
Briefly, monolayers were washed in PBS and equilibrated at 37 C for 30 min. A549 cells
were exposed to IL-1β (10 ng/mL) or DMEM incomplete medium (control) for 6 h. In a
pretreatment protocol, cells were incubated with MPS-LcRGD or MPS-L (equivalent to 30
µM MPS) or LcRGD or antibodies (10 g/mL) and then stimulated with IL-1 (10 ng/mL)
for 1 h. 14C-albumin (0.05 Ci) (Perkin Elmer, Waltham, MA) was added to upper
compartment at 37°C for 1 h, after which contents from the lower compartment were
collected and counted in scintillation counter.
6.2.2.9 Animals
Male Sprague-Dawley rats, weighing 150-200 g, were purchased from Harlan
laboratories and used in all experiments. The protocols were approved by the Institution
Animal Care and Use Committee (IACUC) of the University of Tennessee, Memphis.
6.2.2.10 Nebulization of Liposome Formulations
At least 30 min prior to IL-1β (i.t.) instillation, rats were nebulized with liposome (PL or
MPS-L or MPS-LcRGD) formulations using micropump nebulizer (Aeroneb®, Aerogen,
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Ireland). Nebulization chamber filled with formulations was placed on the snout of rats.
Nebulization was actuated at a rate, 1 mL/min for 3 min. MPS-L or MPS-LcRGD
formulations contain MPS dose, 6.3 mg/mL. (Estimation of MPS in Blood and BALF
samples was done by RP-HPLC method).
6.2.2.11 IL-1β Instillation and BALF Collection
Male Sprague-Dawley rats, weighing 125-150 g were used in the study. Rats were fed
normal diet before the experiment with free access to water. Anesthesia was induced by
intra-peritoneal injection of ketamine/xylazine (87/13 mg/kg). Following anesthesia, a
midline tracheal incision was made to expose the trachea. A 26 gauge needle was
advanced endotracheally to instill IL-1 solution (200 µL, 100 µg/mL in PBS, pH 7.2) or
PBS alone (control). Following the IL-1 instillation, tracheal opening was sutured and
animals were returned to cage. Within 15 min of IL-1 instillation, anti-β1 or anti-αvβ3
or anti-αvβ5 antibodies (1 mg/mL/kg) or a combination were administered intravenously
(i.v.). Twenty four hours post IL-1 administration, the lung vascular bed was flushed
twice by injecting 10 mL ice-cold PBS into right ventricle. Followed by overdose of
pentobarbital (100 mg/kg, i.v), tracheal sutures were cut open to expose trachea. BALF
collection was performed by inserting a 26 gauge needle into trachea and lungs were
lavaged twice with PBS (3 mL). BALF was collected into cryovials and centrifuged at
1100xg, 4 C for 10 min. The supernatant was stored at -70 C for cytokine and chemokine
analysis and the cell pellet was subjected to neutrophils estimation. Aliquots of BALF
were estimated for protein concentration by UV absorbance at 280 nm using albumin
(Bio-Rad) as standard.
6.2.2.12 Estimation of BALF Cytokines, Chemokines and Adhesion Molecules
BALF supernatant collected and stored as described above was analyzed for cytokines
(TNF- ), MCP-1 and ICAM-1 levels by ELISA method according to manufacturer
(R&D Systems, Minneapolis, MN) instructions.
6.2.2.13 Estimation of Lung Neutrophil Content
Neutrophil content was assayed as described previously.329 Lung tissue from each lobe
was pooled (500 mg) and freeze-dried. The samples were then homogenized in HEPES
(50 mM, pH 8.0) at 0.5% w/v with tissue homogenizer (Fisher Scientific, Suwannee,
GA). Homogenized samples were then centrifuged at 12,000xg at 4°C for 30 min and the
supernatant was discarded. The process was repeated twice. The resulting pellet was
homogenized in 0.5% w/v CTAC solution and clarified by repeat centrifugation. The
resultant clear supernatant was analyzed for MPO activity. The same protocol was used to
extract MPO from BALF cell pellets. The collected supernatant from HEPES/CTAC
extracts of lung tissue was diluted 10 fold with 10 mM citrate buffer (pH 5.0) and 100 L
of this solution was pipetted into 4 wells of a 96-well plate. As negative control, “stop
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solution” (4N H2SO4) was added to two of the wells. Then, 100 L of the substrate
solution (3 mM 3,5,5-tetramethylbenzidine dihydrochloride, 120 mM resorcinol and 2.2
mM hydrogen peroxide in distilled water) was added to all the wells and the reaction was
quenched with stop solution at 25°C after 2 min.
A standard curve of MPO activity vs. neutrophils count was developed by homogenizing
a known number of Percoll-purified neutrophils using the same technique used in MPO
extraction from lung and BALF cells. Lung and BALF neutrophil count was estimated
from the standard curve.
6.2.2.14 Histological Examination of Lungs
For histological examination (n = 3 each group), bronchial lavage was omitted and after
vascular perfusion, 10 mL buffered formalin (3.7% v/v) was infused via the pulmonary
artery to fix the lung. Lungs were isolated en bloc after tracheal ligation and preserved in
10% v/v neutral buffered formalin for 24 h at 4 C. Wedge segments from each lobe were
paraffin embedded and 5 mm sections were taken and stained with haematoxylin and
eosin using standard protocol.
6.2.2.15 Statistical Analysis
All data reported are arithmetic means. Error bars represent one SEM. Differences
between means of indicated groups were analyzed by ANOVA with Bonferroni
corrections for multiple comparisons. A P value <0.05 was considered to be statistically
significant.
6.3

Results and Discussion

The colloidal properties of MPS-LcRGD and MPS-L determined by DLS method were
stable over 14 days of shelf life. As shown in Table 6.2, mean diameter of MPS-LcRGD
and MPS-L were comparable; however, the zeta potential of MPS-LcRGD was slightly
higher than MPS-L due to a partial negative charge of the targeting ligand, cRGDpeptide.
6.3.1 AlphaVBeta6 ( v 6) Integrin Receptor Expression in A549 Cells
The v 6 integrin receptors are normally expressed at a low level in lung epithelium, but
can be upregulated by injury and inflammation. To determine whether IL-1 treatment
induces v 6 integrin up-regulation in A549 cells, we performed cell based Western Blot
analysis was performed on A549 cells after treatment with either IL-1 or saline. A549
cells were stimulated with IL-1 for various periods of time. After 3 h, 6 subunit protein
expression increased by 1.8 folds (P<0.05) and after 6 h reached a maximum of 2.9 folds
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Table 6.2
studies.

Physico-chemical properties of MPS-LcRGD used in in vitro and in vivo

Liposomes
PL
PLcRGD
PLcRAD
MPS-L
MPS-LcRGD

Mean diameter,
MPS incorporation
Zeta potential, (mV)
Zavg (nm)
efficiency (% w/v)
98±9
-22.7±4.3
NA
110±6
-17.1±3.8
NA
106±4
-20.8±6.1
NA
113±5
-22.4±3.7
61
117±8
-25.6±2.2
36

Each value represents the mean±SEM (n = 3). NA indicates not applied. NA was applied
to the liposome formulations devoid of MPS encapsulation. PL indicates plain liposomes
and PLcRAD indicates liposomes with RAD as the control targeting ligand, which has no
specificity for integrin receptors.
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(P<0.05) which persisted thereafter (Figure 6.1). The v integrin subunit also showed the
same pattern. To determine whether v 6 integrin receptor protein levels reflected
mRNA expression levels in IL-1β activated A549 cells, we performed RT-PCR analysis
of the cell extracts. Figure 6.1 shows a representative agarose gel demonstrating v 6
integrin expression after stimulation with IL-1 for 0, 3, 6 and 12 h. Stimulation with IL1 revealed an up-regulation of v 6 mRNA expression in A549 cells, with 6 subunit
reached a peak level at 6 h (3.8 folds increase) which decreased thereafter. However, v
integrin subunit mRNA expression persisted for 12 h. The protein expression levels of v
and 6 subunits showed a gradual increase in response to IL-1 stimulation. Quiescent
A549 cells showed constitutive v and 6 subunit integrin mRNA and protein
expression. The increase in v and 6 expression levels at mRNA and protein levels
signifify the role played by the integrin receptors in mediating the pulmonary edema.
6.3.2 Cell Internalization of MPS-LcRGD: CLSM Studies
To evaluate the cell internalization of MPS-LcRGD, A549 cells were analyzed by CLSM
studies. Either quiescent or activated A549 cells were incubated with MPS-LcRGD or
MPS-L (1 mM lipid/106 cells/mL) for 1 h at 37 C. As represented in Figure.6.2,
activated A549 cells incubated with MPS-LcRGD resulted in NBD fluorescence which is
about 3-4 times higher than with MPS-L. In contrast, quiescent A549 cells incubated with
MPS-LcRGD showed a minimal level of NBD fluorescence over activated A549 cells. The
fluorescence intensity of MPS-L emitted from either quiescent or IL-1 activated A549
cells was comparable, but insignificant over the background. The results indicate the
higher affinity of MPS-LcRGD towards activated A549 cells. cRGD peptide is known to
bind to many heterodimer integrins, such as v 3, v 5 and 5 1 while showing
minimal effects on v 6 integrin receptors. Therefore, A549 cells were treated with
integrin antibodies other than anti- v 6 integrin antibody prior to incubation with MPSLcRGD.
6.3.3 Effect of MPS-LcRGD on MCP-1 Expression in A549 Cells
MCP-1 expression in alveolar epithelial cells plays a critical role in monocyte recruitment
from blood circulation into alveolar spaces. Earlier studies have shown that IL-1 is a
potent stimulus for MCP-1 expression in both primary and transformed epithelial cells.
To examine the MCP-1 expression in IL-1 activated A549 cells, ELISA was performed.
As demonstrated in Figure 6.3, MCP-1 protein was constitutively expressed in quiescent
cells. In IL-1β activated cells, a steady and significant (p<0.001) increase in MCP-1
protein expression was observed till 6 h, and persisted thereafter (data not shown). To
investigate whether the effect of IL-1 stimulation on MCP-1 expression would be
inhibited by MPS, A549 cells were pretreated with different control and MPS
encapsulated formulations containing an MPS equivalent to 30 M, before stimulation
with IL-1 (10 ng/mL) for 12 h.
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Figure 6.1
RT-PCR and Western Blot analyses of concentration dependent inhibition
of v 6 integrin expression by MPS.
After the indicated treatments as described in section, 6.2.2.3, cellular lysates from the
experiments were subjected to Western Blot and RT-PCR analyses of integrin subunits
and GADPH. For each set of conditions, three blots were conducted and representatives
were shown. All the blots are a representative of n=3 samples.
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Figure 6.2
Confocal laser fluorescence microscopy of cell internalization of MPS-L
and MPS-LcRGD in quiescent and IL-1 activated A549 cells.
A549 cells were treated with IL-1 (10 ng/mL) prior to treatments with formulations.
After the treatments, unbound liposomes were washed with citrate buffer and cells were
observed under 100,000x magnification. All the liposome treatments were performed at
37 C for 1 h. Top panel shows the fluorescence emitted from quiescent cells and lower
panel shows that from IL-1 treated cells.
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Figure 6.3
ELISA and RT-PCR analyses of MCP-1 expression in A549 cells as a
function of MPS encapsulated formulations.
A549 cells were pre-incubated with MPS-L and MPS-LcRGD (30 M MPS equivalents).
Followed by this, cells were treated with IL-1 at 37 C for 1 h. Supernatants were
collected for chemokines analysis and cells were harvested for RT-PCR analysis. Data
are plotted in nanograms per milliliter as mean SEM. *** indicates significant difference
of MP-LcRGD treatment effect at P<0.001 from the IL-1 stimulation alone.The top panel
shows the ELISA results of MCP-1 expression, while the lower panel represents the RTPCR analysis of the data.
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MPS-LcRGD inhibited MCP-1 protein expression to 26% of the IL-1 stimulation alone.
Similarly, MPS-L attenuated MCP-1 mRNA to 60% of IL-1 stimulated levels. The
results suggest that MPS released from MPS-LcRGD attenuates IL-1 activated MCP-1
expression upon cell internalization. MPS-LcRGD treatments showed no effect on cell
viability in 0.3-30 M range (data not shown). The results from NF- EMSA and
Western Blot analysis also corroborate the evidence that MCP-1 gene, controlled by NFwas modulated using MPS formulation treatments, particularly, MPS-LcRGD.
In summary, A549 cells instilled with IL-1 showed elevated mRNA and protein levels of
MCP-1. Compared with the control, MPS containing formulations treatment reduced
mRNA and protein levels of MCP-1 after IL-1 administration.
6.3.4 Effect of MPS-LcRGD on Monocytes Adhesion to IL-1 Stimulated A549
Monolayers
An IL-1 concentration dependent monocytes adhesion to A549 cells was observed.
Monocytes adhesion to activated A549 cells increase by 280% corresponding to 10
ng/mL of IL-1 dose, respectively. To examine the effect of MPS on monocyte adhesion,
A549 cells were pretreated with MPS-LcRGD (equivalent to 30 µM MPS) for 12 h before
IL-1 (10 ng/mL) stimulation for 6 h. MPS-LcRGD treatment showed a significant
decrease in monocyte adhesion to activated A549 cells. As shown in Figure 6.4, at
concentration equivalent to 30 µM MPS, monocyte adhesion to activated A549 cells was
reduced to near basal levels. To examine the effect of 1 or 6 antibodies, anti- 1 or anti6 were used, it is evident anti- 1 modulates monocytes adhesion to IL-1 in a mildly.
6.3.5 Effect of MPS-LcRGD on ICAM-1 Expression in A549 Cells
Cell adhesion mediated by ICAM-1 is critical for the transendothelial migration of
neutrophils from blood circulation into alveolar spaces. In ALI, interaction between
pathogens and macrophages or leukocytes results in release of cytokines, causing lung
damage. In vivo, enhanced expression of lung ICAM-1 is presumed to be the result of
direct inflammatory stimuli in concert with secondary effects (i.e., cytokines and
chemokines) mediated by inflammatory cells. In this study, the direct effects of IL-1 on
ICAM-1 expression in A549 epithelial cell line are evaluated. Alveolar epithelium shows
constitutive ICAM-1 expression, which is upregulated in response to pro-inflammatory
mediators, such as IL-1 and TNF-α. To examine the ICAM-1 expression, A549 cells
were treated with IL-1 (10 ng/mL) for 0, 3, 6 and 12 h. IL-1 induced a gradual and
significant (P<0.001) increase in mRNA and protein expression compared to the
constitutive expression of quiescent cells (data not shown). Activated A549 cells showed
a maximal, 243% increase in mRNA expression at 6 h followed by a slight decrease
thereafter.
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Figure 6.4
Histogram of the monocyte adhesion as a function of MPS encapsulated
formulation treatments in IL-1 activated A549 cells.
Monocyte adhesion is expressed as percentage of monocytes adhered to A549 cells in
basal and stimulated conditions (IL-1 ). Data are plotted mean SEM, n=3 samples. **
indicates significant (P<0.01) inhibition of monocyte adhesion with MPS-LcRGD in
comparision with IL-1 stimulation alone.
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To investigate the inhibitory potential of MPS on IL-1 induced ICAM-1 up-regulation,
A549 cells were pre-incubated with MPS-LcRGD (equivalent to 0.03-30 M of MPS) for
12 h before stimulation with IL-1 (10 ng/mL) for 6 h. Figure 6.5 shows that MPS
inhibited the up-regulation of ICAM-1 protein expression in a concentration-dependent
manner. At 30 M concentration, MPS attenuated ICAM-1 production to 18% of IL-1
stimulation alone. To further confirm the inhibitory effect of MPS-LcRGD on IL-1
induced ICAM-1 gene expression, the mRNA levels were analyzed by RT–PCR. A549
cells were subjected to the similar treatment as described above. MPS released from
MPS-LcRGD abrogated IL-1 induced ICAM-1 mRNA expression in a dose dependent
manner (data not shown). It was observed that at 30 M concentration, MPS attenuated
82% of IL-1 activated mRNA up-regulation. From the results, it was found that MPS
released from MPS-LcRGD significantly attenuated IL-1 induced ICAM-1 production in
A549 cells, both at the protein and mRNA levels.
6.3.6 Effect of MPS-LcRGD on Neutrophil Adhesion to A549 Monolayers
IL-1 stimulation mediates the adherence of neutrophils to epithelial cells through upregulation of ICAM-1 receptors. A549 cells were exposed to IL-1 for 6 h. After the
monolayers were washed, neutrophils were added and incubated for 20 min. Nonadherent neutrophils were washed away. Neutrophils adhesion increase by 48%, 210%,
and 385% on exposure of A549 cells to 0.1, 1 and 10 ng/mL of IL-1 , respectively (data
not shown). To investigate the effect of MPS on neutrophils adhesion, A549 cells were
pretreated with MPS-LcRGD (equivalent to 30 M of MPS) containing liposome
formulations for 12 h before IL-1 treatment for 6 h. As shown in Figure 6.6, neutrophil
adhesion was reduced to 33% of IL-1 stimulation alone. A combination of antibodies to
1 and 6 significantly reduced the neutrophil adhesion to A549 cells. Anti- 1/ 6
antibodies combination contributed a synergistic effect on inhibition of neutrophil
adhesion. This study reveals the involvement of both 1 and 6 integrins in mediating the
neutrophil migration into alveoli.
6.3.7 Effect of MPS-LcRGD on Epithelial Permeability in IL-1 Induced A549 Cells
IL-1 have been reported to mediate epithelial barrier dysfunction via v 6 integrins, we
therefore analyzed the potential of MPS-LcRGD on the modulation of epithelial cell
permeability. Confluent A549 cells on permeable supports were incubated with IL-1 and
transepithelial permeability was determined by measurement of 14C-albumin flux. IL-1
increased permeability in A549 cells compared to control. The transepithelial albumin
flux increased 220% following IL-1 treatment. However, MPS-LcRGD (equivalent to 30
M MPS) pretreatment reduced the transepithelial permeability of activated A549 cells to
basal levels (P<0.001). To delineate the effect of LcRGD from MPS on transepithelial
permeability, A549 cells were pretreated with LcRGD (equivalent to 33.4 g/mL of cRGDpeptide), which significantly (P<0.05) reduced the 14C-albumin flux to near basal levels.
It has been shown that IL-1 increases alveolar epithelial permeability by activating
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Figure 6.5
Densitometric RT-PCR and Western Blot analyses of ICAM-1 expression
in A549 cells, treated with MPS-LcRGD.
MPS inhibits the expression of ICAM-1 induced by IL-1 . A549 cells were preincubated with MPS-LcRGD (1-100 M MPS equivalents). After 12 h, supernatants were
collected for ICAM-1 analysis and cells were harvested for RT-PCR analysis. Lower
panel represents the Western Blot analysis and top panel represents the densitometric RTPCR analysis of ICAM-1 expression. ** and *** indicate significant levels at P<0.01 and
0.001, respectively from the IL-1 stimulated levels alone.

106

Neutrophil Adhesion

3.0×10 8
2.5×10 8
2.0×10 8
1.5×10 8

**
***

1.0×10 8
5.0×10 7

i-

1/

6

6

iA
nt

A
nt

A
nt

i-

1

G
D

PL

M
PS
M
-L
PS
-L c
R

C
on
t

ro
l(

PB
S)

0

IL-1 (i.t.) + Treatment

Figure 6.6
Histogram of neutrophil adhesion as a function of MPS encapsulated
formulation treatments in IL-1 activated A549 cells.
Freshly isolated neutrophils were isolated and incubated with quiescent and stimulated
A549 cells. A549 cell monolayers were pretreated with MPS-LcRGD (MPS equivalent to
30 M) and antibody (10 g/mL). Data are shown as mean SEM. ** and *** indicate
P<0.01 and P<0.001, respectively from IL-1 stimulated levels alone.
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v 6 integrin receptors in alveolar type II cells. Therefore, we examined their role using
anti- v 6 antibodies. A549 cells were pretreated with anti- v 6 (20 g/mL) antibodies
before IL-1 treatment. 14C-albumin flux was reduced to basal levels across the A549
cells (Figure 6.7). The data indicates the role of v 6 integrin receptors in mediating the
epithelial cell permeability increase in IL-1 stimulated A549 cells. It is also evident that
LcRGD reduce the transepithelial albumin flux by blocking the v 6 integrin receptors.
From the results, it is evident that the targeting ligand blocks the integrin receptors and
seems to prevent the interaction with LAP doman of the TGF- -LAP complex. In both
LcRGD and MPS-LcRGD formulations, a significant reduction was observed. However, a
mild reduction in epithelial permeability was observed with MPS-L. The data signifies
the importance of integrin receptors in mediating the IL-1 stimulated epithelial
permeability.
6.3.8 MPS-LcRGD Inhibits NF- B Nuclear Translocation in A549 Cells
NF- B is a major transcription factor mediating IL-1β induced MCP-1 and ICAM-1
expression through the NF- B binding sites located in the enhancer region of the MCP-1
and ICAM-1 genes, respectively. To explore the inhibition potential of MPS-LcRGD, we
used EMSA to determine whether MPS released from targeted liposomes could affect
NF- B activation in A549 cells. Figure 6.8 demonstrates NF- B activity in response to
IL-1 exposure.
Since activation of NF- B in A549 cells is dependent on phosphorylation and subsequent
degradation of I B , cytoplasmic extracts from IL-1 activated A549 cells in the
presence or absence of MPS-LcRGD was examined by Western blot analysis. In quiescent
cells, low levels of phosphorylated I B (p-I B ) were detected. However, p-I B was
readily detectable following IL-1 treatment. Prior incubation with MPS-LcRGD led to a
concentration dependent inhibition of p-I B . A549 cells pretreatment with MPS-LcRGD
for 12 h caused a substantial accumulation of I B (data not shown) and reduced p-I B
levels compared with IL-1 alone. However, short interval pretreatment with MPS-LcRGD
did not alter I B (data not shown) and p-I B levels. The data indicates that MPS
released from MPS-LcRGD inhibits NF- B transcriptional activity, at least in part, by
increasing I B due to reduced I B phosphorylation and degradation.
The data indicates that the targeting of NF- dependent transcription by MPS represents
a major mechanism of anti-inflammatory action. In support of this statement, MPS
treatment modulated activated NF- in A549 epithelial cells. Furthermore, we now
report that the induction of NF- dependent transcription A549 epithelial cells was
affected by MPS in a concentration dependent manner. Therefore, higher concentrations
of MPS or longer incubation times are necessary to exert the inhibitory effects on A549
cells. Consistent with this, there was noticeable effect of MPS on the expression of MCP1 and ICAM-1, where inhibition of p-I
resulted in a profound repression of MCP-1
and ICAM-1 expression. Thus, NF- inhibitors seem to target processes related to
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Figure 6.7
Histogram of 14C-albumin permeability across A549 cells, pretreated with
MPS encapsulated formulations and antibodies.
Data are shown as mean SEM. *** indicates P<0.001 from IL-1 stimulated levels
alone.

109

Figure 6.8
EMSA (left panel) of NF- elicitation and Western Bot analysis of I
and p-I
expression pattern in A549 cells, pretreated with MPS-LcRGD formulation.
MPS attenuated stimulus loss of I
. A549 cells were pretreated for 12 h with the
cRGD
MPS-L
. Cells stimulated with IL-1 were harvested. NF- activity was analyzed by
EMSA (left panel) on nuclear extracts. A Western Blot analysis (right panel) of total
I
and p-I
was performed on cytoplasmic extracts. All blots are representative of
three experiments.
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corticosteroids in the repression of inflammatory gene expression. This finding may have
a considerable impact in the context of steroid insensitive-ALI.
In summary, we demonstrate that targeting NF- inhibitors with small molecule
inhibitors is effective at preventing the activation of NF- in pulmonary epithelial cells.
Furthermore, this manipulation results in the reduced expression of proinflammatory
genes in both A549 cells. Based on the inflammatory roles of genes, such as ICAM-1, IL6 and MCP-1, and the key role of the alveolar epithelium in the pathogenesis of
ALI/ARDS, we predict that inhibitors of NF- may represent valuable antiinflammatory agents in management of ALI.
6.3.9 Effect of MPS-LcRGD on BALF Protein Concentration in IL-1 Induced Rats
Quantification of BALF protein concentration is considered as an indicator of increase in
lung vascular and epithelial permeability resulting from inflammatory injury. In the
present study, BALF protein concentration was quantified in control and treated groups.
As represented in Figure 6.9, protein concentration in the BALF of IL-1 (i.t.) instilled
group was nearly 3.6 folds that of rats receiving saline (i.t.) (IL-1 group, 0.43 0.07
mg/mL; saline group, 0.12 0.02 mg/mL; P<0.001). A significant inhibition of BALF
protein concentration was observed in rats pretreated with MPS-LcRGD (0.18 0.03
mg/mL; P<0.001) compared to IL-1 (i.t.) instilled group. To delineate the effects of
MPS and cRGD-peptide conjugated liposomes on the inhibition of BALF protein, rats
were pretreated with MPS-L or LcRGD, respectively. Reduction of BALF protein was
observed in rats pretreated with either MPS-L (0.28 0.06 mg/mL; P<0.05) or LcRGD
(0.21 0.02 mg/mL; P<0.01) formulation, but not as significant as MPS-LcRGD. The data
suggests the additive effect of MPS-LcRGD in reducing the BALF protein content.
6.3.10 Effect of MPS-LcRGD on MCP-1 Production in BALF of IL-1 Induced Rats
Since IL-1 induced macrophage and neutrophil migration is largely determined by
MCP-1 expression, we measured the BALF levels at 24 h following IL-1 (i.t.)
instillation in pretreated (MPS-LcRGD, MPS-L or LcRGD) rat groups. Saline and IL-1
alone instilled groups were treated as negative and positive control groups. MPS-LcRGD
treatment resulted in decrease of MCP-1 (1537.4 65.4 pg/mL in IL-1 alone instilled rats
vs. 523.2 92.1 pg/mL in MPS-LcRGD treated rats, P<0.001) and the levels were
comparable to basal levels as that of saline instilled negative control group (Figure 6.10).
MPS-L pretreated group also showed a significant decrease in MCP-1 (987.4 74.1
pg/mL) in IL-1 instilled rats. While LcRGD has no influence on MCP-1 production,
whose levels were similar to that of IL-1 instilled positive control group.
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Figure 6.9
Histogram depicting the inhibition of BALF protein after nebulization of
MPS-LcRGD in male Sprague-Dawley rats.
BALF protein levels were measured by Bio-Rad micro-protein assay. Results are
expressed as mean SEM of four experiments. * and ** indicate statistically signigicant
levels at P<0.05 and 0.01 levels, respectively from IL-1 stimulated levels alone.
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Figure 6.10 Histogram of the inhibition of BALF MCP-1 levels after nebulization of
MPS-LcRGD in male Sprague-Dawley rats.
MCP-1 levels were measured by ELISA. Results are expressed as a mean SEM of four
experiments. ** and *** indicate statistically signigicant levels at P<0.01 and P<0.001
levels, respectively from IL-1 stimulated levels alone.
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6.3.11 Effect of MPS-LcRGD on TNF- Production in BALF of IL-1 Induced Rats
As compared with saline-treated controls, IL-1 (i.t.) instillation induced a significant
increase in BALF levels of TNF- (Figure 6.11). After MPS-LcRGD treatment, BALF
levels of TNF- were significantly (P<0.001) lower and comparable to saline treated rats.
Animals pretreated with MPS solution had lower levels of TNF- but not as significant
(P<0.01) as animals pretreated with MPS-LcRGD. In contrast, BALF levels of TNF- in
animals pretreated with LcRGD had no effect on TNF- production and their levels were
similar to IL-1 (i.t.) instilled positive control group.
6.3.12 Effect of MPS-LcRGD on Neutrophil Migration of IL-1 Induced Rats
A variety of stimuli induce neutrophil migration into the lung. Adhesion molecules and
chemokines have been shown to be involved. Chemokines, such as MCP-1, promote
neutrophil migration into the alveolar compartment. Also, ICAM-1 gradient across the
alveolar barrier is thought to be required for neutrophil sequestration into the vascular
compartment. For quantitative assessment of neutrophil migration into alveolar spaces,
MPO assay of BALF was performed in pretreated rat groups (MPS-LcRGD, MPS-L or
LcRGD) post IL-1 (i.t.) instillation.
As illustrated in Figure 6.12, pretreatment of rats with MPS-L inhibited the neutrophil
migration into alveolar spaces of rats receiving IL-1 (i.t.) as compared with saline
treated rats (1.9 0.1x106; p<0.05 in MPS-L treated group vs 2 0.2x105; P<0.05 in saline
treated group).Inhibition of neutrophil migration was further enhanced (1.1 0.05x106;
P<0.01) with MPS-LcRGD as compared to MPS-L solution or LcRGD pretreated groups.
Further, inhibition of BALF neutrophils significantly increased in rats pretreated with
anti- 1/ 6 (1.4 0.05x106; P<0.01). As estimated by MPO assays, BALF neutrophil
content was not significantly different from the neutrophil number in BALF determined
by Histopaque® assay.
The reduction of lung neutrophil recruitment observed under conditions could in part be
attributed to inhibition of ICAM-1 and MCP-1 levels, which possesses chemotactic
activity for neutrophils. As well, reduced lung neutrophil accumulation mediated by
ICAM-1 and MCP-1 may be a result of reduced intra-pulmonary production of TNF- .
Instillation of IL-1 induced lung injury is the primary stimulus for the upregulation of
the adhesion molecules on alveolar epithelium or endothelium. In this model, both
ICAM-1 and MCP-1 are required for lung neutrophil recruitment. Thus, it is likely that
reduced lung neutrophil recruitment is due to reduced pulmonary production of TNFand subsequent reduction in the up-regulation of adhesion molecules in the pulmonary
vasculature.
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TNF- levels were measured by ELISA. Results are expressed a mean SEM of four
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Figure 6.12 Histogram of inhibition of BALF levels of neutrophils after nebulization
of MPS-LcRGD in male Sprague-Dawley rats.
Neutrophils levels were analyzed by Histopaque and MPO assays. Results are expressed
as a mean SEM of four experiments. Statistically significant differences (* P<0.05, **
P<0.01 and *** P<0.001) compared with IL-1 treatment alone in each experiment.
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6.3.13 Effect of MPS-LcRGD on Neutrophil Accumulation in Lung Parenchyma
Rats received IL-1 (i.t.) or saline as a control and were sacrificed 24 h later. As shown in
Figure 6.13, rats receiving IL-1 showed a 6 fold increase (P<0.001) in lung parenchyma
neutrophil content to 1.8 0.1x107 over saline control. Besides, BALF neutrophils in IL1 (i.t.) treated rats increased 14 folds (P<0.001) to 2.8 0.1x106 over control group. To
investigate the effect of MPS-LcRGD on neutrophil migration into the lung during ALI,
neutrophil accumulation which occurs prior to migration into alveoli was estimated by
MPO assay of the lung tissue. Besides, haematoxylin staining techniques was adopted to
visualize the neutrophil accumulation in paraffin embedded lung parenchyma sections.
From the staining, it is evident that MPS-LcRGD attenuated neutrophil accumulation in
lungs compared to MPS-L or LcRGD.
6.4

Summary

In summary, these studies demonstrate a critical role for the v 6 integrins in mediating
development of alveolar edema caused by IL-1 , which is among the most biologically
important inflammatory mediators in the airspace of patients with early ALI. We
specifically used MPS encapsulated v 6 specific integrin liposomes to deliver the drug
to alveolar epithelial cells, the site of inflammation. In addition to inhibition of integrin
receptors, MPS-LcRGD inhibited inflammation and neutrophil migration in IL-1 instilled
ALI model model. The inhibition of v 6 integrins blocked the IL-1 mediated protein
permeability across the distal lung epithelium and prevented, in large part, the
development of pulmonary edema. The findings reported here have potential clinical
relevance as this mode of treatment may provide new causal therapies for pulmonary
edema from ALI.

115

Figure 6.13 Histological sections of lung parenchyma after haematoxylin treatment to
stain neutrophils.
Lung parenchyma sections represent the edema and neutrophil modulation pattern after
MPS-LcRGD pretreatment.Control (A) shows neat parenchyma cells without edema and a
few neutrophils. IL-1 (B) instilled lung sections shows profuse edema and neutrophil
migration. Non-specific liposomes (C) exhibit profuse edema and a mild reduction in
neutrophil infiltration. Among the lower panel, both MPS-LcRGD (D) and LcRGD (E)
showed reduction in neutrophil levels in alveoli. However, MPS-LcRGD significantly
reduced edema also. All the sections are a representative of n=3 samples.
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CHAPTER 7. INHIBITION OF LUNG INFLAMMATION USING MPS-LAB
7.1

Introduction

Acute lung injury and its more severe form, acute respiratory distress syndrome is
characterized by inflammation at the alveolar-blood capillary interface, resulting in
alveolar influx of protein rich edema fluid and consequently impairment in arterial
oxygenation.4 ALI/ARDS is usually a major cause of acute respiratory failure with high
morbidity and mortality in critically ill patients, affected by various predisposing
insults.4,330 ALI usually arises within 4-72 h of the inciting insults and this period offers
an opportunity for detection of inflammation and initiation of an effective treatment.331
The hallmark event in the pathophysiology of ALI/ARDS is the recruitment of a large
number of neutrophils into alveoli with concomitant production of pro-inflammatory
cytokines.16 Neutrophil recruitment from blood vasculature into alveolar spaces is
orchestrated by sequential up-regulation of cell adhesion molecules (e.g. selectins,
integrins and immunoglobulin supergene adhesion molecules) and their ligands, located
on both vascular endothelial cells and neutrophils.332 The initial tethering and rolling of
neutrophils over the endothelial cells is mediated by selectins and their ligands present on
the apposing cells. During the rolling process, the integrin receptors on neutrophil surface
undergo activation as a result of interaction with chemokines on the inflamed
endothelium. The activated integrins further interact with immunoglobulin adhesion
molecules (e.g. ICAM-1, VCAM-1), upregulated on the inflamed endothelium. These
interactions result in firm adhesion of neutrophils to the endothelium. This is followed by
the transendothelial migration of neutrophils from blood circulation into the alveolar sites
of inflammation.333-335
In this multi-step process of neutrophil migration, firm adhesion is predominantly
mediated by neutrophil 2 integrins in conjunction with ICAM-1 of the endothelium.336
ICAM-1 is constitutively expressed on endothelial cells and its levels are upregulated in
response to inflammatory stimuli, such as LPS, TNF-α and IL-1 .337 The upregulation of
ICAM-1 is usually long lasting with a maximum level at 4-6 h and remains elevated for
24 h.338 This offers a potential opportunity for targeting to the endothelial ICAM-1
molecules using anti-ICAM-1 antibody as a specific targeting ligand. This strategy has
been applied by conjugating anti-ICAM-1 monoclonal antibody onto the surface of
liposomes.
IL-1 stimulates pro-inflammatory cytokine and chemokine release and upregulates
CAMs in alveolar epithelial cells.320 Due to a high chemokine gradient across the alveolar
barrier, leukocytes infiltrate from blood circulation into alveoli, and exacerbate edema
and lung inflammation.321,322 Of the various transcriptional factors, NF- B plays a central
role in regulating the inflammatory genes encoding CAMs, chemokines and
cytokines.75,323 NF- B is a heterodimeric protein present in the cytoplasm in an inactive
form stabilized by binding to the inhibitory protein, I B .74 In response to IL-1
stimulation, I B undergoes phosphorylation and proteolytic degradation. As a result, p117

I B is ubiquitinated allowing nuclear translocation of NF- B, which binds to promoter
regions of the target genes to initiate the transcription of CAMs, chemokines and proinflammatory cytokines.324,325 And inhibitors targeting the activated NF- B would
suppress CAM expression and chemokines release, which eventually prevent migration
of leukocytes.326,327 Glucocorticoids, cited as NF- B inhibitors mediate the effects
through inhibition of NF- B transcriptional activity leading to suppression of proinflammatory genes.328 Taken together, IL-1β mediates: I) 2 integrin dependent
neutrophil migration and II) induction of NF- B dependent pro-inflammatory genes. In
order to reduce both neutrophil migration and inflammation associated with IL-1
stimulation, we used MPS encapsulated and anti-ICAM-1 antibody conjugated liposomes
(MPS-LAb). In the present study, liposomes were chosen for their flexibility: I) to anchor
anti-ICAM-1 Ab onto the surface of liposomes for targeting to 2 integrin receptors
located on alveolar epithelium and II) to encapsulate and deliver MPS to alveolar
endothelial cells for inhibition of pro-inflammatory cytokines (e.g. TNF-α and IL-6),
chemokines (e.g. MCP-1) and CAMs (e.g. ICAM-1) expression.
To determine the effects of the targeting system in vivo, we used IL-1 induced lung
inflammation rat model. MPS-LAb suspension was administered by intravenous route
prior to intra-tracheal (i.t.) instillation of IL-1 in male Sprague-Dawley rats. In vivo
results demonstrated that MPS-LAb treatment show a decrease in neutrophils migration
and pro-inflammatory mediators‟ expression compared to IL-1 instilled (i.t.) positive
control. The results of this study present evidence that MPS-LAb reduces neutrophil
migration by blocking 2 integrin receptors; while MPS release from MPS-LAb exhibited
mild reduction in pulmonary edema.
7.2

Experimental Section

7.2.1 Materials
HSPC, DSPE-PEG2000, DSPE-PEG2000-maleimide were obtained from Avanti Polar
Lipids (Birmingham, AL). MPS and recombinant human interleukin-1 were purchased
from Sigma (St.Louis, MO). Antibodies obtained include: Anti- v (P2W7; sc-9969;
Santa Cruz Biotechnology Inc., Santa Cruz, CA), anti- 6 (H-110; sc-15329; Santa Cruz
Biotechnology Inc), anti- 1 (mAb13, Becton-Dickinson, Bedford, MA), anti- v 3
(LM609; Chemicon, Temecula, CA), anti- v 5 (P1F6; Chemicon) and IgG (Chemicon).
Gel electrophoresis chemicals were obtained from Bio-Rad Inc. (Hercules, CA). All other
chemicals of ACS grade or higher were purchased either from Sigma (St.Louis, MO) or
Fisher Scientific (Suwannee, GA).
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7.2.2 Methods
7.2.2.1 Preparation of Liposomes
MPS encapsulation into liposomes was achieved by transmembrane calcium acetate
gradient method described in Chapter 4. Liposomes were prepared with a lipid
composition of HSPC, CHOL, DSPE-PEG2000 and DSPE-PEG2000-maleimide in 50: 45:
3: 2 molar ratios. Lipid (30 mM total phospholipids) solution in chloroform-methanol
solution (3:1% v/v) was subjected to vacuum drying at 40 C to form a thin dry film,
which was hydrated with calcium acetate buffer (200 mM) at 65 C to form MLVs. These
vesicles were extruded through 200/100 nm sandwiched polycarbonate membrane filters
using LIPEXTM extruder. The MLVs were subjected to 6 extrusion passes to obtain
liposomes with a mean diameter of 100-120 nm.
To create a transmembrane calcium acetate gradient across the liposomes, the
extraliposomal calcium acetate buffer was replaced with 0.9% saline solution by dialysis
(10,000 Da MWCO). Followed by generation of calcium acetate gradient, liposomes
were mixed and incubated with MPS solution [19 mM] at 48°C for 6 min and then cooled
to 4°C. Non-encapsulated MPS and any traces of calcium acetate were removed by
dialysis of MPS-L at 4°C for 6 h.
As shown in Figure 7.1, anti-ICAM-1 anti-body solution (1 mg/mL) was incubated with
mercapto-ethylamine (MEA; 3 mg/mL, pH 6.0) at 30 C for 20 min. Followed by
incubation; the anti-body solution was de-salted to remove MEA using de-salted
columns. The de-salting process was repeated 3 times to remove any traces of MEA.
Now, the anti-body fragments were subjected to fractionation to isolate anti-body
fragments. Fraction number, 6-8 obtained mFAb‟2 fragments and fractions, 16-17
obtained mFab fragments. The isolated mFab‟ fragments were used for conjugation with
DSPE-PEG2000-maleimide in 500 L of HEPES buffer, pH 6.8 for 2 h at 30 C, under a
nitrogen atmosphere. The reaction was stopped with N-ethyl maleimide solution (8 mM).
Now, the lipid-mFab‟ conjugate was dialyzed for 6 h at 4°C to remove N-ethyl
maleimide. The amount of mFab‟ coupled to DSPE-PEG2000-maleimide was estimated
qualitatively by SDS-PAGE and quantitatively by using Bio-Rad protein assay kit.
Approximately, 27% (molar) yield was obtained.
7.2.2.2 SDS-PAGE
Immunoliposomes were run SDS-PAGE under non-reducing conditions to avoid further
fragmentation of anti-body. In this process, reducing agents were not added during the
preparation of both samples. As a result, the resolution of the immunoliposomes is based
on both molecular weight and charge resided on the surface of liposomes (Figure 7.2).
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Figure 7.1
Schematic representation of the coupling of anti-ICAM-1 antibody
fragment tethered to the surface of liposomes.
In step A, antibody fragments were synthesized by using MEA buffer. In step B,
following the cleavage of antibody, antibody fragments were coupled to DSPE-PEG2000maleimide by Michael addition reaction.
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Figure 7.2
SDS-PAGE analysis of DSPE-PEG2000-mFab‟ fragment under nonreducing conditions.
The molecular weight heavy chain is 50,000 Da and that of light chain is 23,000 Da. And
the molecular weight of the lipid is 20,000 Da. Total molecular weight of the conjugate is
93,000 Da which is red circled on lane 3. The bands on lane 1 correspond to standard
molecular weight markers (high molecular weight mixture; Bio-Rad). The bands on lane
2 correspond to light chain and heavy chains.
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7.2.2.3 Insertion of Lipid-antibody Conjugates into Lipid Bilayers of Liposomes
Lipid-antibody was inserted into the bilayers of liposomes by post-insertion method as
described in Chapter 4.
7.2.2.4 Particle Colloidal Properties
Mean diameter and zeta potential of liposomes were evaluated by DLS studies as
described elsewhere.
7.2.2.5 Animals
Male Sprague-Dawley rats were used in all experiments. The experimental protocols
were approved by IACUC of the University of Tennessee, Memphis.
7.2.2.6 Systemic Administration of Liposome Formulations
At least 30 min prior to IL-1β (i.t.) instillation, rats were administered with liposome (PL
or MPS-L or MPS-LAb) formulations at 2 mg/kg. Dose selection was based on initial dose
escalation studies to see the pharmacodynamic effects. Twenty-four hours after the
treatment, animals from all groups were sacrificed and lung tissue samples from each
animal were fixed in 10% v/v buffered formalin.
7.2.2.7 IL-1β Instillation and BALF Collection
Male Sprague-Dawley rats, weighing 125-150 g were used in the study. Rats were fed
normal diet before the experiment with free access to water. Following anesthesia
(ketamine/xylazine, 87/13 mg/kg), a midline tracheal incision was made to expose the
trachea. A 26 gauge needle was advanced endotracheally to instill IL-1 solution (200
µL, 100 µg/mL in PBS, pH 7.2) or PBS alone (control). Following the IL-1 instillation,
tracheal opening was sutured and animals were returned to cage.
Twenty four hours post IL-1 administration, the lung vascular bed was flushed twice by
injecting 10 mL ice-cold PBS into right ventricle. Followed by overdose of pentobarbital
(100 mg/kg, i.v), tracheal sutures were cut open to expose trachea. BALF collection was
performed by inserting a 26 gauge needle into trachea and lungs were lavaged twice with
PBS (3 mL). BALF was collected into cryovials and centrifuged at 1100xg, 4 C for 10
min. The supernatant was stored at -70 C for cytokines and chemokines analysis and the
cell pellet was subjected to neutrophils estimation. Aliquots of BALF were estimated for
protein concentration by UV absorbance at 280 nm using albumin (Bio-Rad) as standard.
Also, post IL-1 administration, blood was collected at different time intervals for
estimation of MPS levels.
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7.2.2.8 Estimation of BALF Cytokines and Chemokines
BALF supernatant collected and stored as described above was analyzed for cytokines
(TNF- ) by ELISA method according to manufacturer (R&D Systems, Minneapolis,
MN) instructions.
7.2.2.9 Estimation of Lung Neutrophil Content
Neutrophil content was assayed as described previously.329
7.2.2.10 Histological Examination of Lungs
Histological examination was performed as described in Chapter 6.
7.2.2.11 Statistical Analysis
All data reported are arithmetic means. Error bars represent one SEM Differences
between means of indicated groups were analyzed by ANOVA with Bonferroni
corrections for multiple comparisons. A P value <0.05 was considered to be statistically
significant.
7.3

Results and Discussion

7.3.1 Physico-chemical Characterization of MPS-LAb
The colloidal properties of MPS-LAb and MPS-L determined by DLS method were stable
over 14 days of shelf life. As shown in Table.7.1, mean particle size and polydispersity
index of MPS-LAb is large than MPS-L. This could be attributed due to the large
molecular weight of the ligand on the surface of liposomes. Zeta potential of MPS-LAb
was lower than MPS-L due to a large content of positive charged amino acids residing on
surface of the antibody.
7.3.2 Effect of MPS-LAb on BALF Protein Concentration in IL-1 Induced Rats
Quantification of BALF protein concentration is considered as an indicator of increase in
lung vascular and epithelial permeability resulting from inflammatory injury. In the
present study, BALF protein concentration was quantified in control and treated groups.
As represented in Figure 7.3, protein concentration in the BALF of IL-1 (i.t.) instilled
group was nearly 2.75 folds that of rats receiving saline (i.t.) (IL-1 group, 0.52 0.03
mg/mL; saline group, 0.18 0.02 mg/mL; p<0.001). A significant inhibition of BALF
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Table 7.1
Liposomes

Physico-chemical properties of MPS-LAb used in in vivo studies.
Mean diameter, Zavg (nm) Zeta potential,

PL
MPS-L
MPS-LAb

113±5
110±18
135±14

(mV)

-22.7±2.8
-20.4±1.4
-9.1±3.7

MPS incorporation
efficiency (% w/v)
NA
59
24

Each value represents the mean±SEM (n = 3). Mean diameter and zeta potential of
liposome formulations were determined at 25 C. NA indicates not applied. NA was
applied to the liposome formulations devoid of MPS encapsulation.
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Figure 7.3
Histogram of inhibition of BALF protein in male Sprague-Dawley rats
after systemic administration of MPS-LAb.
BALF protein levels were measured by Bio-Rad micro-protein assay. Results are
expressed as mean SEM of 3 samples. Statistically significant differences (* P<0.05)
compared with IL-1 treatment alone in each experiment.
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protein concentration was observed in rats pretreated with MPS-LAb (0.26 0.01 mg/mL;
p<0.05) compared to IL-1 (i.t.) instilled group. To delineate the effects of MPS and LAb
on the inhibition of BALF protein, rats were pretreated with MPS-L or LAb, respectively.
A mild reduction of BALF protein was observed in rats pretreated with MPS-L
(0.32 0.02 mg/mL; P>0.05) and LAb (0.44 0.02 mg/mL; P>0.05), which indicate
formulations had no effect on alveolar endothelial permeability. The data suggests that
protein permeability is mediated by pathways other than 2 integrins. The inhibition of
protein permeability observed with MPS-LAb could be due to the synergistic effect of
MPS delivery and anti-ICAM-1 Ab targeting.
7.3.3 Effect of MPS-LAb on MCP-1 Production in BALF of IL-1 Induced Rats
BALF levels at 24 h following IL-1 (i.t.) instillation in pretreated (MPS-LAb, MPS-L or
LAb) rat groups were measured. Saline and IL-1 alone instilled groups were treated as
negative and positive control groups. As shown in Figure 7.4, MPS-LAb treatment
resulted in a decrease of MCP-1 (1499.2 85.2 pg/mL in IL-1 alone instilled rats vs.
540.7 61.2 pg/mL in MPS-LAb treated rats, P<0.05). MPS-L also exerted the similar
effects of MCP-1 inhibition as MPS-LAb. LAb has no influence on MCP-1 production,
whose levels were similar to that of IL-1 instilled positive control group.
7.3.4 Effect of MPS-LAb on TNF- Production in BALF of IL-1 Induced Rats
As compared with saline-treated controls, IL-1 (i.t.) instillation induced a significant
increase in BALF levels of TNF- (Figure 7.5). After MPS-LAb and MPLS-L treatment,
BALF levels of TNF- were significantly (P<0.05) lower. In contrast, BALF levels of
TNF- in animals pretreated with LAb had no effect on TNF- production.
7.3.5 Effect of MPS-LAb on Neutrophil Migration of IL-1 Induced Rats
For quantitative assessment of neutrophil migration into alveolar spaces, MPO assay of
BALF was performed in pretreated rat groups (MPS-LAb, MPS-L or LAb) post IL-1 (i.t.)
instillation. As illustrated in Figure 7.6, pretreatment of rats with LAb inhibited the
neutrophil migration into alveolar spaces of rats receiving IL-1 (i.t.) as compared with
saline treated rats (1.2 0.2x106; p<0.05 in LAb treated group vs. 2.4 0.5x106; P<0.05 in
saline treated group). Inhibition of neutrophil migration was similar to LAb pretreatment.
Only, a mild reduction of BALF neutrophil content was observed with MPS-L.
7.3.6 Effect of MPS-LAb on Neutrophil Accumulation in Lung Parenchyma
Rats received IL-1 (i.t.) or saline as a control, and were sacrificed 24 h later. As shown
in Figure 7.7, rats receiving IL-1 showed a 11.3 fold increase (P<0.001) in lung
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Figure 7.4
Histogram of inhibition of BALF MCP-1 levels in male Sprague-Dawley
rats after systemic administration of MPS-LAb.
Results are expressed as a mean SEM of 3 samples. Statistically significant differences
(* P<0.05) compared with IL-1 treatment alone in each experiment.
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Figure 7.5
Histogram of inhibition of BALF TNF- levels in male Sprague-Dawley
rats after systemic administration of MPS-LAb.
TNF- levels were measured by ELISA. Results are expressed as a mean SEM of 3
samples. Statistically significant differences (* P<0.05) compared with IL-1 treatment
alone in each experiment.
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Figure 7.6
Histogram of inhibition of BALF levels of neutrophils after nebulization
Ab
of MPS-L in male Spague-Dawley rats.
Neutrophil levels were analyzed by Histopaque and MPO assays. Results are expressed
as a mean SEM of 3 samples. Statistically significant differences (* P<0.05, ** P<0.01)
compared with IL-1 treatment alone in each experiment.
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Figure 7.7
Histological sections of lung parenchyma after haematoxylin treatment to
stain neutrophils.
Lung parenchyma sections represent the edema and neutrophil modulation pattern after
MPS-LAb pretreatment. IL-1 instilled lung sections shows profuse edema and neutrophil
migration. Both MPS-LAb and LAb showed neutrophil reduction in alveoli. However,
MPS-LAb significantly reduced edema also. All the sections are representative of n=3
samples.
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parenchyma neutrophil content to 3.2 0.8x108 over saline control. To investigate the
effect of MPS-LAb on neutrophil migration into the lung during ALI, neutrophil
accumulation which occurs prior to migration into alveoli was estimated by MPO assay
of the lung tissue. Besides, haematoxylin staining technique was adopted to visualize the
neutrophil accumulation in paraffin embedded lung parenchyma sections. From the
staining, it is evident that MPS-LAb (P<0.01) completely attenuated neutrophil
accumulation compared to saline control. Also, LAb (P<0.05) exerted a significant
inhibition on lung parenchymal accumulation, which runs in correlation with BALF
neutrophil content.
7.4

Summary

In summary, these studies demonstrate that 2 integrins mediate the neutrophil migration
into alveoli in response to IL-1 stimulation. To disrupt the interaction between 2
integrins and ICAM-1 receptors of alveolar endothelium, anti-ICAM-1 antibody
conjugated liposomes were administered by systemic route. This strategy was adopted as
ICAM-1 receptors could be accessed from the circulation rather than from the alveoli.
MPS-LAb completely attenuated neutrophil migration. However, only a mild reduction in
pulmonary edema and inhibition on inflammatory response were observed. This could
possibly be due to the fact that IL-1 stimulates v 5 and v 6 integrins and mediates
pulmonary edema. Anti-ICAM-1 antibody is not specific to either of the integrins and
hence could exert no inhibitory effects on integrin receptors. In such cases, multiple
ligand targeting strategy or combination approaches using integrin and ICAM-1 receptor
specific targeting agents may favor the inhibition of pulmonary edema and neutrophil
migration.
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CHAPTER 8. SUMMARY AND CONCLUSIONS
The alveolar epithelium and endothelium are prime targets for intervention of lung
inflammation. ALI inflammation is characterized by pulmonary edema, pro-inflammatory
inflammatory mediators‟ production and leukocyte migration into alveoli. Underlying the
inflammation, integrin receptors play a critical role in the mediation of various
pathological events of ALI. Proinflammatory cytokines like TNF-α and IL-1β activate
alveolar epithelium and endothelium via NF-κB pathway. The activated EC excrete
cytokines and chemokines, which in concert with cellular adhesion molecules promote
leukocyte recruitment and migration. Blockade of these processes has attained an
immense attention in recent years, and many new signal transduction inhibitors against
NF-κB were developed.
In this thesis, I developed novel surface modified liposomes aiming at the inhibition of
proinflammatory stimuli in the lung. The first part of the thesis concerns the development
and stabilization of surface modified nano-sized targeted liposomes. In the second part of
the presented work, the drug targeting concept was applied to anti-inflammatory agents,
in order to selectively deliver therapeutic moieties to the affected disease sites. I applied a
cyclic arginine-glycine-D-aspartic acid tri-peptide and anti-ICAM-1 antibody as targeting
ligands. The cRGD-peptide selectively binds to subsets of integrin receptor that are
upregulated on activated epithelium and endothelium, but hardly expressed on quiescent
cells. Anti-ICAM-1 antibody selectively binds to ICAM-1 receptors upregulated on
alveolar endothelium. The task of a carrier is to carry the drug to the disease site. For this
purpose, natural and synthetic polymers, antibodies (ligand and carrier), nanoparticles
and even erythrocytes have been used. I chose liposomes for it is flexible enough for drug
encapsulation, and imparts long circulation and targeting properties. Using functionalized
lipids, I modified the surface of liposomes with cRGD-peptide and anti-ICAM-1 Ab,
leading to a receptor binding drug carriers with high avidity.
However, liposomes are thermodynamically unstable structures and undergo
aggregation/fusion resulting in the loss of colloidal properties of the drug delivery
systems. I addressed the concerns related to the stability of these uniquely designed
targeted drug delivery systems. Lyophilization approach was adopted to improve the
shelf-life of the liposomes. However, lyophilization itself is an aggressive process, which
may be detrimental to the liposomes. Disaccharides and aminoacids were investigated to
exert lyoprotection on these colloidal systems. Our studies showed that trehalose and
sucrose among the sugars, and lysine among the aminoacids protected the liposomes
from aggregation and leakage of the encapsulated drug moieties.
This thesis reports how improved the delivery of the drug to the targeted sites with
cRGD-peptide and anti-ICAM-1 Ab conjugated systems in comparison to the nontargeted systems. The drug targeting systems showed high cell internalization and
adequate drug release, since the uptake eventually led to release of the drug. To enhance
overall delivery of the targeted liposomes, I explored different routes of administration to
take advantage of the spatial and temporal expression of the receptors. Nebulization and
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systemic routes of administration were investigated. Since v 6 integrins are expressed
on the apical side of the alveolar epithelium, I adopted nebulization approach for
targeting to the integrin receptors. Nebulization of MPS-LcRGD was performed prior to IL1 instillation in rats. MPS-LcRGD liposome drug targeting system inhibited the
inflammation and neutrophil migration associated with IL-1 instilled ALI model. The
inhibition of v 6 integrins blocked the IL-1 mediated protein permeability across the
distal lung epithelium, and prevented, in large part, the development of pulmonary
edema. MPS released from the MPS-LcRGD modulated the NF- transcription, and
attenuated the production of pro-inflammatory TNF- and MCP-1 levels. Neutrophil
migration and accumulation in lungs were inhibited. This study demonstrated that route
of administration and targeted delivery system potentiate anti-inflammatory efficacy of
MPS-LcRGD targeted delivery system.
I demonstrated that MPS-LAb could be targeted to ICAM-1 receptors, and thereby reduce
the neutrophil migration into alveoli. MPS-LAb was able to inhibit the pro-inflammatory
cytokines and chemokines production. However, only mild effects on edema were
observed.
In conclusion, I developed receptor specific surface modified nanoparticles to lung in an
attempt to inhibit ALI pathogenesis. I demonstrated that route of administration of the
delivery system plays a critical role to exert beneficial effects on ALI treatment.
Furthermore, I stabilized the targeted liposomes, whose shelf-life was improved. The
research works strengthened the development of novel nanoparticulate systems, in
particular, liposomes for achieving anti-inflammatory drugs with high efficiency and
specificity. Our studies demonstrated that the demands of many of these listed parameters
were met, but the mild outcome for MPS-LAb demands that further work is required to
see the benefits. Nevertheless, our drug targeting approach must be transferred to new
drug moieties. Thereby, we can exploit our experience on targeting surface modified
liposomes as shown in this thesis. The novel drug encapsulation and conjugation
strategies, along with the strategic delivery facilitated improved results.
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